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Abstract 
 
This PhD thesis includes regioselective palladium(0)-catalyzed Suzuki-Miyaura cross-
coupling reactions of isatins, benzoxazols, isoflavones, and coumarins. These classes of 
compounds are of pharmacological relevance. Suzuki-Miyaura cross-coupling reactions 
of 4,7-dichloro-1-methylindoline-2,3-dione afforded arylated isatins. The reactions 
proceeded with very good site-selectivity. The Suzuki-Miyaura reaction of 2,6-
dichlorobenzoxazol, of the bis(triflate) of 4',7-dihydroxyisoflavone, and of the 
bis(triflate) of 4-methyl-6,7-dihydroxycoumarin, with different boronic acids, gave the 
corresponding site-selective mono-arylated, homo bis-arylated and mixed bis-arylated  
derivatives, most of them with very good site-selectivity. The reaction of the bis(triflates) 
of 3-bromo-4-methyl-6,7-dihydroxycoumarin with arylboronic acids gave 
triarylcoumarins in very good yields. The anti-HIV properties of various arylisatins and 
arylcoumarins were studied. 
 
 
Diese Dissertation umfasst Palladium(0)-katalysierte Suzuki-Kreuzkupplungsreaktionen 
von Isatinen, Benzoxazolen Isoflavonen, und Cumarinen. Auf Grund der 
pharmakologischen Bedeutung dieser Substanzklassen wurden unter Anwendung der 
genannten Methodik neue Derivate synthetisiert. Suzuki-Kreuzkupplungsreaktionen von 
4,7-Dichlor-1-methylindolin-2,3-dion ergaben arylierte Isatinderivate. Die Reaktionen 
wiesen eine gute Regioselektivität auf. Die Suzuki-Miyaura-Reaktionen mit dem 
bis(Triflat) des Dichlorbenzoxazols, den Bis(triflaten) des 4',7-Dihydroxyisoflavons und  
des 4-Methyl-6,7-dihydroxycoumarins mit unterschiedlichen Boronsäuren ergaben die 
entsprechenden mono-arylierten, homo bis-arylierten und gemischt bis-arylierten 
Derivate. Der Großteil der Reaktionen verlief dabei mit sehr guter Regioselektivität. Die 
Reaktion des Bis(triflates) des 3-Brom-4-methyl-6,7-dihydroxycumarins mit 
Boronsäuren führte in sehr guten Ausbeuten zu Triarylcoumarinen. Die Anti-HIV 
Eigenschaften verschiedener Arylisatine und Aryl-Cumarine wurden untersucht. 
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1     Back ground and introduction 
1.1  General introduction  
Carbon-carbon bond-formation reactions have played a significant role in the 
development of organic chemistry. The importance of the synthesis of carbon-carbon 
bonds is reflected by the fact that Nobel Prizes in Chemistry have been previously given 
in this area: The Grignard reaction (1912), the Diels-Alder reaction (1950), the Wittig 
reaction (1979), and olefin metathesis developed by Y. Chauvin, R. H. Grubbs, and R. R. 
Schrock (2005). Palladium-catalysed cross-coupling reactions (defined as transition-
metal catalysed substitution of an organic halide or related electrophile by a nucleophile)1 
have been proved to be especially important as carbon-carbon bond formation reactions, 
due to many benefits of these reactions, such as high productivity, atom economy, 
potential recycling of the catalyst and mild reaction conditions. They have been 
increasingly valuable, for example, in the pharmaceutical and fine chemical industries 
and natural product synthesis.2-5  One event that stimulated research in palladium 
catalysis in organic chemistry was the discovery that ethylene is oxidized to acetaldehyde 
by air in a palladium-catalyzed reaction which became the industrially important Wacker 
process.6 In 2010, the Nobel Prize in chemistry was awarded jointly to Richard F. Heck, 
Ei-ichi Negishi and Akira Suzuki for the development of methods for palladium-
catalyzed cross-couplings syntheses. 
 
1.2   Palladium(0) catalysis  
During recent decades an abundance of palladium(0) catalysed coupling reactions has 
been developed. These coupling reactions have found widespread use in large areas of 
chemistry,7 for example in medicinal and pharmacological chemistry,8 total synthesis, 
nanotechnology, and synthesis of advanced materials. Various types of palladium-
catalyzed cross-coupling reactions are known in organic synthesis, such as the Heck, 
Stille, Suzuki, Sonogashira, Tsuji-Trost and Negishi reactions9,10 (Scheme 1). 
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           Heck: R1,  
 
Scheme  1. Palladium(0)-catalyzed cross-coupling reactions. (The picture was taken from 
Angew. Chem. Ind. Ed. 2005, 44, 4442). 
 
Most of the coupling reactions presented above proceed in three steps (Scheme 2). Each 
cycle starts by oxidative addition of an organohalide (I, Br, Cl) to a palladium(0) species 
a triflate or diazonium salt to generate an organo-palladium(II) species.11,12 The second 
step of the reaction is the transmetallation process. In this process an organic moiety is 
transferred from a main group metal, e.g. Mg, Cu, Zn, Sn, B or Si, to a metal that is more 
electronegative, such as palladium, to give a diorganopalladium complex. In the last step 
of the reaction, this complex undergoes a reductive elimination to create a carbon-carbon 
bond and the palladium catalyst is regenerated.13, 14 
 
R3
H
R1
R2 + R4 X
R3
R4
R1
R2
R4 = aryl, benzyl, vinyl
X = Cl, Br, I, OTf
cat. Pd
Heck Reaction
R1 H + R2 X R1 R2
Sonogashira Reaction
cat. Pd
cat. CuX, base
R1 =alkyl, aryl, vinyl
R2 = aryl, benzyl, vinyl
X = Br, Cl, I, OTf
Stile Reaction
R1 SnR3 + R2 X
cat. Pd
R1 R2
R1 = alkyl, alkynyl, aryl, vinyl
R2 = acyl, alkynyl, allyl, benzyl
X = Br, Cl, I, OTf , OAc
X + NuH Nu
cat. Pd
base
X = Br, Cl,OCOR,
NuH = enamines, enolates
Tsuji-Trost Reaction
R1 BY2 + R2 X
cat. Pd
base R
1 R2
R1 = alkyl, aryl, vinyl
R2 = alkyl, alkynyl, vinyl, benzyl
X = Br, Cl, I, OTf , OTs
R1 ZnR2 + R3 X R1 R3
R1 = alkyl, akynyl, aryl, vinyl
R3 = acyl, aryl, benzyl, vinyl
X = Br, I, OTf , OTs
Suzuki Reaction Negishi Reaction
cat. Pd
base
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Scheme 2. General mechanism for palladium(0)-catalyzed cross-coupling reactions. M = 
BY2 (Suzuki), SnR3, (Stille), ZnX (Negishi), MgX (Kumada) or SiR3 (Hiyama) (picture 
was taken from Tetrahedron, 2005, 61, 2245). 
 
1.3   Palladium catalyzed Suzuki Miyaura reaction 
The Suzuki-Miyaura cross-coupling reaction is an extremely versatile methodology for 
the generation of carbon carbon C(sp2)-C(sp2) bonds,15 but more recently it was  extended 
to accommodate carbon atoms in other hybridization states, such as sp3.16 Suzuki 
reactions are defined as Pd catalyzed cross-coupling reactions between organic 
electrophiles, such as aryl-, vinyl- or alkyl-halides or triflate, with organoboron 
compounds in the presence of a stoichiometric amount of base (Scheme 3).17,18 
 
 
 
 
 
 
 
Scheme 3. Palladium catalysed Suzuki coupling. 
Pd(0)
Pd
X
Pd R
X
R
R M
-MX
heterocyclic sp2
carbon atom
oxidative addition
transmetallation
reductive elimination
R-X + R1-BY2
Pd(0)
base
R-R1
R= alkyl, alkenyl, aryl, benzyl, vinyl
R1= alkyl, alkynyl, aryl, vinyl
X= I, Br, Cl, OTf
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The Suzuki-Miyaura reaction is widely used to synthesize poly-olefins, styrenes and 
substituted biphenyls. The first example of this reaction was reported in 1979 by Akira 
Suzuki and co-workers, The reaction of alkyne A with borate B in benzene using 5 mol-
% of tetrakis(triphenylphosphine)palladium Pd(PPh3)4 gave (E)-1,2-diphenylethene D in 
decent yields (Scheme 4). This reaction was done in presence of base, such  as sodium 
ethoxide in ethanol or sodium hydroxide in ethanol.19, 20 
 
 
 
 
 
 
 
 
Scheme 4. An example of a Suzuki coupling reaction. 
 
Organoboranes and boronic acids are attractive coupling partners, as they are widely 
commercially available. Moreover, they are generally relatively tolerant to air and 
moisture, tolerate a wide variety of functional groups, and are easy to handle. The by-
products formed in coupling reactions of organoboranes are usually non-toxic and water 
soluble. All these fearures make organoboranes an attractive class of synthetic 
intermediate from an environmental point of view.15 These interesting advantages make 
the Suzuki-Miyaura cross-coupling reaction an important tool in medicinal chemistry and 
also in the preparation of fine chemicals as well as in large scale pharmaceutical 
industry.21  
  
Several different organoboranes are used in transition-metal-catalyzed coupling reactions, 
for example, organoboronic acid, organoboronic esters and organotrifluoroborate salts 
which have gained popularity during the past few years, due to their low sensitivity to 
oxidation and nucleophilic substitutions. The trifluoroborate salts are easily prepared 
from their corresponding boronic acids or esters by treatment with an excess of 
ArBr
Pd(PPh3)4 (5 mol%)Ph
H
H
B
O
O
HB
O
O
Benzene, NaOH/EtOH
Ph
H
H
Ph
ref lux, 4h
CPhHC
A B C D
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KHF2.
22,23,24 The most frequently employed reagents are organoboronic acids. 
Organoboranes can be synthesized from different substrates, some examples are shown 
below (Scheme 5). 
 
 
Scheme 5. Methods for the synthesis of boronic acids. 
 
A Suzuki-Miyaura cross-coupling reaction of organic aryl, vinyl halides and triflates with 
organoboronic esters can be exemplified by the reaction shown in Scheme 6.19 
     
 
 
 
 
Scheme 6. Suzuki coupling reaction of a boronic ester and bromobenzene. 
 
In the first step of the reaction, the oxidative addition of organic halides or triflates to the 
Pd(0) complex gives a stable trans- б-palladium(II) complex  (Scheme 7).25 The reaction 
proceeds with complete retention of the stereochemistry for alkenyl halides and with 
X B(OR')2 B(OH)2
H3O
+1. RLi
2. B(OR')3
X B(OR)2 B(OH)2
Pd(0), Base
HB(OR)2
SiMe3 BBr2 B(OH)2
BBr3
H B(OR)2 B(OH)2
HB(OR)2
transition-metal catalyst
H3O
+
H3O
+
H3O
+
O
O
B
n-Bu n-Bu
Br Benzene/NaOEt
80 oC, 4h
Pd(PPh3)4
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inversion for allylic and benzylic halides. In the oxidative addition step of the Suzuki 
reaction, the reactivity of the reacting substrates has a vital role to play. Generally, the 
reactivity of various substrates is observed in the following order, Ar-I > Ar-OTf >Ar-Br 
> Ar-Cl and follows the bond strength of the C-X bond to be broken.26,27,28 However, the 
reaction rate can also be influenced by electron-rich spectator ligands, which increase the 
nucleophilicity of the palladium center, or by introduction of electron-poor substituents to 
the aryl substrate.29, 30  
  
Pd0LnBr Pd
Br
L
L
isomerization
Pd
L
L
Br
II
II
cis trans  
Scheme 7. Oxidative addition. 
 
The next step is the transmetallation (Scheme 8) which  is defined as a ligand exchange 
process between two metals, Pd(II) and M. The base supports the transmetallation step of 
the Suzuki reaction.31 The presence of a base usually enhances the nucleophilicity of the 
organoborane compound by formation of an organoborate containing a tetravalent boron 
atom. Different types of bases are used in this reaction, e.g. potassium carbonate, 
potassium phosphate , cesium carbonate and sodium ethoxide. 
 
Scheme 8. Transmetallation processes. 
 
The last step is the reductive elimination (Scheme 9) which can be considered to be the 
reverse process to the oxidative addition.31 This step completes the catalytic cycle and 
Pd
L
L
Br
II
O
O
B
n-Bu O
O
B
O
O
B
O
PhL2Pd
Et
n-Bu
EtO
Pd
L
L
n-Bu
II
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releases Pd (0). Isomerization to the cis complex is required before the reductive 
elimination can occur.  
  
 
Scheme 9. Reductive elimination. 
 
The complete catalytic cycle of Suzuki coupling reactions is shown below (Scheme 10) 
  
 
Scheme 10. Catalytic cycle of Suzuki coupling reaction. 
 
Several catalysts are used for this reaction, e.g. Pd(PPh3)4 and Pd2(dba)3, Pd(PPh3)2Cl2 or  
Pd(OAc)2 together with phosphine ligands (such as PPh3, PCy3, SPhos and XPhos).
32    N-
heterocyclic carbenes33 (Figure 1) are also used as an alternative to phosphine ligands. 
Pd0Ln
NaOEt
NaBr
oxidative addition
transmetallation
PdIILn
Ph
Br
PdIILn
Ph
EtO
O
O
B
n-Bu
O
O
B
EtO
PdIILn
Ph
n-Bu
n-Bu
reductive elimination
Br
Pd
L
L
n-Bu
II
Pd
L
L
n-Bu
II
trans cis
n-Bu
Pd0Ln
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The nucleophilic N-heterocyclic carbene E is the active ligand which is formed in situ 
from F. 
 
 
 
 
 
 
Figure 1. N-hetrocyclic carbene ligands. 
 
Other factors, that also affect the rate of the reaction, are the variation of the solvent of 
the reaction34 and the application of microwave. The use of microwave was reported for 
the first time by Hallberg an co-workers35 in 1996 to enhance the rate of the carbon-
carbon formation (Scheme 11). They confirmed that many metal-catalyzed reactions are 
completed within a few minutes. The reactions were carried out in water, ethylene glycol, 
or DMF, due to the ability of polar solvents to efficiently absorb microwave irradiation.  
 
 
H3C Br
2.8 min, 55 W
Pd(PPh3)4, EtOH
DME. H2O
H3C
ArB(OH)2
55%  
 
Scheme 11. Microwave-assisted Suzuki coupling reaction. 
 
 
 
 
 
 
 
 
 
 
 
N N
..
CH3
CH3
H3C
H3C
H3C
CH3
N N
CH3
CH3
H3C
H3C
H3C
CH3Cl
-
E F
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1.4     Side reactions  
 
Organoboronic acids are relatively stable, due to the low polarity of the boron-carbon 
bond (electronegativity of boron 2.0 and carbon 2.5, according to the Pauling scale). 
Orrganoboronic acids are relatively unwilling to undergo transmetalation with palladium 
(electonegativity of 2.2). In order for arylboronic acids to become sufficiently reactive for 
efficient transmetallation with palladium, they require coordination of a base or Lewis 
base to form a tetracoordinated boronate anion which is more susceptible to 
transmetallation than the free boronic acid.23 
 
Although organoboronic acids are apparently stable, they often undergo side reactions 
during transition-metal-catalyzed coupling reactions. A public side reaction is the 
protodeboronation. Protodeboronation seldom occurs in the absence of transition metals 
under neutral conditions, even at high temperature.36  In highly acidic or basic aqueous 
solutions, on the other hand, protodeboronation may be a fairly fast process.37 Several 
metal ions, Pd(II), Ni(II), Zn(II), Ag(I), Cu(II), can induce protodeboronation in water by 
the formation of an aryl-metal intermediate.38 
 
Other kinds of side reactions are the oxidation of the arylboronic acid to the 
corresponding alcohol. Challenger reported the formation of phenol by treating 
arylboronic acids with hydrogen peroxide in 1930,39 and other oxidants, such as oxone40 
and sodium perborate.41 Scheme 12 explains the mechanism for the oxidation of boronic 
acid in aqueous solution.42 
 
   
 
 
 
 
 
 
 
 
 
Scheme 12. Oxidation of boronic acids. 
 
-BB(OH)2
-OOH OH
OH
OOH
OB(OH)2 +
-OH OH + B(OH)2
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In 1996 and  2005 Moreno-Manas et al. have been reported in their pioneering work on 
palladium-catalyzed biaryl formation by homocoupling of arylboronic acids as a side 
reaction under palladium oxidative conditions.43Amatore and Jutad44 published a 
thorough mechanistic investigation. Their investigation demonstrated that the reaction 
was catalyzed by palladium(II) and required dioxygen to form the active peroxo-
palladium complex, (2-O2)PdL2, generated by reaction of dioxygen and palladium(0) 
(Scheme 13). 
 
 
 
 
 
Scheme 13. Palladium-catalyzed homocoupling of arylboronic acids (pictures were taken 
from refs.44). 
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1.5    Site selective and chemo selectivity Suzuki Miyaura cross-coupling reactions 
Recently, site-selective Suzuki coupling reactions became important. Complex 
compounds can be prepared by successive coupling reactions of substrates containing 
two or more possible reactive sites. The first attack usually occurs at the more electron 
deficient and less sterically hindered postion.45,46 In a couple of years, Prof. Peter 
Langer’s research group studied site-selective Suzuki-Miyaura reactions of 
polyhalogenated heteroaromatic and aromatic compounds or their triflates. The site-
selective Suzuki coupling reaction of indole G was found to be in favour of the 2-position 
(Figure 2). This is due to the fact that the electronic character of C-2 and C-3 appears to 
be sufficiently different and so site-selective transformations are observed.47 2,3-
Dibromoindenone H gives a very good site-selectivity. The first attack occurred at 
position 3.48 
 
 less electron-deficient
more electron-deficient
O
Br
Br
H
 less electron-deficient
more electron-deficient
N
Br
Br
G
Me
2
1
1
2
 
Figure 2. Possible explanation for the site-selectivity of G and H. 
 
The substrates 2,3,4-tribromothiophene (I) and 2,3,5-tribromothiophene  (J) showed a 
very good site selectivity. For compound I, the first coupling occurred at carbon atom C-
2, the second coupling took place at carbon atom C-4. In case of J, the first coupling  is 
preferred at carbon atom C-5 and the second one at carbon atom C-2. The selectivity  can 
be explained based on the different electronic and steric properties of the three different  
C–Br bonds of I and J (Figure 3).49 
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Figure 3. Possible explanation for the site-selectivity of I and J. 
 
The Suzuki-Miyaura reaction also provided excellent results for triflates. Phenolic OH 
groups my be converted into OTf groups by using triflic anhydride, After wards the site-
selectivity of Suzuki reactions were studied. The Langer group reported regioselective 
Suzuki-Miyaura cross-coupling reactions of the bis(trifluoromethylsulfonyloxy) of many 
substrates. For example, for the bis(trifluoromethylsulfonyloxy) of 1,2-
dihydroxyanthraquinone K and 1,3-dihydroxyanthraquinone  L,50 the first attack occurs 
at position 1 which is more sterically hindered, but  also more electron deficient. In case 
of phenyl 1,4-bis(trifluoromethylsulfonyloxy)naphthoate M, the first attack occurs at the 
more sterically hinderd and more electron deficient position 1.51 In case of the 7,8- 
bis(trifluoromethylsulfonyloxy)flavone N, the first palladium(0) catalyzed cross-coupling 
reactions generally occurs at the more electron deficient and sterically less hindered 
position.4,15 Position 7 of compound N is sterically less hindered than position 8. In 
addition, position 7 is considerably more electron-deficient than position 8 (located ortho 
to the ether oxygen atom and meta to the carbonyl group).52 The reactions of all 
mentioned substrates proceeded with excellent site selectivities (Figure 4). 
 
S
Br
Br
Br
S
Br
Br
Br
electron-dificient
sterically hindered
less electron-deficinent
sterically hindered
electron-def icinent
less sterically hindered
3
2
1
less electron-deficinent
most sterically hindered
3
most electron-def icinent
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Figure 4. Possible explanation for the site-selectivity observed for K, L, M, and N .  
      
Interesting results have been obtained investigating the chemoselectivity between the 
bromide and triflate position. It is found that the reactions proceed with very good 
chemo-selectivity in favor of the bromide position53,54 (Figure 5). 
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Figure 5. Possible explanation for the chemo selectivity observed for O, P and Q. 
 
Aryl bromides generally undergo Suzuki-Miyaura reactions faster than aryl triflates.This 
reactivity order is different for other palladium catalyzed cross-coupling reactions. One of 
the justifications for that is based on the high borane-halide affinity. Nevertheless, other 
parameters control the selectivity as well.54        
 
 
 
 
 
 
 
 
 
 
 
 
 
 15 
 
2. Efficient synthesis of arylated methylisatin by site-selective Suzuki-Miyaura    
cross-coupling reactions of the 4,7-dichloro-1-methylisatin , anti HIV activity and 
modeling study   
 
2.1 Introduction 
Isatin molecule (1H-indole-2,3-dione) is a versatile moiety that displays diverse 
biological activities55 such as antibacterial,56 antifugal,57 antiinflammatory58 and 
anticonvulsant agents.59 The synthetic flexibility of isatin has led to the synthesis of a 
varierty of substituted derivatives, however, the susceptibility of isatin to attack by 
nucleophiles at C-3 has resulted in the generation of a large number of 3-substituted isatin 
in particular. This is reflected by numerous biologically active 3-substituted indolin-2-
ones that are reported in the literature.60-62 Most recently, Grewal63 have extensively 
screened the synthesis and various biological activities of isatin derivatives. Further, 
isatin derivatives have received considerable attention due to their potent anticancer 
activities,64-66 meanwhile Liu and colleagues67 identified a class of isatin O-acyl oximes 
that selectivity inhibited neuronal ubiquitin C-terminal hydrolase (UCH-L1) in a H1299 
lung cancer cell line, which is proposed to be linked to tumor progression upon 
upregulation. Lee et al.68 have reported a novel indirubin analog, indirubin-5-nitro-3′-
monoxime, inhibited cell proliferation against various human cancer cells, meanwhile 
sunitinib maleate (Sutent®) had been approved by FDA for the treatment of advanced 
renal carcinoma,69 and gastrointestinal stromal tumors.70 Vine et al.71 have reported that 
the introduction of electron withdrawing groups to the benzene ring of isatin are 
generally found to induce cancer cell death via apoptosis.  
 
Owing to the broad spectrum chemotherapeutic properties of isatin derivatives, several 
researchers72-78 found that such derivatives were ideal drugs for AIDS treatment which 
suppresses HIV replication. Examples of such analogues were 4-[(1,2-dihydro-2-oxo-3H-
indol-3-ylidene)amino]-N-(4,6-dimethyl-2-pyrimidinyl)-benzene sulphonamide  and its 
N-acetyl derivative.79 Furthermore, several isatin derivatives showed remarkable anti-HIV 
activity like sulfonamide-benzene derivatives and Schiff and Mannich bases of isatin.80-82  
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I report here a convenient approach to arylated isatins by what are, to the best of our 
knowledge, the first Suzuki-Miyaura cross-coupling reactions of 4,7-dichloro-1-
methylindoline-2,3-dione. Surprisingly, the reactions proceed with very good 
regioselectivity in favor of position 4. Besides, the new arylated isatin derivatives were 
evaluated for their anti-HIV activity in addition to study of the molecular modeling 
structure. 
 
Figure 6. Some potentially active isatin derivatives. 
 
2.2 Results and discussion 
The commercially available 4,7-dichloroisatin (1) was converted into N-methyl-4,7-
dichloroisatin (2) in 90 % yield by using DMF as a solvent, MeI and K2CO3 as a base at 
rt.83 (Scheme 14). Treatment of 2 with arylboronic acids 3a-f (2.0 equiv.) by applying 
Suzuki-Miyaura reaction afforded the N-methyl-4,7-diarylisatins 4a-f in 52-82 % yield 
(Scheme 15). Both electron-poor and electron-rich arylboronic acids could be 
successfully employed. The best yields were obtained by using Pd(PPh3)4 (6 mol-%) as a 
catalyst and K3PO4 (3.0 equiv) as a base in 1,4-dioxane at 120°C for 8 h. 
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Scheme 14. Synthesis of 2. Reagents and conditions: i, K2CO3 (1.2 equiv.), 
DMF (1 ml per 0.1 mmol of isatin) 1 hr, 4°C, 20°C. CH3I  (1.1 equiv.),   KI  
(cat., 0.2 equiv.),  80°C, 5 h. 
  
 
 
 
     
 
Scheme 15. Synthesis of 4a-f. Reagents and conditions: i, 2 (1.0 equiv), 3 (2.0 
equiv.), K3PO4 (3.0 equiv.), Pd(PPh3)4  (6 mol-%), 1,4-dioxane 120°C, 8 h. 
 
Table  1. Synthesis of 4a-f. 
3,4 Ar 4 (%) a 
a 3,5-(Me)C6H3 61 
b 4-(MeO)C6H4 82 
c 4-ClC6H4 52 
d 4-MeC6H4 58 
e 4-EtC6H4 65 
f 4-FC6H4 72 
                               a Yields of isolated products 
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Optimization of the synthesis of 4a was carried out by using various reaction conditions 
such as K2CO3, KF, K3PO4  and NEt3 as bases, in different solvents like toluene, DMF, 
Dioxane and THF, Pb(OAc)2 and Pd(PPh3)2Cl2 as catalysts at 65-130°C. Table 2 
summarize these conditions  and showing the yield percentages of 4a  (25-83 %). 
 
Table 2. Optimization of the synthesis of 4a. 
              a K3PO4 (3.0 equiv.);  b Dioxane (3 ml);  c 120oC;  d Pd(PPh3)4 (6 mol-%);  e 8 h 
               f Yield of isolated products 
 
Best results were obtained by using K3PO4 as a base, 1,4-dioxane as solvent, Pd(PPh3)4 as 
a catalyst. Suzuki-Miyaura reaction of (2) with arylboronic acids (3) (1.0 equiv.) afforded 
the 7-chloro-4-aryl-1-methylindoline-2,3-dione 5a-d,f-m in 49-87 % yield with very 
good site-selectivity (Scheme 16). During the optimization, it proved to be important to 
use (1.2 equiv) of the arylboronic acid carry out the reaction at 70 instead of 120°C and to 
use 1,4-dioxane as a solvent (reaction time 6 h). Both electron-poor and electron-rich 
arylboronic acids were successfully used. 
 
 
 
 
 
 
 
Scheme 16. Synthesis of 5a-d,f-m. Reagent and conditions: ii, 2 (1.0 equiv), 3 
(1.2 equiv.), K3PO4 (1.5 equiv.), Pd(PPh3)4  (3 mol-%), 1,4-dioxane, 70°C, 6 h. 
Yield (%)f T (h)e Catalytsd T (oC)c Solventb Basea Entry 
25 8 Pd(OAc)2 100 Toluene K3PO4 1 
38 9 Pd(PPh3)4 130 DMF K2CO3 2 
47 10 Pd(OAc)2 80 Dioxane KF 3 
34 7 Pd(PPh3)2Cl2 65 THF NEt3 4 
83 8 Pd(PPh3)4 120 Dioxane K3PO4 5 
25 10 Pd(OAc)2 90 Toluene K2CO3 6 
ii
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5a-d,f-m
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Table 3. Synthesis of 5a-d,f-m. 
 
 
                                               a Yields of isolated products 
 
The structures of the newly prepared compounds were confirmed by their IR, 1H, 13C 
NMR and by mass spectra, where 4a-f, 5a-m, exhibited additional signals for the protons 
of the newly introduced aromatic rings. The aromatic protons have been assigned. In the 
13C NMR spectra of these analogues, carbonyl carbon atoms at C-2 of the isatin ring 
resonated at 158.4-168.3 ppm, while the lower field resonances at  178.2-181.9 ppm 
were assigned for the carbonyl carbon atoms at C-3 of isatin moiety. The signal of C-5 of 
isatin ring were observed at 124.1-127.4 ppm, while the resonances at δ 144.4-148.3 
ppm were assigned to C-7a of the fused rings. In addition, the N-Me group of isatins 
appeared at δ 28.6-33.7 ppm. The aromatic carbon atoms and the substituents were fully 
analysed. Compound 5b was selected for further study via their HMBC84 and NOESY85 
NMR spectroscopic measurements. The gradient‐selected HMBC spectrum of 5b showed 
a 3JC,H heteronuclear correlation of C-4 of isatin ring (C 133.9 ppm) to the H-2’/H-6’ 
proton (H 7.32 ppm) of the aromatic moiety at C-4 of isatin. The 1H, 1H NOESY 
spectrum was characterized by two correlations: one indicated by correlation of protons 
3,5 Ar 5 (%) a 
a 3,5-(Me)2C6H3 63 
b 4-(MeO)C6H4 83 
c 4-ClC6H4 52 
d 4-MeC6H4 79 
f 4-FC6H4 87 
g 4-(EtO)C6H4 85 
h 4-iProC6H4 73 
i 4-tBuC6H4 78 
j 3-MeC6H4 51 
k 3,5-(MeO)2C6H3 87 
l 4-(Acetyl)C6H4 53 
m 4-(Vinyl)C6H4 49 
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of methoxy group at H 3.72 ppm with H-3’/H-5’ of the same aromatic ring at H 6.87 
ppm, while the other one was observed between the H-1’/H-6’ of the aromatic ring at H 
7.32 ppm with H-5 of the isatin ring at H 6.87 ppm (Figure. 7). 
 
     
 
 
 
 
 
 
 
Figure 7. JC,H   correlations in the HMBC (single head arrow), and NOESY (double head 
arrow) correlations of 5b.     
 
 
   
 
  
 
 
 
 
 
 
 
 
Figure 8. Molecular structure of 7-chloro-4-(4-methoxyphenyl)-1-methylindoline-2,3-
dione (5b) in the crystal. Displacement ellipsoids are drawn at 50 % probability level. 
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Figure 9. Molecular structure of 7-chloro-1-methyl-4-(p-tolyl)indoline-2,3-dione (5d) in 
the crystal. Displacement ellipsoids are drawn at 50 % probability level. 
 
Is is interesting to study the regioselectivity of Suzuki-Miayura reaction of dichloroisatin 
2 having two different electron deficient centers (C-4 and C-7). Thus, one-pot Suzuki-
Miayura reaction of 2 with two different arylboronic acids 3 (sequential addition of 1.2 
equiv. of each boronic acid) afforded the N-methyl-4,7-diarylisatins 6a-c in 57-70 % 
yields . The reactions were carried out at 70°C for the first step (to avoid double 
coupling) and at 120°C for second step (Scheme 17). 
 
 
 
        
 
 
 
 
Scheme 17. Synthesis of 6a-c. Reagents and conditions: i, 2 (1.0 equiv), Ar1B(OH)2 (1.2 
equiv.), K3PO4 (1.5 equiv.), Pd(PPh3)4  (3 mol-%), 1,4-dioxane, 70°C 6 h. ii,  Ar
2B(OH)2 
(1.2 equiv.), K3PO4 (1.5 equiv.), Pd(PPh3)4  (3 mol-%), 1,4-dioxane, 120°C 6 h. 
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Table 4. Synthesis of 6a-c. 
3 6 Ar1 Ar2 6 (%)a 
i,d a        4-tBuC6H4 4-MeC6H4 57 
k,b b       3,5-(MeO)2C6H3 4-(MeO)C6H4 70 
d,b c         4-MeC6H4 4-(MeO)C6H4 68 
                     a Yields of isolated products 
 
The above results (Scheme17) revealed that the chlorine residue at C-4 of the isatin ring 
has been initially replaced by an aryl group due to the highler electron deficiency at this 
position compared with position 7. The second replacement occured in the second step 
indicating the lower electron deficiency at C-7 (Figure. 10). 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Stepwise Suzuki-Miayura coupling reaction starting form compound  2. 
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2.3 In vitro anti  HIV assay  
Compounds 2, 4a-f, 5a-d,f-m and 6a-c, were tested for their in vitro anti-HIV-1 (strain 
IIIB) and HIV-2 (strain ROD) activity in human T-lymphocyte (MT-4) cells, using MTT 
method.86 This work was carried out by our collaboration partners (group of Prof. Dr. 
Najim Al-Masoudi). The results are summarized in Table 1, in which the data for 
azidothymidine (DDN/AZT)87 and lamuvidine (3TC)88 were included for comparison 
purposes. Compound 5l was found to be the only compound from the series inhibiting 
HIV-2 replication in cell culture. Compound 5l showed an EC50 value of > 3.47 µM and a 
CC50 value of 13.43 µM, resulting in a selectivity index (SI) of 4 and maximum 
protection of 66 %, meanwhile exhibited no selectivity (SI < 1) against HIV-1 (EC50 = 
13.43 µM). Derivatives 2, 5c, 5g and 5m demonstrated low CC50 values of > 2.21 µM, > 
2.24 µM, 3.11 µM and 2.24 µM, respectively, at concentration of 100 μM, in comparison 
to the other analogues. 
 
Based on the chemical structure of compound 5l, this molecule can be proposed to act as 
NNRTI. However, the activity spectrum that is limited to HIV-2 is completely in contrast 
with what was observed with NNRTIs. However, the above data suggested that the halo 
group binding the benzene ring of isatin backbone (e.g.: 5) considerably increased the 
anti-HIV activity, meanwhile substitution the benzene ring of isatin by an arylketo group 
like 5l would enhanced such inhibition for HIV in comparison to the effectiveness of 
other functional groups.  
 
In conclusion, the identification of 5l as a NNRTI of HIV-2 may be an important lead for 
the development of a more potent and selective molecule which could be used in 
combination with other drugs to treat individuals infected with HIV. 
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Table  5. In-vitro anti-HIV-1a and HIV-2b of new N-methylisatin derivatives 
Entry HIV (IIIB) 
IC50 (µM)c 
HIV (ROD) 
IC50 (µM)c 
CC50      Max. Prot.e   Max. Prot.f 
(µM)d    (%)               (%)                               
SIg  
2 > 2.21 > 2.21 2.21        2                  6 < 1 
4a > 61.75 > 61.75  61.75      5                  5 < 1 
4b > 35.28 > 35.28 35.28      3                  2 < 1 
4c > 10.92 > 10.92 10.92      3                  4 < 1 
4d > 12.30 > 12.30 12.30      4                  2 < 1 
4e > 4.88 > 4.88 4.88        8                  7 < 1 
4f > 12.75 > 12.75 12.75      3                  3 < 1 
5a > 30.35 > 30.35 30.35      3                  5 < 1 
5b 
5c 
5d 
5f 
5g 
5h 
5i 
5j 
5k 
5l 
5m 
6a 
6b 
6c 
> 125.0 
> 2.24 
> 15.12 
> 10.85 
> 3.11 
> 4.39 
> 9.96 
> 12.93 
> 68.33 
> 13.43 
> 2.24 
> 33.16 
> 42.13 
> 12.28 
> 125.0 
> 2.24 
> 15.12 
> 10.85 
> 3.11 
> 4.39 
> 9.96 
> 12.93 
> 68.33 
> 3.47 
> 2.24 
> 33.16 
> 42.13 
> 12.28 
125.0      11                14 
2.24        6                  3 
2.24        3                  3 
10.85      10                7 
3.11        8                  14 
4.39        8                  5 
9.96        6                  6 
12.93      3                  7 
68.33      12                40 
13.43      6                  66 
2.24        1                  6 
33.16      7                  7 
42.13      4                  8 
12.28      3                  6 
< 1 
< 1 
< 1 
< 1 
< 1 
< 1 
< 1 
< 1 
< 1 
< 1 (4) 
< 1 
< 1 
< 1 
< 1 
AZT 0.0019 0.0018 > 25        66                71 > 13144 (> 14245) 
3TC 0.51 2.02 > 20        90                79 > 39 (> 10) 
with strain       measured   2 activity -HIV-anti  b ;B1 activity measured with strain III-HIV-Anti 
a
-HIVcells from the 4 -compound concentration required to achieve 50 % protection of MT cROD; 
that reduces the viability of  compound concentrationd 2 induced cytopathogenic effect; -HIV1 and 
)50/EC50(CC  SI: selectivity index  g(ROD); f ); B(III e4 cells by 50 %; -infected MT-mock 
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2.4 Molecular modeling analysis 
Our molecular docking analysis of the new analogs is based on the modeling studies 
which were performed to understand the binding mode of these analogs with the HIV-RT 
binding pocket (NIBP) (PDB code: 1MU289). The molecular docking was performed 
using SYBYL-X 1.1, and the results were visualized with PYMOL.90 
 
HIV-2 reverse transcriptase (RT) demonstrates an intrinsic resistance to non-nucleoside 
RT inhibitors (NNRTIs), one of two classes of anti-AIDS drugs that target the viral RT, 
however, HIV-2 RT has a similar overall fold to HIV-1 RT but has structural differences 
within the “NNRTI pocket” at both conserved and nonconserved residues.91 Compound 
5l has been selected for the docking modeling study, since showed a good binding energy 
score (‐9.2) (Figure. 11). As shown in Figure 6, the isatin backbone is located in the 
middle of the binding pocket, anchoring the two carbonyl groups at C-2 and C-3 in a 
favorable position for hydrogen bonding with the Lys102 and Thr107 of the reverse 
transcriptase (RT) enzyme, respectively. Further, the amino acids in the binding pocket of 
RT enzyme are mainly lipophilic with aromatic residues.92 Therefore, not only hydrogen 
bonding but hydrophobic interactions also play vital role in deciding anti-HIV activity.93 
The aromatic ring (PhCOMe) of 5l fitted into an aromatic rich subpocket surrounded by 
the aromatic side chain of Tyr188. Detailed analysis of the binding mode showed that the 
aromatic ring of PhCOMe group pointed toward the aromatic ring of Tyr188 residue 
apparently developing ‐stacking interactions, where the electrostatic interaction is 
stabilized by these stacking type interactions. Overall, the combination of hydrophobic 
interaction and hydrogen bondings appears to govern the binding of 5l with HIV-2 RT.  
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Figure 11. Docked conformation of 5l showing two hydrogen bonds: Thr107 with 
oxygen atom at C-3 of isatin ring and Lys102 with oxygen atom at C-2 of the same ring. 
In addition, a hydrophobic interaction was observed between the phenyl group of 
acetophenone moiety at C-4 of isatin backbone and Tyr188 of reverse transcriptase (RT) 
enzyme residues.  
 
2.5 Conclusion 
I have synthesized  arylated methylisatins by Suzuki-Miyaura reactions of 4,7-dichloro-1-
methylisatin (2). The reactions proceed with excellent site-selectivity in favour of 
position 4, due to electronic reasons. All the new analogues were evaluated by our 
collaboration partners in vitro for their antiviral activity against the replication of HIV-1 
and HIV-2 in MT4 cells using MTT assay. Compound 5l, with an 4-acetylgroup at C(4) 
of the isatin backbone, showed an EC50 value of >3.47 μM against HIV-2 with a 
therapeutic index (SI) of 4. This means that 5l was cytotoxic to MT-4 cells at a CC50 
value of 13.43 μM; also compounds 2, 5c, 5g and 5m were cytotoxic to MT-4 cells 
within > 2.21-3.11 μM concentration range. In a docking study, 5l interacted with several 
amino acids in the reverse transcriptase (RT) binding site of HIV. 
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3. Efficient synthesis of arylated benzoxazoles by site-selective Suzuki-Miyaura cross 
    coupling reactions of the 2,6-dichlorobenzoxazole  
                  
3.1 Introduction 
The benzoxazole unit is an important heterocyclic core structure which occurs in several 
natural products. Examples include pseudopteroxazole and salvianen (Figure 12).94,95 
Benzoxazoles also represent important molecules in medicinal chemistry.96 Previous 
reports revealed that substituted benzoxazoles, such as the drug fenoxaprop, possess 
diverse chemotherapeutic activities, including antibiotic,97 antimicrobial,98-102 
antivirial103, and antitumor activities.104  
     
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Benzoxazoles in natural products and drugs. 
 
Traditional methods for the synthesis of substituted benzoxazoles include the 
condensation of ortho-aminophenols with aldehydes.105 Recently, general methods for the 
copper-catalyzed intramolecular C-O coupling reaction of 2-haloanilides were 
reported.106  Nagasawa et al. reported that 2-arylbenzoxazoles can be prepared by copper-
catalyzed intramolecular oxidative C-O coupling of benzanilides.107 Palladium catalyzed 
multi-component reactions of aryl halides, isocyanides, and aminoalcohols have also 
been used for the synthesis of benzoxazoles.108 In recent years, site-selective Pd catalyzed 
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cross-coupling reactions have attracted considerable attention.109,110 Herein, I report a 
new approach to arylated benzoxazoles by site-selective Suzuki-Miyaura cross-coupling 
reactions of commercially available 2,6-dichlorobenzoxazole (7) with arylboronic acids. 
 
3.2 Results and discussion 
The Suzuki-Miayura reaction of commercially available 2,6-dichlorobenzoxazole 7 with 
2.2 equiv. of various arylboronic acids 3a-c,e,n afforded the 2,6-diarylbenzoxazoles 8a-e 
in 75-89 % yields (Scheme 18, Table 6). The reactions had to be carried out at a higher 
temperature (120°C) as compared to the synthesis of mono arylated products 9. Very 
good yields were obtained for products derived from both electron rich and poor 
arylboronic acids. 
                         
   
     
 
 
Scheme 18. Synthesis of 8a-e. Reagents and conditions: i, 7 (1.0 equiv.), 3a-c,e,n (2.2 
equiv.), Pd(PPh3)4 (26 mg, 6 mol-%), K2CO3 (aq. solution, 2 M), 1,4-dioxane, 120°C, 8 h. 
 
Table 6. Synthesis of 8a-e. 
3 8 Ar 8 (%) a 
a a 3,5-(Me)2C6H3 89 
b b 4-(MeO)C6H4 88 
c c 4-ClC6H4 75 
e d 4-EtC6H4 88 
n e 3-FC6H4 75 
                            a Yields of isolated products 
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The Suzuki-Miayura reaction of 2,6-dichlorobenzoxazole 7 with 1.2 equiv. of arylboronic 
acids 3a-c,e,g-j,m-r afforded the 2-aryl-6-chlorobenzoxazoles  9a-n in 75-89 % yields 
with very good site-selectivity  (Scheme 19, Table 7).        
       
The reactions were carried out under standard conditions for  Suzuki-Miyaura  reactions 
Pd(PPh3)4 (3.0 mol-%) was employed as the catalyst and an aqueous solution of  K2CO3 
was used as the base (dioxane, 80°C, 6 h). Very good yields were obtained for both 
electron rich and poor arylboronic acids. During the optimization, it proved to be 
important to carry out the reactions at 80°C. A higher temperature resulted in the 
formation of significant amounts of diarylated products. 
 
 
                               
 
 
Scheme 19. Synthesis of  9a-n. Reagents and conditions: i, 7 (1.0 equiv), 3a-c,e,g-j,m-r 
(1.2 equiv.), Pd(PPh3)4 (3 mol-%), K2CO3 (aq. solution, 2 M), 1,4-dioxane, 80°C, 6 h. 
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Table 7. Synthesis of 9a-n. 
3 9 Ar 9 (%) a 
a a 3,5-(Me)2C6H3 90 
b b 4-(MeO)C6H4 90 
c c 4-ClC6H4 88 
e d 4-EtC6H4 81 
g e 4-EtOC6H4 80 
h f 4-iProC6H4 75 
i g 4-tBuC6H4 72 
j h 3-MeC6H4 87 
m i 4-(Vinyl)C6H4 65 
n j 3-FC6H4 83 
o k 2,3,4-(MeO)3C6H2 80 
p l C6H5 90 
q m 4-(F3C)C6H4 83 
r n 3-(MeO)C6H4 75 
                           a Yields of isolated products 
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The structure of product 9b was elucidated by 2D NMR spectroscopy (NOESY, COSY, 
HMBC, HSQC). A clear and important HMBC correlation between the ortho protons of 
the 4-methoxyphenyl group and  carbon C-2 of oxazol ring  was visible, which confirmed 
that the aryl moiety is attached at  carbon C-2.                                
  
 
 
 
 
 
Figure 13. Important HMBC (single head arrows), NOESY (double head arrows) 
correlations of 9b.  
 
The one-pot reaction of 7 with two different arylboronic acids was next studied. The 
reaction of 7 with 1.2 equiv. of an arylboronic acid and subsequent addition of a second 
arylboronic acid (1.2 equiv.) afforded the 2,6-diarylbenzoxazoles 10a,b containing two 
different aryl groups in good yields (Scheme 20, Table 8). During the optimization, it 
proved to be important to carry out the first step at 80°C and the second step at 120 °C. It  
was also proved to be important to add a fresh portion of catalyst together with the 
second aryl boronic acid. The structure of 10b was independently confirmed by X-ray 
crystal structure analysis (Figure 14). 
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i,ii
1) Ar1B(OH)2
2) Ar2B(OH)2
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7 10a,b  
Scheme 20. Synthesis of 10a-b. Reagents and conditions: i,  7 (1.0 equiv), Ar1B(OH)2 
)1.2 equiv.), Pd(PPh3)4 (3 mol-%), K2CO3 (aq. solution, 2 M), 1,4-dioxane, 80°C, 6 h; ii,  
Ar2B(OH)2 (1.2 equiv.), Pd(PPh3)4 (3 mol-%), K2CO3 (aq. solution, 2 M), 120°C, 8 h. 
 
Table 8. Synthesis of 10a-b. 
3 10 Ar1 Ar2 10 (%)a 
c,a a 4-ClC6H4 3,5-(Me)2C6H3 84 
i,b b 4-tBuC6H4 4-(MeO)C6H4 72 
                   a Yields of isolated produc                                                                                                      
 
 
Figure 14. Molecular structure of 2-(4-tert-butylphenyl)-6-(4-methoxyphenyl)-
benzoxazole 10b in the crystal. Displacement ellipsoids are drawn at 50 % probability 
level.                                 
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The structures of the newly prepared compounds were confirmed by their IR, 1H, 13C 
NMR and by mass spectra, where 8a-e, 9a-n, 10a-b exhibited additional signals for the 
protons of the newly introduced aromatic ring. 
 
The site-selectivity in favour of position 2 can be explained by the fact that carbon C-2 is 
more electron deficient than carbon C-6. Palladium catalyzed cross-coupling reactions 
usually occur at the electronically more deficient position. 109,110 
 
 
 
 
       
       
       
       
       
                    
 
 
Figure  15. possible explanation for the reaction. 
 
 
 
3.3  Conclusion  
 
I have successfully synthesized homo 2,6-diarylbenzoxazole derivatives of the 2,6-
dichlorobenzoxazole by Suzuki-Miyaura reactions. Starting with the same benzoxazole 2-
monoaryl and mixed 2,6-diaryl derivatives could be prepared in a highly site-selective 
way. The monoarylated products were isolated with good site-selectivity, employing 
electron-rich and electron-poor arylboronic  acids. In conclusion, a general Pd(0)-
catalyzed arylation of 2,6-dichlorobenzoxazole with a number of arylboronic acids was 
achieved by Suzuki-Miyaura reactions. The first attack proceeded with very good site-
selectivity at position C-2 which is more electron deficient. 
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4.  Efficient synthesis of arylated isoflavones by site-selective Suzuki-Miyaura cross  
     coupling reactions of the bis(triflates) of 4´,7-dihydroxyisoflavone 
 
4.1 Introduction 
Flavones and Isoflavones (3-arylchromones) are very important oxygenated heterocyclic 
compounds, which belong to the flavonoid group that occur naturally as secondary 
metabolites in fruits, vegetables, seeds and flowers. They play important roles in plant 
development, reproduction and defence and possess a wide range of biological and 
pharmaceutical  activities. This includes antiviral, anti-inflammatory, hepatoprotective, 
antioxidant, antithrombotic, vasodilating and anticarcenogenic activity combining high 
efficiency and low toxicity.111-114 Many studies have shown that e.g. Chrysin has anti-
inflammatory, anti-cancer and anti-oxidative, and anti-HIV effects.115 The natural 
occurring anti-oxidant tangeretin (Fig. 16) shows significant protective effects against 
Parkinson’s disease.116 The main synthetic methods of flavones include the Kostanecki 
reaction, Allan and Robinson synthesis, the Baker-Venkataraman rearrangement and 
several more methods.117-120 several applications of palladium catalyzed cross-coupling 
reactions to flavone-derived halides or triflates have been reported to date121. Flavones 
and Isoflavones are avaliable by transition-metal-catalyzed cross-coupling reactions, such 
as the cyclization of 2-halophenols with terminal acetylenes and carbon monoxide122 or 
by Suzuki-Miyaura cross-coupling reactions of halogenated chromones.123 Flavones have 
been prepared by oxidative addtion of arylboronic acid to chromones124 Prof. Langer’s 
group recently reported the synthesis of arylated flavones by regioselective Suzuki-
Miyaura reactions of the bis(triflates) of 5,7- and 7,8-dihydroxyflavones.125-126  
Herein, I report a convenient approach to arylated isoflavones by what are, to the best of 
my knowledge, the first Suzuki-Miyaura cross-coupling reactions of   the bis(triflates) of 
4´,7-dihydroxyisoflavone. 
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Figure 16. Some examples of flavones natural product. 
 
4.2 Results and discussion  
Commercially available 4´,7-Dihydroxyisoflavone (11) was converted to 4-oxo-3-[4-
(trifluoromethylsulfonyloxy)phenyl]-4H-chromen-7-yl trifluoromethanesulfonate 12 in 
high yield (Scheme 21). 
 
       
             
 
 
 
Scheme 21. Synthesis of 12. Reagents and conditions: i, 11 (1.0 equiv.), pyridine (1.2 
equiv.),  CH2Cl2 (20 ml.), Tf2O (1.2 equiv.), 50°C, 4 h.  
 
 Figure 17.  Molecular structure of 4-oxo-3-[4-(trifluoromethylsulfonyloxy)phenyl]-4H-
chromen-7-yl trifluoro-methanesulfonate 12 in the crystal. Displacement ellipsoids are 
drawn at 50 % probability level. 
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The Suzuki-Miyaura reaction of 12 with arylboronic acids 3b,e,g,h (2.2 equiv.), in the 
presence of (2.2 equiv, 6 mol-%), Pd(PPh3)4 , K2CO3 (2 M, 2 ml), DMF (4 ml), gave the 
4´,7- Bis(aryl)isoflavones 13a-d in 71-82 % yields  (Scheme 22, Table 9). During the 
optimization, it proved to be important to carry out the reactions at 130°C. A higher 
temperature resulted in the formation of significant amounts of diarylated products 13. 
 
      
O
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O
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O
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Scheme 22. Synthesis of 13a-d. Reagents and conditions: i, 12 (1.0 equiv.), 3b,e,g,h (2.2 
equiv.), Pd(PPh3)4 (2.2 equiv, 6 mol-%), K2CO3 (2 M, 2 ml), DMF (4 ml), 130°C, 10 h. 
 
Table  9. Synthesis of 13a-d. 
3 13 Ar 13 (%) a 
b a 4-(MeO)C6H4 82 
e b 4-EtC6H4 71 
g c 4-(OEt)C6H4 77 
h d 4-iProC6H4 80 
                            a Yields of isolated products 
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Optimization of the synthesis of 13a was carried out by using various condition reactions, 
such as K2CO3, KF and NEt3 as bases, in different solvents like toluene, dioxane, DMF   
and THF, besides Pb(OAc)2 and Pd(PPh3)2Cl2 as catalysts at 80-130
oC. In Table 10 are 
summarized these conditions showing the yield percentages of 13a (25-85 %).  
 
Table 10. Optimization of the synthesis of 13a. 
Yield(%)f T(h)e Catalytsd T(0C)c Solventb Basea Entry 
25 8 Pd(OAC)2 100 Toluene K3PO4 1 
38 9 Pd(PPh3)4 110 DMF KF 2 
47 10 Pd(OAC)2 80 Dioxane KF 3 
34 7     Pd(PPh3)2Cl2 120 THF NEt3 4 
45 8 Pd(PPh3)4 120 Dioxane K3PO4 5 
25 10 Pd(OAC)2 90 Toluene K2CO3 6 
85 10 Pd(PPh3)4 130 DMF K2CO3 7 
 
   a K2CO3 (2 M, 2 ml); b DMF (4 ml); c 130oC;  d Pd(PPh3)4(6 mol-%);  e 10 h;    f Yield of  
    isolated products 
 
     
Best results were obtained by using K2CO3 as a base, DMF as solvent, Pd(PPh3)4 as a 
catalyst. Suzuki-Miyaura reaction of 12 with only (1.0 equiv.)  of 3a-c,e-i,l,q-t  in the 
presence of Pd(PPh3)4 (3 mol-%), K2CO3 (2 M, 1 ml), DMF (4 ml), 85°C, 6 h, afforded 
the 4-(4-oxo-7-aryl-4H-chromen-3yl)phenyl trifluoromethanesulfonates 14a-l in 52-88 % 
yields (Scheme 23, Table11). The reactions proceeded with very good rigio-selectivity in 
favour of position 7.  Very good yields were obtained for products derived from both 
electron poor and rich arylboronic acids. The structure of 14a was confirmed by X-ray 
structure (Figure 19). 
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Scheme 23. Synthesis of 14a-l. Reagents and conditions: i, 12 (1.0 equiv.), 3a-c,e-i,l,q,s,t  
(1.0 equiv.), Pd(PPh3)4 (3 mol-%), K2CO3 (2 M, 1 ml), DMF (4 ml), 85°C, 6 h. 
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Table 11. Synthesis of 14a-l. 
3 14 Ar 14 (%) a 
a a 3,5-(Me)2C6H3 76 
b b 4-(MeO)C6H4 80 
c c 4-ClC6H4 58 
e d 4-EtC6H4 70 
f e 4-FC6H4 62 
g f 4-(EtO)C6H4 88 
h g 4-iProC6H4 78 
i h 4-tBuC6H4 65 
l i 4-(Acetyl)C6H4 52 
q j 4-(F3C)C6H4 66 
s k 3-ClC6H4 58 
t l 3,4-(Me)2C6H3 70 
                            a Yields of isolated products 
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Figure 18. Molecular structure of 4-[7-(3,5-dimethylphenyl]-4-oxo-4H-chromen-3-
yl)phenyl trifluoromethanesulfonate (14a) in the crystal. Displacement ellipsoids are 
drawn at 50 % probability level. 
 
The structure of product 14b was elucidated by 2D NMR spectroscopy (NOESY, COSY, 
HMBC, HSQC). A clear and important NOESY correlation between hydrogen atoms H-6 
and H-8 with the ortho protons of the 4-methoxyphenyl group was found.                  
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Figure 19. Important NOESY correlations of 14b. 
 
The one-pot reaction of 12 with two different arylboronic acids (sequential addition of 
the arylboronic acids) afforded 4´,7- bis(aryl)isoflavones 15a-c in 57-68 % yield (Scheme 
24). The reaction was carried out at 85 °C for the first step (to avoid double coupling) and 
at 130°C in the second step. An additional amount of catalyst and base had to be added 
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together with the second arylboronic acid, also DMF (4 ml) has to be added to complete 
the reaction.  
 
                                                     
Scheme 24. Synthesis of 15a-c. Reagents and conditions: i, Ar1B(OH) (1.0 equiv.), 
Pd(PPh3)4 (3 mol-%), K2CO3 (2 M, 1 ml), DMF (4 ml), 85°C, 6 h.; ii, Ar
2B(OH) (2.0 
equiv.), Pd(PPh3)4 (6 mol-%), K2CO3 (2 M, 2 ml), DMF (4 ml), 130°C, 10 h. 
 
 
Table 12. Synthesis of 15a-c. 
3 15 Ar1 Ar2 15 (%)a 
e,b a 4-EtC6H4 4-(MeO)C6H4 70 
a,b b 3,5-(Me)2C6H3 4-(MeO)C6H4 81 
t,b c 3,4-(Me)2C6H3 4-(MeO)C6H4 60 
                 a Yields of isolated products 
The structures of the newly prepared compounds were confirmed by their    IR, 1H, 13C 
NMR and by mass spectra, where 13a-d, 14a-l, 15a-c exhibited additional signals for the 
protons of the newly introduced aromatic ring. 
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Positions 4' and 7 of bis(triflates) 12 are sterically similar. However, the regioselectivity 
of Suzuki-reactions of bis(triflates) 12 in favor of position seven can be explained by 
electronic reasons. Position seven is located para to the electron-withdrawing vinylogous 
ester group. 
 
 
            
              
 
 
 
 
 
Figure 20. Possible explanation for the reaction of bis(triflates) 12. 
 
 
4.3 Conclusion 
 
I have successfully synthesized homo 4´,7-diaryl derivatives of the 4´,7-
bis(trifluoromethylsulfonyloxy)isoflavone by Suzuki-Miyaura reactions. Starting with the 
same isoflavone 7-monoaryl and mixed 4´,7-diaryl derivatives could be prepared in a 
highly site-selective way. In an equimolar reaction the first attack proceeded with very 
good regio-selectivity at position C-7 which is more electron deficient. This method 
provides a conveniet access to aryl-substituted isoflavones which are not readily available 
by other methoed. 
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5.1  Efficient synthesis of arylated coumarins   by   site-selective    Suzuki-Miyaura  
       cross-coupling reactions of the 6,7-bis(trifluoromethanesulphonyloxy)-4-methyl- 
       2H-chromen-2-one and in vitro anti HIV activity 
 
5.1.1 Introduction 
Coumarin and its derivatives are an important classes of heterocyclic compounds which 
occur in many natural products with pharmacological activities.127-132 For example, 
wedelolactone , its isolated from Eclipta elba, and ellagic acid showed highly potential 
biological activity,133-136 while other coumestans were isolated from the roots of 
Hedysarum multijugum,137 and exhibited anti-HIV activity.138 Coumarin compounds are 
known to possess a wide range of biological activities such as antibacterial,139 
anticancer,140,141  and anticoagulants effects.142  Furthermore they may act as anti-HIV 
protease inhibitors,143 anti-HIV integrases,144-145 serine protease inhibitors,146 inhibitors of 
steroid 5α-reductase,147 and NO synthase inhibitors.148 Geiparvarin , a naturally occurring 
product bearing the coumarin residue, has been shown to possess a significant inhibitory 
activity against a variety of cell lines including sarcoma 180, Lewis lung carcinoma, P-
388 lymphocytic leukaemia, and Walker 256 carcinosarcoma.149 New furanocoumar in 
ethers of falcarindol, named japonagelol, have been prepared as novel antiproliferative 
agents.150 In addition, coumarins are widely used as additives in food, perfumes, 
agrochemicals, cosmetics, and dispersed fluorescent and laser dyes.127,151-153 Coumarins 
can be synthesized by various methods, such as Pechmann,154   Perkin,155 Knoevenagel,156 
and Wittig,157-159 reactions.  Palladium-catalyzed site-selective cross-coupling reactions 
of  3-bromo-4-trifluormethylsulfonyloxycoumarin  or  3-bromo-4-tosyloxycoumarin 
provide an efficient and facile route for the synthesis of 3,4-disubstituted coumarins.160 
Herein, I report a new and convenient synthesis of arylated coumarins by site-selective 
Suzuki-Miyaura cross-coupling reactions of the  bis(triflates) of   4-methyl-6,7-
dihydroxycoumarin aiming at an evaluation of their anti-HIV activity. The products 
reported herein are not readily available by other methods. 
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Figure 21. Natural occurring coumarin derivatives. 
 
5.1.2 Results and discussion 
4-Methyl-6,7-dihydroxycoumarin (16) has been selected as a key intermediate for the 
synthesis of new coumarin analogues. Thus, treatment of 16 with triflic anhydride (2.4 
equiv.) in the presence of Et3N (4.0 equiv) at -78
oC afforded the bis(triflates) analogue 17 
in 75 % yield. Reaction of 17 with arylboronic acids 3 (2.0 equiv.) via Suzuki-Miyaura 
reaction gave 4-methyl-6,7-diarylcoumarines 18a-e in 70-88 % yield (Scheme 26). Both 
electron-poor and electron-rich arylboronic acids could be successfully employed. The 
best yields were obtained by using Pd(PPh3)4 (6 mol-%) as a catalyst and K3PO4 (3.0 
equiv) as a base in dioxane at 120°C for 6 h. 
The structures of 17 and 18a-e were assigned on the basis of their 1H and 13C NMR, and 
mass spectra. In The 1H NMR spectra H-3 of the coumarin ring appeared in the region δ 
6.22-6.37 ppm as a doublet (JCH3,H3 ~ 1.2 Hz), while methyl groups at C-4 were resonated 
in the region δ 2.38-2.41 ppm as a doublet as well. H-5 and H-8 protons appeared as 
broad singlets in the regions δ 7.41-7.53 and δ 7.27-7.59 ppm, respectively. The other  
aromatic protons and those of the methoxy and other methyl groups were fully analyzed. 
The 13C NMR spectra of 17 and 18a-e contained similar resonance signals of the 
coumarin carbons ring C-2 - C-8a. The higher-field signals between δC 158.2 and 160.9 
ppm were assigned to the carbonyl group of the benzopyran ring (C-2), while the 
resonances in the regions of δC 112.4-115.1 ppm were assigned to C-3. The chemical 
shifts in the regions δC 151.4-154.4 and 150.5-152.5 ppm were attributed to C-4 and C-
8a, respectively. The resonances at δC 137.1-141.1 and δC 110.9-118.5 ppm were 
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assigned to the coumarin carbons C-7, and C-8, respectively. C-4a carbon atom appeared 
between δC 117.6 and 120.1 ppm, except for 17, which resonated at δC 112.7 ppm. The 
resonances at the regions δC 125.1-126.4 ppm were attributed to C-5, C-6 and carbons of 
aromatic ring, whereas the methyl groups at C-4 appeared in the range δC 17.6-20.3 ppm. 
The carbon atom of CF3 group of 17 appeared as a doublet at δC 117.9 ppm (JC,F = 317.0 
Hz). 
    
                  
 
 
 
Scheme 25. Synthesis of 17, Reagent and conditions: i Et3N, CH2Cl2, 20°C, then Tf2O, -
87C to 20°C, 6 h. 
The structure of 17 was  independently  confirmed by  X-ray crystal  structure analysis 
(Figure 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Molecular structure of 6,7-bis(trifluoromethanesulphonyloxy)-4-methyl-2H-
chromen-2-one 17 in the crystal. Displacement ellipsoids are drawn at the 50 % 
probability level. 
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Scheme  26. Synthesis of 18a-e. Reagent and conditions: i, 17 (1.0 equiv), 3 a-c,g,p (2.0 
equiv.), K3PO4 (3.0 equiv.), Pd(PPh3)4  (6 mol-%), 1,4-dioxane 120°C, 6 h.  
 
Table  13. Synthesis of 18a-e. 
3 18 Ar 18 (%) a 
a a 3,5-(Me)2C6H3 75 
b b 4-(MeO)C6H4 83 
c c 4-ClC6H4 83 
g d 4-(EtO)C6H4 88 
p e C6H4 70 
                              a Yields of isolated products 
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Figure 23. Molecular structure of 6,7-bis(4-ethoxyphenyl)-4-methyl-2H-chromen-2-one 
18d in the crystal. Displacement ellipsoids are drawn at the 50 % probability level. 
 
Next, treatment of 17 with arylboronic acids 3 (1.2 equiv.) via Suzuki-Miyaura reaction 
furnished 7-aryl-4-methyl-6-trifluorosulfonyloxy-coumarins 19a-m in 70-90 % yield 
with highly site-selectivity (Scheme 27). During the optimization, it proved to be 
important to use (1.2 equiv.) of the arylboronic acid and to carry out the reaction at 70 oC 
instead of 120 °C by using dioxane as a solvent for 6 h. Both electron-poor and electron-
rich arylboronic acids were successfully used. 
 
The one-pot Suzuki-Miayura reaction of bis-triflates 17 with two different arylboronic 
acids 3 (sequential addition of 1.2 equiv. of each boronic acid), first with 4-
methoxphenylboronic acid (3b) (1.2 equiv.) gave the unseparated 19b, which on further 
treatment with arylboronic acids 3a,c,f,j (1.2 equiv.) afforded the 6,7-diaryl-4-
methylcoumarin 20a-d 73-81% yields. The reactions were carried out at 70°C for the first 
step (to avoid double coupling) and at 120°C for the second step. 
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Scheme 27. Synthesis of 19a-m. Reagent and conditions: i, 17 (1.0 equiv), 3a-f,g,i-j,o-r 
(1.2 equiv.), K3PO4 (1.5 equiv.), Pd(PPh3)4  (3 mol-%), 1,4-dioxane, 70°C, 6 h. 
 
Table 14. Synthesis of 19a-m. 
3 19 Ar 19 (%) a 
a a 3,5-(Me)2C6H3 75 
b b 4-(MeO)C6H4 80 
c c 4-ClC6H4 85 
d d 4-MeC6H4 75 
e e 4-EtC6H4 84 
f f 4-FC6H4 78 
g g 4-(EtO)C6H4 90 
i h 4-tBuC6H4 77 
j i 3-MeC6H4 80 
o j 2,3,4(MeO)3C6H2 90 
p k C6H5 72 
q l 4-(F4C)C6H4 83 
r m 3-(MeO)C6H4 70 
                                   a Yields of isolated products                     
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Scheme 28. Synthesis of 20a-d. Reagent and conditions: i, 2 (1.0 equiv), Ar1B(OH)2 (1.2 
equiv.), K3PO4 (1.5 equiv.), Pd(PPh3)4  (3 mol-%), 1,4-dioxane, 70°C 6 h. ii, Ar
2B(OH)2 
(1.2 equiv.), K3PO4 (1.5 equiv.), Pd(PPh3)4  (3 mol-%), 1,4-dioxane, 120°C 6 h.  
 
Table 15. Synthesis of 20a-d. 
3 20       Ar1     Ar2 20 (%)a 
b,c a 4-(MeO)C6H4 4-ClC6H4 73 
b,f b 4-(MeO)C6H4 4-FC6H4 78 
b,j c 4-(MeO)C6H4 3-MeC6H4 75 
b,a d 4-(MeO)C6H4 3,5(Me)2C6H3 81 
                        a Yields of isolated products 
 
Compounds  19a-m were identified from the 1H NMR and 13C NMR spectra, which 
showed almost similar resonances of benzopyran ring atoms as those of 18a-e. H-3, and 
methyl group at C-4 appeared as two doublets with long range couplings in the regions δH 
2.31-2.42 and 6.24-6.33 ppm, respectively (JCH3,H3 ~ 1.3 Hz). H-5 and H-8 protons 
appeared as broad singlets in the regions δH 7.52-7.36 and 7.45-7.52 ppm, respectively. 
The aromatic protons resonated as multiplets or doublets between δH 6.80 and 7.47 ppm, 
while the other alkyl protons were fully analyzed.  
 
In the 13C-NMR spectra of 19a-m, the resonances at δc = 158.4-163.9 ppm were 
attributed to the carbonyl group (C-2). The carbon atoms C-3 and C-4 of the benzopyran 
ring resonated in the regions δc = 113.8-115.6 and 158.6-150.9 ppm, respectively, while 
C-4a and C-5 appeared in the regions δc = 115.5-119.5 and 115.1-117.5 ppm, 
respectively. Aromatic C-6 - C-8a, atoms and carbons atoms of the substituents were 
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fully assigned. Compound 19b was selected for further NMR studies. In the gradient-
selected HMBC spectrum161 of 19b, the olefinic proton (H-3) at δH = 6.50 ppm showed 
two 2JC,H couplings: one to the carbonyl carbon atom of the the coumarin ring (C-2) at δC 
160.9 ppm and the other coupling was with C-4 at δC 151.3 ppm. A 3JC,H between 
coupling between H-8 of coumarin ring at δH 6.60 ppm and aromatic carbon atom (C-1') 
at δC 136.8 ppm was assigned. Furthermore, in the NOESY spectrum,162 a correlation 
between the protons of methyl group at C-4 and H-3 as well as between H-8 of coumarin 
ring and the aromatic protons H-2' and H-6' (Figure 24) was detected.  
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Figure  24.  JC,H correlations in the HMBC (single head arrows), and NOESY (double 
head arrows) correlations of 19b. 
 
The 1H NMR and 13C NMR spectra of 20a-d were in agreement with the suggested 
structures. The resonances of H-5 and H-8 prortons oriented in the regions at δH 7.46-
7.48 and 7.26-7.28 ppm, respectively, which differ from those of the analogues 19a-m  
due to the substitution of the triflates group at C-6 by the aryl moieties. In the 13C NMR 
spectra, C-5 and C-6 carbon atoms appeared in the regions δC 129.7-130.5 and 131.0-
135.4 ppm, respectively, whereas C-8 carbon atoms were resonated in the region δC 
117.1-117.8 ppm. Additional support of the proposed structures comes from mass 
spectral data.Mass spectra of the prepared compounds 19 and 20 showed the correct 
molecular ions, (M+·), as suggested by their molecular formulas. 
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The structure of 19b was independently confirmed by X-ray crystal structure analysis 
(Figure. 25). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Molecular structure of 7-(4-methoxyphenyl)-4-methyl-6-O-
trifluoromethanesulphonyloxy-2H-chromen-2-one (19b) in the crystal. Displacement 
ellipsoids are drawn at the 50 % probability level. 
 
Positions six and seven of bis (triflates) 17 are sterically similar. However, the 
regioselectivity of Suzuki reactions of bis (triflates) 17 in favor of position seven can be 
explained by electronic reasons. Position seven is located para to the electron-
withdrawing vinylogous ester group, while position six is located para to the electron-
donating oxygen atom. 
                       
                    
 
 
 
 
 
Figure  26. possible explanation for the reaction . 
1
2
more electron deficient
less electron def icient
O O
Me
TfO
TfO
Second attack
First attack
 51 
 
The reactions proceed with excellent regioselectivity in faver of the electronically more 
deficient position.   
         
5.1.3   In vitro anti HIV activity 
Compounds 18a-e, 19a-m and 20a-d were tested by our collaboration partners (group of 
Prof. Dr. Najim Al-Masoudi) for their in vitro anti-HIV-1 (strain IIIB) and HIV-2 (strain 
ROD) activity in human (MT-4) cells based on an MTT assay.163 The results are 
summarized in Table 16, in which the data for nevirapine (BOE/BIRG587)164 and 
azidothymidine (DDN/AZT)165 are included for comparison purposes. Compound-
induced cytotoxicity was also measured in MT-4 cells parallel with the antiviral activity. 
 
Compounds 18a and 19j were found to be the only compounds from the series inhibiting 
HIV-1 replication in a cell culture, which showed an IC50 of 4.57 μg mL-1 and 13.20 μg 
mL-1 with CC50 of 14.40 μg mL-1 and 61.34 μg mL-1, respectively, resulting in a 
selectivity index of 3 and 5. On the other hand, 19k, 20a, and 20d showed some activity 
against  HIV-1 (IIIB strain) with IC50 > 2.13,  > 2.06 and > 2.08 μg mL-1, respectively, but 
no  selectivity was witnessed (SI  < 1). 
  
However, implantation of methyl groups in 3 and 5 positions of both phenyl groups at C-
6 and C-7 of the coumarin ring (compound 18a) or methyl group in 3 position of phenyl 
residue at C-7 together with the triflates at C-6 of the coumarin ring (compound 19j) 
considerably increased the anti-HIV-1, anti-HIV-1 activity, in comparison to the 
effectiveness of other functional groups. 
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Table 16. In vitro anti-HIV-1a and HIV-2b activity and cytotoxicity of some new 
coumarins. 
Entry 
HIV-1 (IIIB) 
IC50 (µg mL-1)c 
HIV-2 (ROD) 
IC50 (µg mL-1)c 
CC50 
(µg mL-1)d 
SIe 
(IIIB) 
SIe 
(ROD) 
17 >43.50 >43.50 43.50 <1 <1 
18a 4.57 >14.40 14.40 3 <1 
18b >11.00 >11.00 11.00 <1 <1 
18c >15.98 >15.98 15.98 <1 <1 
18p >13.78 >13.78 13.78 <1 <1 
18g >37.31 >37.31 37.31 <1 <1 
19a >33.10 >33.10 33.10 <1 <1 
19b >10.60 >10.60 ≥10.60 <orX1 <orX1 
19c >30.65 >35.65 35.65 <1 <1 
19d >12.55 >12.55 12.55 <1 <1 
19e >27.20 >27.20 ≥27.20 <orX11 <orX1 
19f >10.63 >10.63 10.63 <1 <1 
19g >80.33 >80.33 80.33 <1 <1 
19h 
19i 
19j 
19k 
19l 
20a 
20b 
20c 
20d 
Nevirapine 
>11.00 
13.20 
>18.86 
>2.13 
>10.28 
>2.06 
>10.92 
>7.40 
>2.08 
0.050  
>11.00 
>61.34 
>18.86 
>2.13 
>10.28 
>2.06 
>10.92 
>7.40 
>2.08 
>4.00 
11.00 
61.34 
18.86 
2.13 
10.28 
2.06 
10.92 
7.40 
2.08 
>4.00 
<1 
5 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
>80 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
 AZT 0.0022  0.00094 >25  >11363 >26596 
a Anti-HIV-1 activity measured with  strain IIIB;        b  anti-HIV-2 activity         measured     with 
 Strain ROD; c compound concentration required to achieve 50% protection of MT-4 cells from 
the HIV-1 and HIV-2-induced cytopathic effect;d compound concentration that reduces the 
viability of mock-infected MT-4 cells by 50 %; e SI: selectivity index (CC50/IC50) 
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5.1.4  Conclusion 
I have successfully synthesized homo 6,7-diaryl derivatives of the 4-methyl-6,7-
(trifluoromethylsulfonyloxy)coumarin by Suzuki-Miyaura reactions. Starting with the 
same coumarin 7-monoaryl and mixed 6,7-diaryl derivatives could be prepared in a 
highly site-selective way.The first attack proceeded with very good regio-selectivity at 
position C-7 which is more electron deficient. 
The anti-HIV activity and the selectivity of these compounds are too limited to perform 
extensive mode-of-action studies, and 18a and  19j might be considered as a new lead in 
the development of antiviral agents as non-nucleoside reverse transcriptase inhibitors.  
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5.2  Arylation of 3-bromo-4-methyl-6,7-triflate coumarin by Suzuki-Miyaura cross-  
       coupling reactions 
        
5.2.1 Results and discussion 
 
At first I would like to present a simple bromination method to prepare   3-bromo-6,7-
dihydroxy-4-methyl-2H-chromen-2-one (21)  in one step, and high yield by using 
bromine. The bromodihydroxycoumarin was prepared by reaction of commercially 
available 4-methyl-6,7-dihdroxycoumarin (16) with bromine in glacial acitic acid within 
2 h    (Scheme 29) . 
 
O O
Me
HO
HO O O
Me
HO
HO
Br
16 21
i
Br2
 
 
Scheme    29. Synthesis of 21 Reagent and conditions: i 16 (1.0 equiv), Br2 (2.0 equiv), 
CH3CO2H (20 ml), 30C, 2 h.  
 
The structure of 21 was independently confirmed by 1H NMR ,13C, mass spectroscopy 
and 2D NMR (Figure 27). 
 
                                             
O O
HO Br
H
HO
H C H3
NOESY
HMBC  
Figure   27.  JC,H   correlations in the  HMBC (single head arrow), and NOESY (double 
head arrow) correlations of  21.  
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In the next step synthesis of 3-bromo-4-methyl-2-oxo-2H-chromene-6,7-
diylbis(trifluoromethanesulfonate) (22) by the treatment of compound (21) with Tf2O at   
-78°C. The mixture was allowed to warm to 20°C and stirred for 6 h.  
                                                                                                                   
                           
O
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HO
HO O
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TfO
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Scheme 30. Synthesis of 22. Reagent and conditions: i 21 (1.0 equiv), Et3N (4.0 equiv), 
CH2Cl2, 20°C; Tf2O (2.4 equiv), -78C to 20°C, 6 h.  
 
The structure of 22   was independently confirmed by X-ray ceystal structure analysis 
(Figure 28). 
 
                                            
                                                          
 
 
 
 
 
 
 
 
                                       
 
Figure 28. Molecular structure of 3-bromo-4-methyl-2-oxo-2H-chromene-6,7-
diylbis(trifluoromethanesulfonate) (22) in the crystal. Displacement ellipsoids are drawn 
at the 50 % probability level. 
 
 56 
 
The Suzuki-Miyaura reaction of 22  with arylboronic acids 3a-j,o,q,r,u (3.1 equiv.) 
afforded 4-methyl-3,6,7-tris(aryl)coumarines 23a-o 60- 84 % yields  (Scheme 31, Table 
17). The best yields were obtained when the reactions were carried out using Pd(pph3)4 as 
the catalyst and K2CO3 as the base (dioxane, 120°C, 10 h). Both electron-rich and 
electron-poor arylboronic acid were successfully employed. The yield of the products 
derived from arylboronic acids containing electron-withdrawing substituents, which are 
less nucleophilic, were lower than the yield of products derived from arylboronic acid 
containing electron-donating substituents. Unfortunately, all attempts to develop 
regioselective Suzuki-Miyaura reactions failed. 
 
                     
O
Me
TfO
TfO O O O
Me
Ar
Ar
i
ArB(OH)2Br Ar
22 23a-o  
 
Scheme   31. Synthesis of 23a-o. Reagents and conditions: i, 22 (1.0 equiv.), 3a-j,o,q,r-u 
(3.1 equiv.), Pd(PPh3)4 (14 mg, 9 mol-%), K2CO3 (aq. solution, 2 M), 1,4-dioxane, 
120°C, 10 h. 
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Table 17. Synthesis of 23a-o. 
3 23 Ar 23 (%) a 
a a 3,5-(Me)2C6H3 70 
b b 4-(MeO)C6H4 80 
c c 4-ClC6H4 60 
d d 4-MeC6H4 75 
e e 4-EtC6H4 75 
f f 4-FC6H4 70 
g g 4-(EtO)C6H4 84 
h h 4-iProC6H4 77 
i i 4-tBuC6H4 62 
j j 3-MeC6H4 70 
o k 2,3,4-(MeO)3C6H2 80 
q l 4-(F3C)C6H4 63 
r m 3-(MeO)C6H4 80 
t n 3,4-(Me)2C6H4 60 
u o 4-iPrC6H4 70 
                               a Yields of isolated products 
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The structure of 23f was independently confirmed by 2D NMR (Figure 29). 
                                        
O O
FF
F
HMBC
H3 C
NOESY
 
Figure   29.  JC,H   correlations in the  HMBC (single head arrow), and NOESY (double 
head arrow) correlations of  23f. 
The structure of 23i was independently confirmed by X-ray crystal structure analysis 
(Figure 30). 
Figure 30. Ortep plot of 23i. 
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5.2.2 Conclusion 
I have synthesized 4-methyl-3,6,7-tris(aryl)coumarines (23)  from 3-bromo-4-methyl-2-
oxo-2H-chromene-6,7-diyl bis(trifluoromethanesulfonate) by Suzuki-Miyaura reactions. 
Both electron-poor and rich-arylboronic acids were successfully employed, This method 
provides a conveniet access to triarylsubstituted coumarines which are not readily 
available by other methods. Unfortunately, all attempts to develop regioselective Suzuki-
Miyaura reactions failed.    
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SUMMARY 
 
A significant part of this dissertation has been published (see list of publications). The 
task of my thesis was to study palladium(0) catalyzed Suzuki cross-coupling reactions of 
various types of triflates or bromine compounds of different molecules (isatins, 
banzoxazols, isoflavones, coumarines). The triflates are readily available from the 
corresponding hydroxy compounds. The issue of site-selectivity plays an important role 
in my thesis. In this context, steric and electronic parameters have been investigated. 
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I was studying palladium(0) catalyzed Suzuki cross-coupling reactions of 4,7-
dichloromethylisatin. The reactions proceed with excellent site-selectivity. The first 
attack occurs at position C-4 which is more electron deficient than position C-7 (Scheme 
I). Palladium catalyzed cross-coupling reactions usually occur at the electronically more 
deficient position.  
 
 
Scheme I 
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Suzuki-Miyaura reactions of the 2,6-dichlorobenzoxazole proceed with very good site-
selectivity in favour of position C-2 which is more electron deficient than position C-6 
(Scheme II). Palladium catalyzed cross-coupling reactions usually occur at the 
electronically more deficient position. 
 
 
 
 
Scheme II 
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The reaction of 4´,7-dihydroxyisoflavone with two equivalent of triflic anhydride leads to 
preparations of 4´,7-bis(trifluoromethylsulfonyloxy)isoflavone.The subsequent Suzuki-
Miyaura reaction of the product allows  the synthesis of  7-monoaryl, homo 4´,7-diaryl 
and imixed 4´,7-diaryl derivatives. The reactions proceed with very good site-selectivity 
in favour of position C-7 which is more electron deficient than position C-4´ (Scheme 
III). 
 
         
                                                       Scheme III 
 
 
 
 
1.0 eq Ar1B(OH)2
1.0 eq Ar2B(OH)2
1.0 eq ArB(OH)2 2.0 eq ArB(OH)2
2.4 eq (Tf2O)2O
O
HO
O
OH
O
TfO
O
OTf
O
Ar
O
ArO
Ar
O
OTf
O
Ar1
O
Ar2
11
12
13a-d
15a-d
14a-l
 64 
 
The treatment of 4-methyl-6,7-dihydroxycoumarin with two equivalent of triflic 
anhydride leads to preparations of  4-methyl-6,7-
bis(trifluoromethylsulfonyloxy)coumarin.The subsequent  palladium(0) catalyzed 
reaction of the product afforded various  4-methyl-6,7-di(aryl)coumarins.The reactions 
proceed with very good site-selectivity in favour of position C-7 which is more electron 
deficient than position C-6 (Scheme IV). 
 
 
 
 
                                                                 Scheme IV  
 
 
1.0 eq Ar1B(OH)2
1.0 eq Ar2B(OH)2
1.0 eq ArB(OH)2 2.0 eq ArB(OH)2
2.4 eq (Tf 2O)2O
O
Me
HO
HO O
O
Me
TfO
TfO OO
Me
TfO
Ar O O
Me
Ar
Ar O
O
Me
O
Ar2
Ar1
16
17
18a-e
20a-d
19a-m
 65 
 
 
 
Development simple bromination method to prepare 3-bromo-6,7-dihydroxy-4-methyl-
2H-chromen-2-one in one step.The treatment of the bromocoumarin with two equivalent 
of triflic anhydride leads to preparations of 3-bromo-6,7-bis(trifluoromethylsulfonyloxy)-
coumarin.The palladium(0) catalyzed Suzuki cross-coupling reaction of the product 
afforded various 3,6,7-triarylcoumarins  in very good yields (Scheme V). 
 
 
 
              
       
 
 
 
 
 
 
 
 
 
Scheme V 
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7.    Experimental Section 
7.1  General:  Equipment, Chemicals and Work Technique 
NMR Spectroscopy  
Bruker AC 250, Bruker ARX 300, Bruker ARX 500. For NMR characterization the one-
dimensional 1H NMR, proton-decoupled 13C NMR, and DEPT 135 spectra were 
collected. If necessary, other techniques (NOESY, COSY, HMQC, HMBC) were applied 
as well. All NMR spectra presented in this work were collected in CDCl3 solution. All 
chemical shifts are given in ppm.  
References (1H NMR): TMS (δ = 0.00) or residual CHCl3 (δ = 7.26) were taken as 
internal standard.  
References (13C NMR): TMS (δ = 0.0) or residual CHCl3 (δ = 77.0) were taken as 
internal standard.  
Multiplicities are given as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, br = broad signal. More complex coupling patterns are represented by 
combinations of the respective symbols. For example, td indicates a triplet of doublets 
with the larger coupling constant associated with the first symbol (here: triplet). 
  
Infrared Spectroscopy (IR)  
Nicolet 205 FT-IR, Nicolet Protége 460 FT-IR. Peaks are given the following 
assignments: w = weak, m = medium, s = strong, br = broad.  
 
Mass Spektrometry (MS)  
AMD MS40, Varian MAT CH 7, MAT 731 (EI, 70 eV), Intecta AMD 402 (EI, 70 eV 
and CI), Finnigan MAT 95 (CI, 200 eV).  
 
High Resolution Mass Spectrometry (HRMS)  
Varian MAT 311, Intecta AMD 402.  
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Elemental Analysis  
LECO CHNS-932, Thermoquest Flash EA 1112.  
Melting Points  
Micro heating table HMK 67/1825 Kuestner (Büchi Apparatus), Leitz Labolux 12 Pol 
with heating table Mettler FP 90. Melting points are uncorrected.  
X-ray Structures 
Bruker X8Apex diffractometer with CCD camera (Mo Kα radiation and graphite 
monochromator, λ = 0.71073 Å). The space group is determined by the XPREP program 
and the structures were solved via the SHELX-97 program package. Refinements were 
carried out according to the minimum square error method.  
Thin Layer Chromatography (TLC)  
Merck Kieselgel 60 F254 on aluminium foil from Macherey-Nagel. Detection was 
carried out under UV light at 254 nm and 365 nm. As colourizing reagent the following 
mixtures were used: 1-2/100 p-Anisaldehyde or vanillin, 10/100 glacial acetic acid, 5/100 
sulphuric acid, 83-84/100 methanol.  
Column Chromatography  
Column chromatography was performed with Merck Silica Gel 60 or Macherey-Nagel 
Silica Gel 60 (0.063-0.200 mm, 70-230 mesh). The finer Merck Silica Gel 60 (0.040-
0.063 mm, 230-400 mesh) was chosen when appropriate.  
 
Chemicals and work technique 
 
All solvents for using were distilled by standard methods. All reactions were carried out 
under an inert atmosphere, oxygen and humidity exclusion. All of the chemicals are standard, 
commercially available from Merck®, Aldrich®, Arcos® and others.    
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7.2 Procedures and spectroscopic data 
Synthesis of 4,7-dichloro-1-methylindoline-2,3-dione (2): 
Isatin (1 equiv.) was taken up in anhydrous DMF (1 ml per 0.1 mmol 
isatin) and cooled on ice with stirring. Solid K2CO3 (1.2 equv.) was 
added in one portion, and the dark colored suspension was brought to 
room temperature and stirred for afurther 1 h.The appropriate CH3I (1.1 
equiv.) and KI (0.2 equiv.) were added, and the reaction material had been consumed 
(TLC). The reaction mixture was poured into HCl (0.5 M, 50 ml) and extracted with ethyl 
acetate (1 x 50 ml).The ethyl acetate layer was washed with brine and dried over 
Mg2SO4. The solvent was removed, and the curde product was purified via flash column 
chromatography using CH2Cl2, 2 was isolated as orange solid (69 mg, 90 %);  mp 173- 
175°C. 1H NMR (300 MHz, CDCl3): δ =  3.57 (s, 3H, CH3), 6.95 (d, J = 8.78 Hz, 1H, 
ArH), 7.37 (d, J = 8.78 Hz, 1H, ArH).13C-NMR (75.4 MHz, CDCl3):  = 29.8 (NCH3), 
115.7, 116.6 (C), 126.6 (CH), 132.8 (C), 140.3 (CH), 147.7 (C), 157.7, 179.3 (CO). IR 
(KBr, cm-1): v = 3450, 3075, 3063, 2952, 2921, 2851, 1788 (w), 1728, 1584 (s), 1584, 
1494 (w). GC-MS (EI, 70 eV): m/z (%) = 228 ([M]+, 2x[35Cl]  ,100), 203 (21), 201 (21), 
200 (10), 174 (78), 160 (12), 158 (16), 151 (12), 111 (17). HRMS (EI, 70 eV): calcd for 
C9H5
35Cl2NO2 [M]
+: 228.96973; found: 228.96932. 
 
General procedure for synthesis (4a-f) 
The reactions were carried out in a pressure tube.To a dioxane suspension (3 ml) of 2 (70 
mg, 0.3043 mmol), Pd(PPh3)4 (21 mg, 6 mol-%, 0.01818 mmol), arylboronic acid 3 
)0.669 mmol) K3PO4 (202 mg, 0.91302 mmol) was added.The mixture was heated at 
120oC under Argon atmosphere for 8 h. The reaction mixture was diluted with water and 
extracted with CH2Cl2 (3 x 25 ml). The combined organic layers were dried (Na2SO4), 
filtered and the filtrate was concentrated in vacuo. The residue was purified by flash 
chromatography (silica gel, EtOAc / heptane = 8:2).  
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4,7-Bis(3,5-dimethylphenyl)-1-methylindoline-2,3-dione (4a): 
Starting with 2 ( 70 mg,  0.3043 mmol ) , 3a (100 mg, 
0.6695 mmol), Pd(PPh3)4 (21 mg, 6 mol-%, 0.01818 
mmol),  K3PO4 (202 mg, 0.9130 mmol),  and 1,4-dioxane 
(3 ml), 4a was isolated as a red solid (69 mg, 61 %);  
mp164 -166°C.1H NMR (300 MHz, CDCl3): δ =  2.29 (s, 
12H, 4xCH3), 3.20 (s, 3H, CH3), 6.70 (d, J = 8.6 Hz, 2H, ArH), 6.97 (d, J = 8.3 Hz, 2H, 
ArH), 7.16 - 7.19 (m, 2H, ArH), 7.57 (t, J = 8.3 Hz, 2H, ArH).13C NMR (75.46 MHz, 
CDCl3):  = 21.3 (4xCH3), 33.7 (NCH3), 126.7, 130.8, 137.5 (CH), 125.7, 129.7 (C), 
131.8, 137.5, 139.2 (CH), 143.3, 145.0, 147.6, 147.8, 152.2, 157.3, 157.5, 158.2 (C),  
166.4, 180.9 (CO). IR (KBr, cm-1): v  = 3075, 2953, 2919, 2852 (w), 1742, 1723 (s), 
1605, 1585, 1564, 1499 (m).  GC-MS (EI, 70 eV):  m/z (%) =  369 ([M]+,100),  344 (23), 
332 (11), 220 (16), 163 (10), 120 (10) . HRMS (EI, 70 eV) calcd for C25H23NO2 ([M]
+):  
369.17233 found:  369.17211. 
 
4,7-Bis(4-methoxyphenyl)-1-methylindoline-2,3-dione (4b):  
Starting with 2 ( 70 mg,  0.3043 mmol ) , 3b 
(102 mg, 0.6695 mmol), Pd(PPh3)4 (21 mg, 6 
mol-%, 0.01818 mmol),  K3PO4 (202 mg, 
0.91302 mmol),  and 1,4-dioxane (3 ml), 4b was 
isolated as a red solid (93 mg, 82 %);  mp 220-222°C.1H NMR (300 MHz, CDCl3): δ = 
3.20 (s, 6H, 2xOCH3), 3.79 (s, 3H, CH3), 6.73 (dd, J = 8.3, 2.4 Hz, 2H, ArH), 6.97 (d, J = 
8.0 Hz, 2H, ArH), 7.16 - 7.19 (m, 4H, ArH), 7.55 (d, J = 8.0 Hz, 2H, ArH). 13C NMR 
(75.46 MHz, CDCl3):  = 20.8 (NCH3), 33.7 (2xOCH3), 38.1 (C), 119.3, 124.7, 125.1, 
128.6, 128.9, 129.6 (CH), 130.6, 130.8, 132.4, 132.4, 134.9, 144.3, 146.5 (C), 160.6, 
181.2 (CO).  IR (KBr, cm-1): v  = 3074, 2952, 2918, 2851 (w), 1743, 1724 (m), 1605, 
1586, 1564, 1497, 1488 (s).  GC-MS (EI, 70 eV):  m/z (%) =  373 ([M]+,100),  364 (23), 
365 (11), 310 (16), 311 (32), 210 (34), 174 (10), 134 (23) . HRMS (EI, 70 eV) calcd for 
C23H19NO4 ([M]
+):  373.13141;  found:  373.13100. 
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4,7-Bis(4-chlorophenyl)-1-methylindoline-2,3-dione (4c):  
Starting with 2 ( 70 mg,  0.3043 mmol ) , 3c (104 mg, 
0.6695 mmol), Pd(PPh3)4 (21 mg, 6 mol-%, 0.01818 
mmol), K3PO4 (202 mg, 0.91302 mmol),  and 1,4-
dioxane (3 ml), 4c was isolated as a red solid (60 mg, 
52 %);  mp 231-232°C. 1H NMR (300 MHz, CDCl3): δ = 3.20 (s, 3H, CH3), 6.81 (d, J = 
8.2 Hz, 2H, ArH), 7.10 (d, J = 8.1 Hz, 2H, ArH), 7.22 - 7.26 (m, 4H, ArH),  7.10 (t, J = 
7.8 Hz, 2H, ArH). 13C NMR (75.46 MHz, CDCl3):  = 33.0 (NCH3), 107.8, 112.6, 119.2, 
124.5, 127.2, 128.4 (C), 129.2, 130.9 (CH), 132.5, 134.9 (C), 140.7, 144.1, 146.6, 151.3 
(CH), 156.4, 180.9 (CO).  IR (KBr, cm-1): v  = 3074, 2952, 2919, 2851 (w), 1743, 1724 
(s), 1605, 1586, 1565, 1499 (m).  GC-MS (EI, 70 eV):  m/z (%) =  381  ([M]+, 2x 
[35Cl],100),  352 (23), 252 (11), 250 (16) . HRMS (EI, 70 eV) calcd for C21H13
35Cl2NO2  
([M]+, 2x [35Cl]):  381.03233;  found:  381.03211. 
 
1-Methyl-4,7-dip-tolylindoline-2,3-dione (4d):  
Starting with 2 ( 70 mg,  0.3043 mmol ) , 3d (90 
mg, 0.6695 mmol), Pd(PPh3)4 (21 mg, 6 mol-%, 
0.01818 mmol), K3PO4 (202 mg, 0.91302 mmol), 
and 1,4-dioxane (3 ml), 4d was isolated as a red 
solid (60 mg, 58 %);  mp154-155°C. 1H NMR (300 MHz, CDCl3): δ =  2.27 (s, 6H, 
2xCH3), 3.19 (s, 3H, CH3), 6.73 (d, J = 8.3 Hz, 2H, ArH), 6.99 (d, J = 8.0 Hz, 2H, ArH), 
7.16 (t, J = 7.8 Hz, 4H, ArH), 7.57 (t, J = 8.3 Hz, 2H, ArH). 13C NMR (75.46 MHz, 
CDCl3):  = 26.8 (2xCH3), 33.7 (NCH3), 108.1, 113.7, 120 (CH), 125.7, 129.7 (C), 131.8, 
137.5, 139.2 (CH), 143.3, 145.0, 147.6, 147.6, 152.2, 157.9 (C),  165.4, 181.9 (CO).  IR 
(KBr, cm-1): v  = 3074, 2952, 2918, 2851 (w), 1743, 1724 (s), 1605, 1586, 1564, 1497 
(m).  GC-MS (EI, 70 eV):  m/z (%) =  341 ([M]+,100),  244 (23), 232 (11), 210 (16), 164 
(10) . HRMS (EI, 70 eV) calcd for C23H19NO2 ([M]
+):  341.14158,  found:  341.14124. 
 
 
 
 
N Me
O
O
Cl Cl
N Me
O
O
Me Me
 71 
 
4,7-Bis(4-ethylphenyl)-1-methylindoline-2,3-dione (4e): 
Starting with 2 ( 70 mg,  0.3043 mmol ) , 3e (100 
mg, 0.6695 mmol), Pd(PPh3)4 (21 mg, 6 mol-%, 
0.01818 mmol), K3PO4 (202 mg, 0.91302 mmol),  
and 1,4-dioxane (3 ml), 4e was isolated as a red 
solid (73 mg, 65 %);  mp 123-125°C.1H NMR (300 MHz, CDCl3): δ = 1.30 (m, 6H, 
2xCH3), 2.22 (m, 4H, 2xCH2), 3.19 (s, 3H, CH3), 6.73 (dd, J = 8.3, 2.4 Hz, 2H, ArH), 
6.99 (d, J = 8.0 Hz, 2H, ArH), 7.16 (d, J = 7.8 Hz, 4H, ArH), 7.57 (t, J = 8.3 Hz, 2H, 
ArH). 13C NMR (75.46 MHz, CDCl3):  = 20.8 (2xCH3), 24.6 (2xCH2), 33.7 (NCH3), 
37.1 (C), 119.1, 124.8, 125.0, 128.7, 128.8, 129.6 (CH), 130.7, 130.9, 132.4, 132.5, 
134.9, 144.1, 146.6 (C), 160.4, 180.2 (CO).  IR (KBr, cm-1): v  = 3074, 2952, 2918, 2851 
(w), 1743, 1724 (s), 1605, 1586, 1564, 1497 (m).  GC-MS (EI, 70 eV):  m/z (%) =  369 
([M]+,100),  344 (23), 332 (11), 210 (16), 164 (10), 154 (23) . HRMS (EI, 70 eV) calcd 
for C25H23NO2 ([M]
+):  369.17288,  found:  369.17255. 
 
4,7-Bis(4-fluorophenyl)-1-methylindoline-2,3-dione (4f): 
 Starting with 2 ( 70 mg,  0.3043 mmol ) , 3f (92 mg, 
0.6695 mmol), Pd(PPh3)4 (21 mg, 6 mol-%, 0.01818 
mmol),  K3PO4 (202 mg, 0.91302 mmol),  and 1,4-
dioxane (3 ml), 4f was isolated as a red solid (76 mg, 
72 %);  mp 190-192°C. 1H NMR (300 MHz, CDCl3): δ =  3.10 (s, 3H, CH3), 6.75 - 6.79 
(m, 2H, ArH), 6.94 - 7.05 (m, 4H, ArH), 7.31 (t, J = 8.2 Hz, 2H, ArH), 7.46 - 7.50 (m, 
2H, ArH). 13C NMR (75.46 MHz, CDCl3):  = 19.6 (NCH3), 69.2, 77.2, 100.6 (d, J = 
26.4 Hz ), 100.7 (d, J = 22.6 Hz ), 100.8 (d, J = 20.6 Hz ), 110.9 (d, J = 30.6 Hz )(CH), 
115.2 (q, JF,C = 322.1 Hz), 115.5 (q, JF,C = 280.1 Hz)(CF), 124.4, 125.7, 128.9 (C), 130.2 
(q, JF,C = 280.1 Hz)(CF), 130.9  (q, JF,C = 280.1 Hz)(CF), 146.2 (C), 160.3, 180.1 (CO).
 19F 
NMR (282 MHz, CDCl3): δ =  -114.4,  -112.0 (ArF). IR (KBr, cm-1): v =  3273, 3065, 
2957, 2922, 2851 (w), 1782 (s), 1727, 1716, 1687, 1603, 1580 (w). GC-MS (EI, 70 eV):  
m/z (%) =  394 ([M]+, 100),  370 (17),  369 (30), 265 (10), 255 (23), 188 (34), 165 (12). 
HRMS (EI, 70 eV) calcd for  C21H13F2NO2 [M]
+:  349.09144 ;  found:  349.09100. 
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General procedure for synthesis (5a-d,f-m) 
The reactions were carried out in a pressure tube.To a 1,4-dioxane suspension (3 ml) of 2 
(70 mg, 0.3043 mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 0.00952 mmol), and arylboronic acid 
)0.365 mmol) was added K3PO4 (96 mg, 0.4565 mmol), The mixture was heated at 70oC 
under Argon atmosphere for 6 h. The reaction mixture was diluted with water and 
extracted with CH2Cl2 (3 x 25 ml). The combined organic layers were dried (Na2SO4), 
filtered and the filtrate was concentrated in vacuo. The residue was purified by flash 
chromatography (silica gel, EtOAc / heptane = 8:2 ). 
  
7-Chloro-4-(3,5-dimethylphenyl)-1-methylindoline-2,3-dione (5a):          
 Starting with 2 (70 mg, 0.3043 mmol), 3a (65 mg, 0.365 
mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 0.00952 mmol), K3PO4 
(96 mg, 0.4565 mmol), and 1,4-dioxane (3 ml), 5a was 
isolated as a red solid (57 mg, 63 %); mp 124-125°C. 1H  
NMR (300 MHz, CDCl3): δ = 2.29 (s, 6H, 2xCH3), 3.59 (s, 3H, CH3), 6.87 (d, J = 8.4 
Hz, 1H, ArH), 7.11-7.16 (m, 3H, ArH), 7.41 (d, J = 8.3 Hz, 1H, ArH). 13C NMR (62.9 
MHz, CDCl3):  = 20.2 (2xCH3), 28.9 (NCH3), 114.9 (C), 125.5, 125.9, 130.0 (CH), 
134.0, 136.8 (C), 138.5 (CH), 141.5, 142.3, 145.6, 146.1 (C), 157.2, 180.0 (CO).  IR 
(KBr, cm-1): v = 3446, 3073, 3047, 3032, 2950, 2922, 2853 (w), 1727 (s), 1637 (w), 
1585, 1581, 1557 (w). GC-MS (EI, 70 eV): m/z (%) = 299 ([M]+, [35Cl],100), 272 (12), 
255 (23), 250 (30), 246 (11), 244 (16), 228 (15), 222 (18), 221 (25), 199 (17). HRMS (EI, 
70 eV) calcd for C17H14
35ClNO2 ([M]
+): 299,07076 ;  found: 299.07033. 
 
7-Chloro-4-(4-methoxyphenyl)-1-methylindoline-2,3-dione (5b):                    
Starting with 2 (70 mg, 0.3043 mmol), 3b (54 mg, 0.356 
mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 0.00952 mmol), 
K3PO4 (96 mg, 0.4565 mmol), and 1,4-dioxane (3 ml), 5b 
was isolated as a red solid (76 mg, 83 %); mp 114-115°C. 
1H  NMR (300 MHz, CDCl3): δ = 3.47 (s, 3H, CH3), 3.72 (s, 3H, OCH3), 6.87 (dd, J = 
4.3, 8.7 Hz, 3H, ArH), 7.32 (d, J = 8.6 Hz, 2H, ArH), 7.40 (d, J = 8.2 Hz, 1H, ArH). 13C 
NMR (62.9 MHz, CDCl3):  = 28.9 (NCH3), 54.5 (OCH3), 112.7 (CH), 115.3 (C), 126.3 
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(CH), 127.0, 129.4 (C), 128.6 (CH), 133.9 (C), 138.5 (CH), 141.0, 146.2, 157.4 (C), 
159.5, 180.5 (CO).  IR (KBr, cm-1):  v = 3068, 3044, 3019, 2999, 2956, 2845 (w), 1741, 
1728, 1605, 1591, 1561 (m). GC-MS (EI, 70 eV): m/z (%) = 303 ([M]+, [37Cl], 34), 301 
([M]+, [35Cl], 100), 275 (12), 273 (33), 272 (15), 245 (13), 244 (17), 242 (37), 238 (11), 
230 (21), 210 (46), 173 (12), 167 (16). HRMS (EI, 70 eV), calcd for C16H12
37ClNO3 
([M]+): 303.04783 ;  found:  303.04707 ; calcd for C16H12
35ClNO3 ([M]
+): 301.04983 ;  
found: 301.05002. 
 
7-Chloro-4-(4-chlorophenyl)-1-methylindoline-2,3-dione (5c):  
Starting with 2 (70 mg, 0.3043 mmol), 3c (57 mg, 0.365 
mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 0.00952 mmol), K3PO4 
(96 mg, 0.4565 mmol), and 1,4-dioxane (3 ml), 5c was 
isolated as a red solid (48 mg, 52 %); mp 183-184°C. 1H  
NMR (300 MHz, CDCl3): δ = 3.14 (s, 3H, CH3), 6.87 (d, J = 8.4 Hz, 1H, ArH), 7.28 - 
7.34 (m, 4H, ArH), 7.47 (d, J = 8.7 Hz, 1H, ArH). 13C NMR (62.9 MHz, CDCl3):  = 
30.0 (NCH3), 114.7, 116.1 (C), 125.2, 127.7, 128.9 (CH), 132.2 (C), 138.3 (CH), 138.2, 
141.5, 146.2 (C), 160.5, 179.0 (CO). IR (KBr, cm-1): v = 3077, 2952, 2921, 2852 (w), 
1730, 1580, 1558 (s), 1610 (w). GC-MS (EI, 70 eV): m/z (%) = 305 ([M]+, 2x[35Cl],  97), 
279 (13), 259 (16), 277 (25), 250 (10), 249 (12), 248 (14), 242 (38), 216 (14), 164 (32). 
HRMS (EI, 70 eV) : calcd for C15H9
35Cl2NO2 ([M]
+): 305.00049 ;  found:  305.00044. 
 
7-Chloro-1-methyl-4-p-tolylindoline-2,3-dione (5d):                 
Starting with 2 (70 mg, 0.3034 mmol), 3d (49 mg, 0.365 
mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 0.00952 mmol), K3PO4 
(96 mg, 0.4565 mmol), and 1,4-dioxane (3 ml), 5d was 
isolated as a red solid (69 mg, 79 %); mp 141-142°C. 1H  
NMR (300 MHz, CDCl3): δ = 1.53 (s, 3H, CH3), 2.34 (s, 3H, CH3), 6.82 (d, J = 8.4 Hz, 
1H, ArH), 7.09 (d, J = 8.2 Hz, 2H, ArH), 7.18 (d, J = 8.0 Hz, 2H, ArH), 7.38 (d, J = 8.0 
Hz, 1H, ArH). 13C NMR (62.9 MHz, CDCl3):  = 21.3 (CH3), 28.8 (NCH3), 114.7, 115.1 
(C), 125.2, 127.7, 127.9 (CH), 131.2 (C), 138.4 (CH), 138.6, 141.1, 146.1, 146.8 (C), 
157.5, 180.0 (CO).  IR (KBr, cm-1):  v = 3469, 3451, 3089, 3068, 3043, 3026, 3003, 2952, 
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2919, 2854 (w), 1731 (s), 1610 (w), 1589, 1580, 1559 (w). GC-MS (EI, 70 eV): m/z (%) 
= 287 ([M]+, [37Cl], 35), 285 ([M]+, [35Cl], 97), 270 (13), 259 (10), 257 (33), 256 (23), 
244 (16), 229 (15), 228 (18), 227 (14), 195 (16). HRMS (EI, 70 eV) calcd for 
C16H12
37ClNO2 ([M]
+): 287.05271 ; found: 287.05245 ; calcd for C16H12
35ClNO2 ([M]
+): 
285.05566 ;  found:  285.05522. 
 
7-Chloro-4-(4-fluorophenyl)-1-methylindoline-2,3-dione (5f):          
Starting with 2 (70 mg, 0.3043 mmol), 3f (50 mg, 0.365 
mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 0.00952 mmol), K3PO4 
(96 mg, 0.4565 mmol), and 1,4-dioxane (3 ml), 5f was 
isolated as a red solid (77 mg, 87 %); mp 202-203°C. 1H  
NMR (300 MHz, CDCl3): δ = 3.59 (s, 3H, CH3), 6.90 (d, J = 8.9 Hz, 1H, ArH), 7.05 (t, J 
= 8.3 Hz, 2H, ArH), 7.33 - 7.35 (m, 2H, ArH), 7.45 (d, J = 8.5 Hz, 1H, ArH). 13C NMR 
(75.46 MHz, CDCl3):  = 28.9 (NCH3), 114.2 (d, J = 21.6 Hz ), 115.3 (d, J = 8.2 Hz) 
(CH), 125.2, 125.6 (CH), 129.8 (q, JF,C = 245.1 Hz, CF), 138.7, 139.9 (d, J = 3.3 Hz), 
146.3, 147.1, 157.1 (C), 164.0, 180.1 (CO). 19F NMR (282 MHz, CDCl3): δ =  -111.5 
(ArF). IR (KBr, cm-1): v = 3458, 3081, 2956, 2916, 2849 (w), 1736, 1727 (s), 1637 (w), 
1596, 1569 (M). GC-MS (EI, 70 eV): m/z (%) = 291 ([M]+, [37Cl], 22),  289 ([M]+, [35Cl], 
62), 261 (23), 260 (10), 233 (13), 232 (20), 199 (15), 182 (13). HRMS (EI, 70 eV) : calcd 
for C15H9
37ClFNO2 ([M]
+): 289.03004 ;  found:  289.03004 ; calcd for C15H9
35ClFNO2 
([M]+): 291.02709;  found: 291.02803. 
 
7-Chloro-4-(4-ethoxyphenyl)-1-methylindoline-2,3-dione (5g):           
 Starting with 2 (70 mg, 0.3043 mmol), 3g (61 mg, 0.365 
mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 0.00952 mmol), 
K3PO4 (96 mg, 0.4565 mmol), and 1,4-dioxane (3 ml), 
5g was isolated as a red solid (82 mg, 85 %); mp 154-
15°C. 1H NMR (300 MHz, CDCl3): δ = 1.14 (t, J = 8.0 Hz 3H, CH3), 3.18 (s, 3H, CH3), 
3.32 (q, J = 6.5, 2.8 Hz 2H, CH2), 7.28 (t, J = 8.0 Hz, 3H, ArH), 7.36 - 7.38 (m, 3H, 
ArH). 13C NMR (62.9 MHz, CDCl3):  = 13.9 (CH3), 28.8 (NCH3), 58.8 (OCH2), 113.1 
(CH) 126.5, 127.0, 127.4, 127.5 (C), 131.9, 132.2, 134.4 (CH), 131.2, 146.8 (C), 157.5, 
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180.0 (CO).  IR (KBr, cm-1):  v = 3056, 3021, 2972, 2962, 2923, 2898, 2852 (w), 1726 
(s), 1608, 1581, 1559,1514, 1501 (w). GC-MS (EI, 70 eV): m/z (%) =317 ([M]+, [37Cl], 
34), 315 ([M]+, [35Cl], 100), 287 (21), 259 (27), 258 (21), 242 (23), 230 (20), 224 (20), 
196 (67). HRMS (EI, 70 eV) calcd for C17H14
37ClNO3 ([M]
+): 317.06327;  found: 
317.06310; calcd for C17H14
35ClNO3 ([M]
+): 315.06567;  found:  315.06544. 
 
7-Chloro-4-(4-isopropoxyphenyl)-1-methylindoline-2,3-dione (5h):                     
Starting with 2 (70 mg, 0.3043 mmol), 3h (64 mg, 0.365 
mmol), Pd(PPh3) (11 mg, 3 mol-%, 0.00952 mmol), 
K3PO4 (96 mg, 0.4565 mmol), and 1,4-dioxane (3 ml), 5h 
was isolated as a red solid (73 mg, 73 %); mp 178-180 
°C. 1H  NMR (300 MHz, CDCl3): δ = 1.19 (d, J = 6.4 Hz, 6H, 2xCH3), 3.32 (s, 3H, CH3), 
3.61 - 3.65 (m, 1H, CH), 6.80 (d, J = 8.2 Hz, 1H, ArH), 6.91 (d, J = 8.5 Hz, 2H, ArH), 
7.29 - 7.35 (m, 3H, ArH). 13C NMR (62.9 MHz, CDCl3):  = 21.0 (2xCH3), 28.9 (NCH3), 
68.9 (OCH), 114.3, 125.9, 139.5, 141.0 (CH), 115.3 (C), 126.3 (CH), 146.6, 138.5, 139.4, 
146.1, 146.6, 156.5 (C), 159.5, 178.2 (CO). IR (KBr, cm-1): v = 3444, 3062, 3022, 2978, 
2951, 2945 (w), 1728, 1579 (s), 1563, 1514, 1479 (m). GC-MS (EI, 70 eV): m/z (%) = 
331 ([M]+, [37Cl], 24), 329 ([M]+, [35Cl], 100), 289 (23), 288 (14), 287 (77), 245 (13), 261 
(23), 260 (18), 259 (74), 258 (22), 242 (24), 197 (14). HRMS (EI, 70 eV), calcd for 
C18H16
37ClNO3 ([M]
+): 331.07895 ;  found:  331.07837 ; calcd for C18H16
35ClNO3 ([M]
+): 
329.08116 ;  found: 329.08132. 
 
4-(4-Tert-butylphenyl)-7-chloro-1-methylindoline-2,3-dione (5i): 
Starting with 2 (70 mg, 0.3043 mmol), 3i (65 mg, 0.365 
mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 0.00952 mmol), K3PO4 
(96 mg, 0.4565 mmol), and 1,4-dioxane (3 ml), 5i was 
isolated as a red solid (78 mg, 78 %); mp 104-105°C. 1H  
NMR (300 MHz, CDCl3): δ = 1.53 (s, 9H, 3xCH3), 2.34 (s, 3H, CH3), 6.81 (d, J = 8.6 
Hz, 2H, ArH), 7.02 (d, J = 8.0 Hz, 2H, ArH), 7.18 (d, J = 8.0 Hz, 2H, ArH). 13C NMR 
(62.9 MHz, CDCl3):  = 19.3 (3xCH3), 35.8 (NCH3), 114.7, 115.1 (C), 125.2, 127.7, 
127.9 (CH), 131.2 (C), 138.4 (CH), 138.6, 141.1, 146.1, 146.8 (C), 157.5, 180.0 (CO).  IR 
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(KBr, cm-1): v = 3469, 3451, 3089, 3068, 3043, 3026, 3003, 2952, 2919, 2854 (w), 1731 
(s), 1610 (w), 1589, 1580, 1559 (w). GC-MS (EI, 70 eV): m/z (%) = 327 ([M]+, [35Cl], 
97), 270 (13), 259 (10), 257 (33), 256 (23), 244 (16), 229 (15), 228 (18), 227 (14), 195 
(16). HRMS (EI, 70 eV) calcd for C19H18
35ClNO2 ([M]
+): 327.10261 ;  found:  
327.10245. 
 
4-7-Chloro-1-methyl-4-m-tolylindoline-2,3-dione (5j):          
Starting with 2 (70 mg, 0.3043 mmol), 3j (49 mg, 0.365 
mmol), Pd(PPh3)4(11 mg, 3 mol-%, 0.00952 mmol), K3PO4 
(96 mg, 0.4565 mmol), and 1,4-dioxane (3 ml), 5j was 
isolated as a red solid (44 mg, 51 %); mp 211-212°C. 1H  
NMR (300 MHz, CDCl3): δ = 2.30 (s, 3H, CH3), 3.38 (s, 3H, CH3), 6.87 (d, J = 8.4 Hz, 
1H, ArH), 7.12 - 7.23 (m, 4H, ArH), 7.41 (d, J = 8.3 Hz, 1H, ArH). 13C NMR (62.9 MHz, 
CDCl3):  = 20.3 (CH3), 28.9 (NCH3), 115.0, 115.2 (C), 124.8, 125.2, 125.9, 127.1, 
128.4, 129.0 (CH), 134.0, 136.9, 140.1, 141.2, 146.1, (C), 157.2, 180.0 (CO).  IR (KBr, 
cm-1):  v = 3447, 3074, 3048, 3033, 2952, 2921, 2854 (w), 1728 (s), 1637 (w), 1588, 
1581, 1558 (w). GC-MS (EI, 70 eV): m/z (%) = 287 ([M]+, [37Cl], 35), 285 ([M]+, [35Cl], 
97), 270 (13), 259 (10), 257 (33), 256 (23), 244 (16), 229 (15), 228 (18), 227 (14), 195 
(16). HRMS (EI, 70 eV) calcd for C16H12
37ClNO2 ([M]
+): 287.05271 ;  found: 287.05245 
; calcd for C16H12
35ClNO2 ([M]
+): 285.05566 ;  found:  285.05522. 
 
7-Chloro-4-(3,5-dimethoxyphenyl)-1-methylindoline-2,3-dione (5k):   
Starting with 2 (70 mg, 0.3043 mmol), 3k (67 mg, 0.365 
mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 0.00952 mmol), 
K3PO4 (96 mg, 0.4565 mmol), and 1,4-dioxane (3 ml), 5k 
was isolated as a red solid (88 mg, 87 %); mp 121-122°C. 
1H  NMR (300 MHz, CDCl3): δ = 3.58 (3H, CH3), 3.72 (6H, 2xOCH3), 6.43 - 6.49 (m, 
3H, ArH),  6.92 (d, J = 8.7 Hz, 1H, ArH), 7.42 (d, J = 8.4 Hz, 1H, ArH).13C NMR (62.9 
MHz, CDCl3):  = 30.0 (NCH3), 55.5 (2xOCH3), 101.6, 106.9 (CH), 116.3 (C), 126.8, 
128.0, 129.5 (CH),  134.4, 134.6, 135.0, 137.0,  141.3, 147.3,  (C), 158.5, 160.5 (CO).  IR 
(KBr, cm-1):  v = 3455, 3094, 3077, 3053, 3011, 2947, 2841 (w), 1731 (s), 1695, 1684, 
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1652, 1646, 1635, 1601(w). GC-MS (EI, 70 eV): m/z (%) = 331 ([M]+, [35Cl], 100), 316 
(13), 303 (11), 302 (21), 288 (11), 252 (16), 245 (10). HRMS (EI, 70 eV) calcd for 
C17H14
35ClNO4 ([M]
+): 331.06114 ;  found:  331.06122. 
 
4-(4-Acetylphenyl)-7-chloro-1-methylindoline-2,3-dione (5l): 
Starting with 2 (70 mg, 0.3043 mmol), 3l (61 mg, 0.365 
mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 0.00952 mmol), K3PO4 
(96 mg, 0.4565 mmol), and 1,4-dioxane (3 ml), 5l was 
isolated as a red solid (51 mg, 53 %); mp 74-75°C. 1H  NMR 
(300 MHz, CDCl3): δ =  2.52 (s, 3H, COCH3), 3.56 (s, 3H, CH3), 6.95 (d, J = 8.4 Hz, 1H, 
ArH), 7.49 (t, J = 8.7 Hz, 3H, ArH), 7.93 (d, J = 8.8 Hz, 2H, ArH).13C NMR (62.9 MHz, 
CDCl3):  = 26.7 (COCH3), 30.7 (NCH3), 116.2, 117.1 (C), 127.4, 128.1 (CH), 128.3 (C), 
129.1 (CH), 130.8, 133.2, 137.4 (C), 139.9 (CH), 158.5 (C), 181.1, 197.5 (CO).  IR (KBr, 
cm-1):  v = 3072, 3058, 3006, 2958, 2921, 2850 (w), 1731, 1681, 1583, 1556 (s). GC-MS 
(EI, 70 eV): m/z (%) = 315 ([M]+, [37Cl], 30), 313 ([M]+, [35Cl], 88), 298 (28), 285 (11), 
272 (33), 271 (16), 244 (14), 242 (40), 214 (13), 207 (11), 180 (36), 164 (22), 150 (25). 
HRMS (EI, 70 eV), calcd for C17H12
37ClNO3 ([M]
+): 315.04707 ;  found:  315.04762 ; 
calcd for C17H12
35ClNO3 ([M]
+): 313.05002 ;  found: 313.04983. 
 
7-Chloro-1-methyl-4-(4-vinylphenyl)indoline-2,3-dione (5m):                    
Starting with 2 (70 mg, 0.3043 mmol), 3m (53 mg, 0.365 
mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 0.00952 mmol), K3PO4 
(96 mg, 0.4565 mmol), and 1,4-dioxane (3 ml), 5m was 
isolated as a red solid (44 mg, 49 %); mp 188-189°C. 1H  
NMR (300 MHz, CDCl3): δ = 3.56 (3H, CH3), 5.09 (d, J = 1.8 Hz, 1H, CH), 5.76 (d, J = 
1.9 Hz, 1H, CH), 6.67 (q, J = 7.06, 2.16 Hz, 1H, CH), 6.91 (d, J = 8.9 Hz, 2H, ArH), 7.33 
- 7.42 (m, 4H, ArH). 13C NMR  (62.9 MHz, CDCl3):  = 29.9 (NCH3), 115.12 (CH2), 
116.59 (C), 126.12, 126.31, 126.86, 129.18 (CH),  13451, 136.23, 138.61 (C), 139.75 
(CH), 140.43, 141.73 (C), 158.30, 180.11 (CO). IR (KBr, cm-1):  v = 3449, 3067, 2944, 
2922, 2851 (w), 1734 (s), 1627 (w), 1581 (s), 1554, 1478, 1458, 1438 (w). GC-MS (EI, 
70 eV): m/z (%) = 299 ([M]+, [37Cl], 34), 297 ([M]+, [35Cl], 100), 271 (14), 270 (17), 269 
NO
O
Me
Cl
O
N
OO
Me
Cl
 78 
 
(42), 268 (30), 252 (16), 242 (21), 240 (40), 239 (11), 234 (18). HRMS (EI, 70 eV), calcd 
for C17H12
37ClNO2 ([M]
+): 299.05216;  found:  299.05303; calcd for C17H12
35ClNO2 
([M]+): 297.05511 ;  found:  297.05455. 
General procedure for synthesis (6a-c) 
The reactions were carried out in a pressure tube.To a 1,4-dioxane suspension (3 ml) of 2 
(70 mg, 0.304 mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 0.00952 mmol), and arylboronic acid 
Ar1B(OH) )0.365 mmol) was added K3PO4 (96 mg, 0.4565 mmol), The mixture was 
heated at 70 oC under Argon atmosphere for 6 h. The mixture was cooled to 20oC. 
arylboronic acid Ar2B(OH) )0.365 mmol) was added Pd(PPh3)4 (11 mg, 3 mol-%, 
0.00952 mmol),  K3PO4 (96 mg, 0.4565 mmol), The mixture was heated at 120 
oC under 
Argon atmosphere for 6 h. The reaction mixture was diluted with water and extracted 
with CH2Cl2 (3 x 25 ml). The combined organic layers were dried (Na2SO4), filtered and 
the filtrate was concentrated in vacuo. The residue was purified by flash chromatography 
(silica gel, EtOAc / heptane = 8:2). 
  
4-(4-Tert-butylphenyl)-1-methyl-7-p-tolylindoline-2,3-dione (6a): 
Starting with 2 ( 70 mg,  0.3043 mmol ) , 3i (65 
mg, 0.365 mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 
0.00952 mmol), K3PO4 (96 mg, 0.4565 mmol), 3d 
(49 mg, 0.365 mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 
0.00952 mmol), K3PO4 (96 mg, 0.4565 mmol), and 1,4-dioxane (3 ml), 6a was isolated 
as a red solid (66 mg, 57 %);   mp 172-174°C. 1H NMR (300 MHz, CDCl3): δ = 1.34 (s, 
9H, 3xCH3), 2.31 (s, 3H, CH3),  3.19 (s, 3H, CH3), 6.71 (d, J = 8.4 Hz, 2H, ArH), 6.66 (d, 
J = 8.1 Hz, 2H, ArH), 7.11 (t, J = 7.3 Hz, 4H, ArH), 7.57 (d, J = 8.3 Hz, 2H, ArH).13C 
NMR (75.46 MHz, CDCl3):  = 19.1 (3xCH3), 20.2 (NCH3), 33.7 (CH3), 124.1, 124.5 
(C), 124.7, 127.7, 127.9, 128.5 (CH), 132.0, 133.4 (C), 137.2, 139.6 (CH), 141.2, 147.8, 
148.3, 151.1 (C), 158.3, 181.9 (CO).  IR (KBr, cm-1): v = 3074, 2952, 2918, 2851 (w), 
1743, 1724 (s), 1605, 1586, 1564, 1497 (m). GC-MS (EI, 70 eV):  m/z (%) =  383  
([M]+,100), 369 (27), 368 (94), 340 (18), 327 (22), 326 (30), 313 (12), 312 (43), 310 (10), 
299 (10), 296 (11), 284 (10), 283 (12), 282(10), 141 (22). HRMS (EI, 70 eV) calcd for 
C26H25NO2 ([M]
+): 383.18853,  found:  383.18788. 
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4-(3,5-Dimethoxyphenyl)-7-(4-methoxyphenyl)-1-methylindoline-2,3-dione (6b):  
Starting with 2 ( 70 mg,  0.3043 mmol ) , 3k (67 
mg, 0.365 mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 
0.00952 mmol), K3PO4 (96 mg, 0.4565 mmol), 3b 
(54 mg, 0.365 mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 
0.00952 mmol), K3PO4 (96 mg, 0.4565 mmol), and 
1,4-dioxane (3 ml), 6b was isolated as a red solid (86 mg, 70 %);   mp 172-174°C. 1H 
NMR (300 MHz, CDCl3): δ =  2.40 (s, 3H, CH3),  3.59 (s, 9H, 3xOCH3), 6.70 (d, J = 8.4 
Hz, 2H, ArH), 7.12 (t, J = 7.3 Hz, 5H, ArH), 7.55 (d, J = 8.3 Hz, 2H, ArH). 13C NMR 
(75.46 MHz, CDCl3):  = 20.2 (NCH3), 33.7 (3xOCH3), 124.1, 124.5 (C), 124.7, 127.7, 
127.9, 128.5 (CH), 132.0, 133.4 (C), 137.2, 139.6, 140.1 (CH), 141.2, 147.8, 148.3, 
151.1, 152.3 (C), 168.3, 180.9 (CO).  IR (KBr, cm-1): v  = 3070, 2951, 2917, 2851 (w), 
1747, 1723 (s), 1604, 1585, 1564, 1497 (m). GC-MS (EI, 70 eV):  m/z (%) = 403  
([M]+,100), 379 (27), 378 (94), 350 (18), 337 (22), 323 (12), 322 (43), 320 (10), 289 (10), 
286 (11), 284 (13), 283 (12), 282(10), 141 (22). HRMS (EI, 70 eV) calcd for C24H21NO5 
([M]+): 403.14197,  found:  403.14145. 
 
7-(4-Methoxyphenyl)-1-methyl-4-p-tolylindoline-2,3-dione (6c):  
Starting with 2 ( 70 mg,  0.3043 mmol ) , 3d (49 
mg, 0.365 mmol), Pd(PPh3)4 (11 mg, 3 mol-%, 
0.00952 mmol), K3PO4 (96 mg, 0.4565 mmol), 
3b (55 mg, 0.365 mmol), Pd(PPh3)4 (11 mg, 3 
mol-%, 0.00952 mmol), K3PO4 (96 mg, 0.4565 mmol), and 1,4-dioxane (3 ml), (6c) was 
isolated as a red solid (74 mg, 68 %);   mp 172-174°C. 1H NMR (300 MHz, CDCl3): δ =  
2.35 (s, 3H, CH3),  3.54 (s, 3H, OCH3), 6.71 (d, J = 8.1 Hz, 2H, ArH), 6.64 (d, J = 8.6 
Hz, 2H, ArH), 7.11- 7.15 (m,4H, ArH), 7.50 (d, J = 8.0 Hz, 2H, ArH). 13C NMR (75.46 
MHz, CDCl3):  = 20.2 (NCH3), 33.7 (OCH3), 124.1, 124.5 (C), 124.7, 127.7, 127.9, 
128.5 (CH), 132.0, 133.4 (C), 137.2, 139.6 (CH), 141.2, 147.8, 148.3, 151.1 (C), 158.3, 
181.9 (CO).  IR (KBr, cm-1): v  = 3174, 2952, 2818, 2751 (w), 1843, 1824 (s), 1705, 
1686, 1564, 1497 (m). GC-MS (EI, 70 eV):  m/z (%) =  357  ([M]+,100), 349 (27), 348 
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(94), 340 (18), 326 (30), 310 (17), 283 (13), 280 (10), 145 (22). HRMS (EI, 70 eV) calcd 
for C23H19NO3 ([M]
+): 357.13649;  found:  357.13623. 
 
General procedure for synthesis (8a-e) 
The reactions were carried out in a pressure tube. To a 1,4-dioxane suspension (3 ml)  of 
7 arylboronic acid (2.2 equiv.), aqueous K2CO3 and Pd(PPh3)4 (6 mol-%) was heated at 
120 °C for 8 h under argon atmosphere. After cooling to 20°C, H2O was added and the 
reaction mixture was extracted with CH2Cl2 (3 x 25 ml). The organic layers were dried 
(Na2SO4), filtered and concentrated in vacuo. The residue was purified by column 
chromatography (silicagel, heptane/EtAOc = 8:2).   
   
2,6-Bis(3,5-dimethylphenyl)benzoxazole (8a): 
 Starting with 7 (70 mg, 0.372 nmol), 3a (122 mg, 
0.8184 mmol) and Pd(pph3)4 (26 mg, 6mol-%, 
0.0225 mmol) , K2CO3 (2 M, 1.0 ml), and 1,4-
dioxane (3 ml), 8a was isolated as a white solid 
(109 mg, 89 %), mp 169-170oC.1H NMR (300 
MHz, CDCl3): δ = 2.32 (s, 6H, 2xCH3), 2.34 (s, 6H, 2xCH3),  6.94 (br. s, 1H, ArH), 7.09 
(br. s, 1H, ArH), 7.17 (br. s, 2H, ArH), 7.48 (dd, J = 1.8, 8.0 Hz, 1H, ArH) 7.67 - 7.70 
(m, 2H, ArH), 7.82 (br. s, 2H, ArH). 13C NMR (75.4 MHz, CDCl3): δ = 21.25 (2xCH3), 
22.70 (2xCH3), 109.0, 119.6, 124.1, 125.3, 125.41 (CH), 126.9 (C), 129.0, 133.3 (CH), 
133.3, 138.4, 138.6, 139.1, 140.9, 141.3, 151.3, 125.3, 129.0 (C). IR (KBr, cm-1): v = 
3008, 2951, 2916, 2855, 2732, 1888, 1760, 1737, 1619 (w),1592, 1551, 1459, 1410 (m). 
GC-MS (EI, 70 eV): m/z (%) = 328 ([M+H]+, 23), 327 ([M]+, 100), 311 (10). HRMS (EI, 
70 eV) calcd for C23H21NO [M]
+: 327.16177 ; found: 327.16159 . 
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2,6-Bis(4-methoxyphenyl)benzoxazole (8b):                      
Starting with 7 (70 mg, 0.372 mmol), 3b (124 
mg, 0.8184 mmol) and Pd(pph3)4 (26 mg, 
6mol-%, 0.0225 mmol) , K2CO3 (2 M, 1.0 ml), 
and 1,4-dioxane (3 ml), 8b was isolated as a 
white solid (108 mg, 88 %), mp 180-182oC.1H NMR (300 MHz, CDCl3): δ = 3.79 (d, J = 
8.0 Hz, 6H, 2xOCH3), 6.93 (t, J = 7.4 Hz, 4H, ArH), 7.42-7.45 (m, 3H, ArH), 7.61-7.67 
(m, 2H, ArH), 8.12 (d, J = 8.5 Hz, 2H, ArH). 13C NMR (75.4 MHz, CDCl3): δ = 55.3, 
55.4 (OCH3), 107.3, 113.3, 113.4, 118.4 (CH), 118.7 (C), 122.6, 127.3, 128.3 
(CH),132.4, 137.1, 140.1, 150.3, 158.2, 161.2, 162.3 (C). IR (KBr, cm-1): v = 3071, 3038, 
3012, 2955 (w), 2920, 2851 (s), 2548, 2478, 2418, 2402, 1892, 1730 (w), 1614, 1603, 
1580, 1556, 1520 (m). GC-MS (EI, 70 eV): m/z (%) = 332 ([M+H]+, 23), 331 ([M]+, 
100), 317 (10), 316 (46), 288 (10), 165 (14). HRMS (EI, 70 eV) calcd for C21H17NO3 
[M]+: 331.12029 ; found: 331.120195.   
                                                                                                                                  
2,6-Bis(4-chlorophenyl)benzoxazole (8c):  
Starting with 7 (70 mg, 0.372 mmol), 3c (122 mg, 
0.8184 mmol) and Pd(pph3)4 (26 mg, 6 mol-%, 
0.0225 mmol), K2CO3 (2 M, 1.0 ml), and 1,4-
dioxane (3 ml), 8a was isolated as a white solid (95 
mg,75 %), mp 370-372oC .1H NMR (300 MHz, CDCl3): δ = 7.37 (dd, J = 2.2, 8.2 Hz, 
1H, ArH), 7.41 (d,  J =8.6 Hz, 2H, ArH), 7.54 - 7.58 (m, 3H, ArH), 7.59 - 7.65 (m, 3H, 
ArH),   8.22 (d, J = 8.7 Hz, 2H, ArH).13C NMR (62.9 MHz, CDCl3): δ = 110.2, 119.4, 
124.3 (CH), 124.7 (C), 126.4, 127.1, 127.3, 128.1 (CH), 129.7, 133.3, 137.2, 139.9, 
142.1, 149.9, 162.3 (C). IR (KBr, cm-1): v = 3092, 3066, 3044, 3028, 2923, 2852, 1927, 
1910, 1878, 1616, 1602, 1580, 1564, 1551, 1513 (w) . GC-MS (EI, 70 eV): m/z (%) =  
340  ([M]+,2x[35Cl], 100),  305 (15), 98 (17) . HRMS (EI, 70 eV) calcd for C19H11
35Cl2 
NO ([M]+, 2x[35Cl]):  340.2013 found 340.0301. 
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2,6-Bis(4-ethylphenyl)benzoxazole (8d):  
Starting with 7 (70 mg, 0.372 nmol), 3e (97 mg, 
0.8184 mmol) and Pd(pph3)4 (26 mg, 6 mol-%, 
0.0225 mmol) , K2CO3 (2 M, 1.0 ml), and 1,4-
dioxane (3 ml),  8d was isolated as a white solid (108 mg, 88 %), mp 74-77oC.  1H NMR 
(300 MHz, CDCl3): δ = 1.20 (t, J = 7.5 Hz, 6H, 2xCH3), 2.68 (q, J = 7.5 Hz, 4H, 2xCH2), 
7.21 (d, J = 8.0 Hz, 2H, ArH), 7.26 (d, J = 8.0 Hz, 2H, ArH), 7.46-7.50 (m, 3H, ArH), 
7.66 - 7.70 (m, 2H, ArH), 8.10 (d, J = 8.0 Hz, 2H, ArH). 13C NMR (75.4 MHz, CDCl3): δ 
= 15.2, 15.5 (CH3), 28.5, 28.9 (CH2), 108.8, 119.7, 123.9 (CH), 124.6 (C), 127.3, 127.7, 
128.4, 128.5 (CH), 138.3, 138.7, 141.3, 143.6, 148.2, 151.3, 163.6 (C). IR (KBr, cm-1): v 
= 3023 (w), 2959, 2926, 2868, 1617 (m), 1603, 1577, 1567, 1551, 1520 (w). GC-MS (EI, 
70 eV): m/z (%) = 328 ([M+H]+, 25), 327 ([M]+, 100), 312 (60), 297 (19), 152 (10), 148 
(17). HRMS (EI, 70 eV) calcd for C23H21NO [M]
+: 327.16177; found: 327.161480 . 
                                                                                              
2,6-Bis(3-fluorophenyl)benzoxazol (8e): 
 Starting with 7 (70 mg, 0.372 mmol), 3n (112 mg, 
0.8184 mmol), Pd(PPh3)4 (26 mg, 6 mol-%, 0.0225 
mmol), K2CO3 (2 M, 1.0 ml), and 1,4-dioxane (3 ml), 8e 
was isolated  as a white solid (86 mg , 75 %), mp 100°C. 
1H NMR (300 MHz, CDCl3): δ = 7.14-7.18  (m, 2H, ArH), 7.21 - 7.25 (m, 1H, ArH), 
7.30 -7.33 (m, 1H, ArH), 7.35 (d, J = 8.15 Hz, 1H, ArH), 7.38 - 7.40 (m, 1H, ArH), 7.48 
(dd, J = 2.71 , 8.15 Hz, 1H, ArH ), 7.67 (d, J = 2.10 Hz, 1H, ArH), 7.72  (d, J = 8.06 Hz, 
1H, ArH), 7.84 - 7.88 (m, 1H, ArH), 7.95 - 7.98 (m, 1H, ArH) .13C NMR (75.5 MHz, 
CDCl3): δ = 108.1 (CH), 114.1 (d, JC,F = 21.0 Hz,CH), 114.2 (d, JC,F = 21.0 Hz,CH), 114.4 
(d, JC,F = 21.8 Hz,CH), 117.5 (d, JC,F = 21.1 Hz,CH), 119.2 (CH), 121.9 (d, JC,F = 2.7 
Hz,CH), 122.3 (d, JC,F = 2.7 Hz,CH), 123.2 (CH), 130.4  (d, JC,F = 8.4 Hz,CH), 130.6 (d, 
JC,F = 8.0 Hz,CH), 136.9 (d, JC,F = 2.3 Hz,C), 140.7, 141.8, 141.9 (C),  161.4 (d, JC,F = 3.5 
Hz,C), 163.5 (d, JC,F = 247.5 Hz,CF), 163.8 (d, JC,F = 245.5 Hz,CF),   150.3 (C). 
19F  NMR  
(282.40 MHz , CDCl3 ): δ = -111.6, -112.6 (ArF) . IR (KBr, cm-1): v =  3088.9, 3069.3, 
2954.1, 2922.3, 2852.5, 1946.2, 1873.5, 1789.0, 1731.0, 1608.6 (w), 1577.2, 1556.6 (m). 
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GC-MS (EI, 70 eV): m/z (%) = 308 ([M+H]+, 20), 307 ([M]+, 100), 157 (33). HRMS 
(EI,70eV) calcdfor C19H11F2NO[M]
+: 307.08032; found: 307.080780. 
                                                                                               
General procedure for synthesis (9a-n) 
 The reactions were carried out in a pressure tube. To a 1,4-dioxane suspension (3 ml)  of 
7 arylboronic acid (1.2 equiv.), aqueous K2CO3 and Pd(PPh3)4 (3 mol-%) was heated at 
80 °C for 6 h under argon atmosphere. After cooling to 20°C, H2O was added and the 
reaction mixture was extracted with CH2Cl2 (3 x 25 ml). The organic layers were dried 
(Na2SO4), filtered and concentrated in vacuo. The residue was purified by column 
chromatography (silicagel, heptane/EtOAc = 9:1).  
                             
6-Chloro-2-(3,5-dimethyl)benzoxazole(9a):                                                                   
Starting with 7 (70 mg, 0.372 nmol), 3a (66 mg, 0.446 
mmol) and Pd(pph3)4 (13 mg, 3 mol-%, 0.01125 mmol), 
K2CO3 (2M, 1.0 ml), and 1,4-dioxane (3 ml), 9a  was 
isolated as a white solid (86 mg, 90 %), mp 98-100oC.1H 
NMR (300 MHz, CDCl3): δ = 3.80 (s, 6H, 2xCH3), 7.09 (dr, s, 1H, ArH), 7.24 (dd, J = 
1.9, 8.4 Hz, 1H, ArH), 7.48 (d, J = 2.0 Hz, 1H, ArH),  7.56 (d,  J = 8.4 Hz, 1H, ArH), 
8.07 (br, s, 2H, ArH).13C NMR (62.9 MHz, CDCl3): δ = 20.1 (2xCH3), 110.1, 116.6, 
119.2 (C), 123.3, 124.1, 124.3 (CH), 125.3 (C), 127.3 (CH), 129.4 (C), 132.5 (CH), 
139.8, 149.8 (C). IR (KBr, cm-1): v = 1865, 17321, 1616, 1600 (w), 1556, 1451, 1425 
(m). GC-MS (EI, 70 eV): m/z (%) = GC-MS (EI, 70 eV): m/z (%) = 259 ([M]+, [37Cl], 
33), 258 ([M+H]+, [35Cl], 22), 257 ([M]+, [35Cl], 100), 256 (20), HRMS (ESI-TOF/MS): 
calcd for C15H12
37ClNO2 ([M+H]
+, [37Cl]): 259.05724, found 259.057595, calcd for 
C15H12
35ClNO2 ([M+H]
+, [35Cl]): 257.06019; found: 257.060137. 
 
6-Chloro-2-(4-methoxyphenyl)benzoxazole (9b): 
Starting with 7 (70 mg, 0.372 nmol), 3b  (67 mg, 0.446 
mmol) and Pd(pph3)4 (13 mg, 3 mol-%, 0.01125 mmol), 
K2CO3 (2 M, 1.0 ml), and 1,4-dioxane (3 ml), 9b was isolated as a white solid (87 mg, 90 
%), mp140-142oC.1H NMR (300 MHz, CDCl3): δ = 3.80 (s, 3H, OCH3), 6.94 (d, J = 9.1 
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Hz, 2H, ArH), 7.22 (dd, J = 1.9, 8.4 Hz, 1H, ArH), 7.46 (d, J = 2.0 Hz, 1H, ArH),  7.54 
(d,  J = 8.4 Hz, 1H, ArH), 8.07 (d, J = 9.0 Hz, 2H, ArH). 13C NMR (62.9 MHz, CDCl3): δ 
= 55.4 (OCH3), 111.0, 114.4 (CH), 119.1 (C), 120.0, 125.0, 129.4 (CH), 130.0, 141.0, 
150.8, 162.5, 163.8 (C). IR (KBr, cm): v = 3073, 3042, 3004, 2978, 2946, 2902, 2840, 
2038, 1917, 1866 (w), 1616, 1601 (m), 1580 (w), 1502 (m), 1467 (w). GC-MS (EI, 70 
eV): m/z (%) = 261 ([M]+,
 [37Cl], 30), 260 ([M+H]+, [35Cl],  15), 259 ([M]+, [35Cl], 100),  
244  (32), 216 (27) . HRMS (ESI-TOF/MS) calcd for C14H10
35Cl NO2 ([M+H]
+, [35Cl]):  
260.478  :found 260.046 . 
                                                                                           
6-Chloro-2-(4-chlorophenyl)benzoxazole (9c):             
Starting with 7 (70 mg, 0.372 mmol), 3c (66 mg, 0.446 
mmol) and Pd(pph3)4 (13 mg, 3 mol-%, 0.01125 mmol), 
K2CO3 (2 M, 1.0 ml), and 1,4-dioxane (3 ml), 9c  was isolated as a white solid (86 mg, 88 
%), mp 197-200oC .1H NMR (300 MHz, CDCl3): δ = 7.27 (dd, J = 1.9, 8.5 Hz, 1H, ArH), 
7.35 - 7.39 (m, 1H, ArH), 7.49 - 7.53  (m, 2H, ArH), 7.63 (d,  J = 8.5 Hz, 2H, ArH), 8.22 
(d, J = 8.36 Hz, 1H, ArH).13C NMR (62.9 MHz, CDCl3): δ = 111.2, 120.4, 125.3, 125.7, 
129.1 (CH), 130.7,  134.3, 138.2, 140.9, 143.1, 150.9 (C). IR (KBr, cm-1): v = 3091, 
3065, 3043, 3027, 2922, 2851, 1926, 1909, 1879, 1615, 1601, 1579, 1563, 1550, 1512 
(w) . GC-MS (EI, 70 eV): m/z (%) =  266 ([M]+ ,[37Cl],  34), 265 ([M+H]+, [35Cl],  21), 
264  ([M]+,[35Cl], 100),  242 (19), 63 (13) . HRMS (EI, 70 eV) calcd for C13H7
37Cl2 NO 
([M]+, [37Cl]):  266.04159 found 266.04216. calcd for C13H7
35Cl2 NO ([M]
+, [35Cl]):  
264.04454; found : 264.04216. 
                                                                                           
6-Chloro-2-(4-ethylphenyl)benzoxazole (9d): 
Starting with 7 (70 mg, 0.372 mmol), 3e (53 mg, 0.446 
mmol) and Pd(pph3)4 (13 mg, 3 mol-%, 0.01125 mmol), 
K2CO3 (2 M, 1.0 ml), and 1,4-dioxane (3 ml), 9d was isolated as a white solid ( 78 mg, 
81 %), mp 90-92oC.1H NMR (300 MHz, CDCl3): δ =1.21 (t, J = 7.3 Hz  3H, CH3), 2.65 
(q, J = 7.5 Hz  2H, CH2), 7.25 (m, 3H, ArH), 7.49 (d, J = 1.8 Hz, 1H, ArH), 7.57 (d, J 
=8.4 Hz, 1H, ArH), 8.05 (d, J = 8.2 Hz, 2H, ArH).13C NMR (75.4 MHz, CDCl3): δ = 15.2 
(CH3), 29.7 (CH2), 111.1 , 120.2 (CH), 124.1 (C),125.1, 127.7, 128.5 (CH), 130.4, 141.0, 
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148.6, 150.8, 163.9 (C). IR (KBr, cm-1): v = 3028, 2961, 2927, 2869, 2852, 1939, 1864, 
1741, 1682 (w), 1615 (s), 1602, 1575, 1555, 1496, 1487 (w). GC-MS (EI, 70 eV): m/z 
(%) = 259 ([M]+, [37Cl], 33), 258 ([M+H]+, [35Cl], 21), 257, ([M]+, [35Cl], 100),  256  
(15), 244  (33) 243 (18). . HRMS (EI, 70 eV) calcd for C15H12
37ClNO ([M]+,[37Cl]): 
259.05724 found 259.057607. calcd for C15H12
35ClNO ([M]+, [35Cl]):  259.05724; found : 
259.057607.                                                                                                      
6-Chloro-2-(4-ethoxyphenyl)benzoxazole (9e): 
Starting with 7 (70 mg, 0.372 nmol), 3g (74 mg, 0.446 
mmol) and Pd(pph3)4 (13 mg, 3 mol-%, 0.01125 mmol), 
K2CO3 (2 M, 1.0 ml), and 1,4-dioxane (3 ml), 9e was isolated as a white solid (91 mg, 89 
%), mp145-147oC.1H NMR (300 MHz, CDCl3): δ = 1.37 (t, J = 2.0 Hz, 3H, CH3), 3.94 
(q, J = 1.2, 8.1 Hz, 2H, OCH2),  6.87 (d, J = 8.2 Hz, 2H, ArH), 7.13 (dd, J = 1.5, 8.4 Hz, 
1H, ArH), 7.54 (d, J = 8.2 Hz, 2H, ArH), 8.23 (d, J = 8.1 Hz, 2H, ArH). 13C NMR (62.9 
MHz, CDCl3): δ = 1.34 (CH3), 58.8 (OCH2), 111.1, 114.3 (CH), 119.2 (C), 125.4, 129.3, 
129.4 (CH), 133.2, 142.2, 153.8, 161.4, 163.5 (C). IR (KBr, cm-1): v = 3073, 3042, 3004, 
2978, 2946, 2902, 2840, 2038, 1917, 1866 (w), 1616, 1601 (m), 1580 (w), 1502 (m).GC-
MS (EI, 70 eV): m/z (%) = 275 ([M]+ , [37Cl], 20), 273 ([M]+, [35Cl], 100),  247 (33), 246 
(15), 245 (80), 216 (11) . HRMS (ESI-TOF/MS) calcd for C15H12
37Cl NO2 ([M]
+, [37Cl]): 
275.05216;  found: 275.05252, calcd for C15H12
35Cl NO2 ([M]
+, [35Cl]):  273.05511;  
found: 273.05477. 
 
6-Chloro-2-(4-isopropoxyphenyl)benzoxazole (9f): 
Starting with 7 (70 mg, 0.372 nmol), 3h (80 mg, 0.446 
mmol) and Pd(pph3)4 (13 mg, 3 mol-%, 0.01125 
mmol), K2CO3 (2 M, 1.0 ml), and 1,4-dioxane (3 ml), 
9f was isolated as a white solid (80 mg, 75 %), mp145-147oC .1H NMR (300 MHz, 
CDCl3): δ = 1.30 (d, J = 3.5 Hz, 6H, 2xCH3), 4.49 (q, J = 1.3, 8.2 Hz, 1H, OCH),  6.94 
(d, J = 8.0 Hz, 2H, ArH), 7.59 (dd, J = 1.5, 8.4 Hz, 1H, ArH), 7.50 (d, J = 8.2 Hz, 2H, 
ArH), 8.11 (d, J = 8.1 Hz, 2H, ArH).13C NMR (62.9 MHz, CDCl3): δ = 21.97 (2xCH3), 
70.17 (OCH), 121.1, 116.3 (CH), 119.3 (C), 123.2, 125.6, 128.3 (CH), 137.2, 143.2, 
154.8, 162.4, 163.3 (C). IR (KBr, cm-1): v = 3073, 3042, 3004, 2840, 2038, 1917, 1866 
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(w), 1616, 1601 (m), 1580 (w), 1502 (m). GC-MS (EI, 70 eV): m/z (%) = 287 ([M]+, 
[35Cl], 100), 247 (33), 246 (16), 245 (90). HRMS (ESI-TOF/MS) calcd for C16H14
35Cl 
NO2 ([M]
+, [35Cl]):  287.07131,  found 287.07122. 
2-(4-Tert-butylphenyl)-6-chlorobenzoxazole(9g):                                                            
Starting with 7 (70 mg, 0.372 mmol), 3i (79 mg, 0.446 
mmol) and Pd(pph3)4 (13 mg, 3 mol-%, 0.01125 mmol) , 
K2CO3 (2 M, 1.0 ml), and 1,4-dioxane (3 ml), 9g  was isolated as a white solid ( 77 mg, 
72 %), mp 98oC.1H NMR (300 MHz, CDCl3): δ = 0.5 (s, 9H, 3xCH3), 6.47 (dd, J = 1.9, 
8.4 Hz, 1H, ArH), 6.71 (m, 3H, ArH), 6.81 (d, J = 8.4  Hz 1H, ArH), 7.29 (d, J = 8.5 Hz 
2H, ArH).13C NMR (75.4 MHz, CDCl3): δ = 31.1 (3xCH3), 35.1 (C), 111.1, 120.3 (CH), 
123.8 (C), 125.1, 125.9, 126.2 (CH), 130.4, 141.0, 150.8, 155.4, 163.9 (C) . IR (KBr, cm-
1): v = 3093, 3062, 3041, 2956, 2924, 2902, 2860, 1916, 1692, 1673 (w), 1617 (m), 1601, 
1573, 1553 (w), 1495, 1459 (m). GC-MS (EI, 70 eV): m/z (%) = 287 ([M]+, [37Cl], 13), 
286 ([M+H]+, [35Cl],  10), 285, ([M]+, [35Cl], 100), 272 (34), 271 (19), 242 (17). HRMS 
(EI, 70 eV) calcd for C17H16
37Cl NO ([M]+, [37Cl]):  287.08854; found: 287.08896, calcd 
for C17H16
35Cl NO ([M]+, [35Cl]): 285.09149; found: 285.98189 . 
                                                                                                    
6-Chloro-2-m-tolylbenzoxazole (9h): 
Starting with 7 (70 mg, 0.372 mmol), 3j (60 mg, 0.446 mmol) 
and Pd(pph3)4 (13 mg, 3 mol-%, 0.01125 mmol), K2CO3 (2 
M, 1.0 ml), and 1,4-dioxane (3 ml), 9h was isolated as a 
white solid (79 mg, 87 %), mp 99-101oC .1H NMR (300 MHz, CDCl3): δ = 2.36 (s, 3H, 
CH3), 7.23 (dd, J = 2.0, 8.7 Hz, 1H, ArH), 7.27 (d, J = 6.3  Hz, 1H, ArH), 7.32 (d, J = 8.0 
Hz, 1H, ArH),  7.47 (d,  J =2.1 Hz, 1H, ArH), 7.56 (d, J = 8.62 Hz, 1H, ArH), 7.91 (t, J = 
7.3 Hz, 2H, ArH).13C NMR (62.9 MHz, CDCl3): δ = 21.3 (CH3), 111.1, 120.3, 124.7, 
125.2 (CH), 126.5 (C), 128.1, 128.8, 130.5 (CH), 132.6, 138.8, 140.8, 150.8, 163.8 (C). 
IR (KBr, cm-1): v = 3085, 3063, 3040, 3023, 2953, 2922, 2855, 1955, 1865, 1828, 1789, 
1731, 1619, 1602 (w), 1552 (m), 1504 (w), 1485 (m), 1470 (w), 1452, 1427 (m). GC-MS 
(EI, 70 eV): m/z (%) = 245  ([M]+ ,[37Cl],  34), 244 ([M+H]+, [35Cl],  21), 243, ([M]+, [ 
35Cl], 100),  242 (19), 63 (13) . HRMS (EI, 70 eV) calcd for C14H10
37Cl NO ([M]+,[37Cl]):  
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245.04159; found: 245.04216. calcd for C14H10
35Cl NO ([M]+, [35Cl]):  243.04454; found: 
245.04216.                                                                                                 
6-Chloro-2-(4-vinylphenyl)benzoxazole (9i): 
Starting with 7 (70 mg, 0.372 nmol), 3m (66 mg, 0.446 
mmol) and Pd(pph3)4 (13 mg, 3 mol-%, 0.01125 mmol), 
K2CO3 (2 M, 1.0 ml), and 1,4-dioxane (3 ml), 9i was isolated as a white solid (62 mg, 65 
%), mp130-132oC.1H NMR (300 MHz, CDCl3): δ = 5.33 (d, J = 8.0 Hz, 1H, CH), 5.93 
(d, J = 8.1 Hz, 1H, CH), 6.79 (q, J = 1.2, 8.1 Hz, 1H, CH), 6.33 (d, J = 8.2 Hz, 2H, ArH), 
7.10 (dd, J = 1.6, 8.2 Hz, 1H, ArH), 7.30 (d,  J = 8.5 Hz, 2H, ArH), 8.33 (d, J = 8.1 Hz, 
2H, ArH).13C NMR (62.9 MHz, CDCl3): δ = 111.2 (CH2), 136.2 , 117.1, 117.3 (CH), 
119.3 (C), 120.1, 125.3, 129.4 (CH), 133.0, 143.1, 152.8, 162.4, 163.2 (C). IR (KBr, cm-
1): v = 3042, 3004, 2902, 2840, 2038, 1917, 1866 (w), 1616, 1601 (m), 1580 (w), 1502 
(m), 1467 (w). GC-MS (EI, 70 eV): m/z (%) = 255 ([M]+, [35Cl], 100),  242 (33), 241 
(15), 235 (80), 211 (11) . HRMS (ESI-TOF/MS) calcd for C15H10
35Cl NO ([M]+, [35Cl]):  
255.04509;  found: 255.04533. 
 
6-Chloro-2-(3-fluorophenyl)benzoxazole(9j):                                                                         
Starting with 7 (70 mg, 0.372 mmol), 3n (61 mg, 0.446 
mmol), Pd(PPh3)4 (13 mg, 3 mol-%, 0.01125 mmol), K2CO3 
(2 M, 1.0 ml), and 1,4-dioxane (3 ml), 9j was isolated  as a 
white solid (77 mg , 83 %), mp 122-124°C. 1H NMR (300 MHz, CDCl3): δ = 7.14 - 7.21 
(m, 1H, ArH), 7.28 (dd, J = 2.11, 8.23  Hz, 1H, ArH), 7.39 - 7.47 (m, 1H, ArH),  7.53  (d, 
J = 2.11 Hz, 1H, ArH), 7.60 (d, J = 8.45  Hz, 1H, ArH), 7.82 - 7.86  (m, 1H, ArH), 7.93-
7.96 (m, 1H, ArH).13C NMR (75.5 MHz, CDCl3): δ = 111.3 (CH), 114.55 (d, JC,F = 2.0 
Hz, CH),  118.70 (d, JC,F = 21.8 Hz, CH), 120.7 (CH), 123.3  (d, JC,F = 3  Hz, CH), 125.5  
(CH), 128.6 (C), 130.7 (d, JC,F =8.0 Hz, CH), 131.1, 140.7, 150.9, 161.2 (C), 163.0 (d, JC,F 
= 245 Hz, CF) .
19F  NMR  (282.40 MHz , CDCl3 ): δ = -111.52 (ArF). IR (KBr, cm-1): v = 
3078, 3065, 3041, 2953, 2921, 2851, 1953, 1937, 1872, 1607.7, 1589 (w), 1555 
(m),1519, 1504 (w). GC-MS (EI, 70 eV): m/z (%) = 249  ([M]+, [37Cl], 30), 248 ([M+H]+, 
[35Cl], 12),  247 ([M]+, [35Cl], 100), 219 (10), 184 (10), 63 (10), HRMS (ESI-TOF/MS): 
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calcd for C13H7
37ClFNO ([M+H]+, [37Cl]): 250.02467 , found 250.02516. calcd for 
C14H7
35ClFNO ([M+H]+, [35Cl]): 248.0273, found 248.02771. 
6-Chloro-2-(2,3,4-trimethoxyphenyl)benzoxazole (9k):                                    
Starting with 7 (70 mg, 0.372 mmol), 3o (80 mg, 0.446 
mmol) and Pd(pph3)4 (13 mg, 3 mol-%, 0.01125 mmol) , 
K2CO3 (2 M, 1.0 ml), and 1,4-dioxane (3 ml), 9k  was 
isolated as a white solid ( 95 mg, 80 %), mp 76-78oC.1H NMR (300 MHz, CDCl3): δ = 
3.86 (s, 6H, 2xOCH3), 3.94 (s, 3H, OCH3), 6.73 (d, J = 8.8 Hz, 1H, ArH), 7.22 (dd, J = 
1.6, 8.0 Hz, 1H, ArH), 7.49 (d, J = 1.8 Hz, 1H, ArH), 7.59 (d, J = 8.8 1H, ArH), 7.77 (d, J 
= 8.8  Hz, 1H, ArH).13C NMR (75.4 MHz, CDCl3): δ = 56.1, 61.1, 61.7 (OCH3), 107.7, 
111.0, (CH), 114.0 (C), 120.4, 124.9, 125.8 (CH), 130.2, 140,9, 143.2, 150.5, 153.6, 
156.7, 161.9 (C). IR (KBr, cm-1): v = 3091, 3068, 2994, 2962, 2935, 2874, 2849, 2838, 
1862, 1609 (w), 1592 (m), 1573, 1555 (w), 1487, 1454, 1441, 1428, 1408 (s). GC-MS 
(EI, 70 eV): m/z (%) = 321 ([M]+, [37Cl], 32), 220 ([M+H]+, [35Cl],  19), 319, ([M]+, 
[35Cl], 100),  304  (19), 290 (26) 230 (25). HRMS (EI, 70 eV) calcd for C16H14
35Cl NO4 
([M]+, [35Cl]):  319.06059;  found: 319.06103 . 
 
6-Chloro-2-phenylbenzoxazole(9l):                                                                                   
Starting with 7 (70 mg, 0.372 mmol), 3p (60 mg, 0.446 mmol) 
and Pd(pph3)4 (13 mg, 3 mol-%, 0.01125 mmol) , K2CO3 (2 M, 
1.0 ml), and 1,4-dioxane (3 ml),  9l was isolated as a white solid ( 77 mg, 90 %), mp 92-
94 oC.1H NMR (300 MHz, CDCl3): δ = 7.25  (dd, J = 1.1, 8.1 Hz, 1H, ArH), 7.44 -7.47 
(m, 3H, ArH), 7.52 (d, J = 1.0 Hz, 1H, ArH), 7.59 (d, J = 8.1 Hz 1H, ArH), 8.14 (dd, J = 
2.0, 8.6 Hz, 2H, ArH). 13C NMR (75.4 MHz, CDCl3): δ = 110.6 (C), 111.2 (CH), 120.0 
(C), 120.4, 125.0 (CH), 126.6 (C), 127.6, 128.9 (CH), 130.0, 130.6 (C), 131.8 (CH). IR 
(KBr, cm-1): v = 3090, 3059, 3040, 2953, 2921, 2851, 1958, 1893, 1865, 1747, 1615, 
1600, 1573, 1567 (w), 1551 (m),1538, 1531, 1519, 1504, 1488 (w). GC-MS (EI, 70 eV): 
m/z (%) = 231  ([M]+ , [37Cl],  44), 230 ([M+H]+, [35Cl],  20), 229, ([M]+, [35Cl], 100),  
201  (13), 166 (26) . HRMS (EI, 70 eV) calcd for C13H8
37Cl NO ([M]+ , [37Cl]):  
231.02594; found: 231.02641. calcd for C13H8
35Cl NO ([M]+ , [35Cl]):  229.02889; found: 
229.02889.                                                                                                                                                                                                         
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6-Chloro-2-[4-(trifluoromethyl)phenyl]benzoxazol(9m):                                                       
Starting with  7 (70 mg, 0.372 mmol), 3q  (84 mg, 0.446 
mmol), Pd(PPh3)4 (13 mg, 3 mol-%, 0.01125 mmol), 
K2CO3 (2 M, 1.0 ml), and 1,4-dioxane (3 ml), 9m was isolated  as a white solid (92 mg , 
83 %), mp 112-115°C. 1H NMR (300 MHz, CDCl3): δ = 7.29  (dd, J = 1.72, 8.50  Hz, 
1H, ArH), 7.54 (d, J = 2.37 Hz, 1H, ArH), 7.61 (d, J = 8.70 Hz, 1H, ArH), 7.72 (d, J = 
8.30 Hz, 2H, ArH), 8.26 (d, J = 8.64 Hz, 2H, ArH).13C NMR (75.5 MHz, CDCl3): δ = 
111.4 , 120.9 (CH), 123.4 (q, JC,F = 271 Hz,CF),  125.7, 126.0 (q, JC,F = 3.8 Hz, CH) , 
127.9 (CH), 130.0, 131.5 (C), 133.2 (d, JC,F = 32.0 Hz,C), 140.6, 151.0, 162.1 (C). 
19F  
NMR  (282.40 MHz , CDCl3 ): δ = -63.04 (ArCF3),  . IR (KBr, cm-1): v = 3100, 3080, 
2954, 2922, 2852, 2638, 1931, 1889, 1804, 1683 (w), 1614, 1605 (m), 1569 (w), 1557 
(m), 1512, 1500 (w), 1461 (s), 1426, 1409 (m). GC-MS (EI, 70 eV): m/z (%) = 299  
([M]+, [37Cl], 32), 298 ([M+H]+, [35Cl], 16), 297 ([M]+, [35Cl], 100), 269 (10), 63 (17) 
HRMS (ESI-TOF/MS): calcd for C14H7
37ClF3NO ([M+H]
+, [37Cl]): 299.01333 ; found: 
299.01347. calcd for C14H7
35ClF3NO ([M+H]
+, [35Cl]): 297.01628 ; found: 297.01630. 
 
6-Chloro-2-(3-methoxyphenyl)benzoxazol (9n): 
Starting with 7 (70 mg, 0.372 nmol), 3r (68 mg, 0.446 
mmol) and Pd(pph3)4 (13 mg, 3 mol-%, 0.01125 mmol), 
K2CO3 (2 M, 1.0 ml), and 1,4-dioxane (3 ml), 9n was 
isolated as a white solid (72 mg, 75 %), mp145-147oC.1H NMR (300 MHz, CDCl3): δ = 
3.85 (s, 3H, OCH3),  6.74 (d, J = 8.1 Hz, 2H, ArH), 7.21 (dd, J = 1.7, 8.3 Hz, 1H, ArH), 
7.44 (d, J = 2.0 Hz, 1H, ArH), 7.53 (d,  J = 8.0 Hz, 1H, ArH), 8.03 (d, J = 8.0 Hz, 2H, 
ArH).13C NMR (62.9 MHz, CDCl3): δ = 55.3 (OCH3), 111.1, 114.3 (CH), 119.2 (C), 
120.2, 125.4, 129.3 (CH), 133.0, 141.2, 152.8, 162.4, 163.7 (C). IR (KBr, cm-1): v = 
3073, 3042, 3004, 2978, 2946, 2902, 2840, 2038, 1917, 1866 (w), 1616, 1601 (m), 1580 
(w), 1502 (m), 1467 (w). GC-MS (EI, 70 eV): m/z (%) = 259 ([M]+, [35Cl], 100), 244 
(32), 216 (27), 211 (10), 195 (23), 122(15) . HRMS (ESI-TOF/MS) calcd for C14H10
35Cl 
NO2 ([M+H]
+, [35Cl]):  259.03946; found: 259.03923. 
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General procedure for synthesis (10a-b) 
The reactions were carried out in a pressure tube. To a 1,4-dioxane suspension (3 ml)  of 
7 arylboronic acid Ar1B(OH)2 (1.2 equiv.) and Pd(PPh3)4 (3 mol-%) was added an 
aqueous solution of K2CO3 and the resulting solution was degassed by bubbling argon 
through the solution for 10 min. The mixture was heated at 80°C under an argon 
atmosphere for 6 h. The mixture was cooled to 20°C. Arylboronic acid Ar2B(OH)2 (1.2 
equiv.)  and Pd(PPh3)4 (3 mol-%), K2CO3 (2 M, 0.1 ml) and 1,4-dioxane (2 ml) were 
added. The reaction mixture was heated under an argon atmosphere for 8 h at 120°C. 
Then it was diluted with H2O and extracted with CH2Cl2 (3 × 25 ml). The combined 
organic layers were dried (Na2SO4), filtered and the filtrate was concentrated in vacuo. 
The residue was purified by flash chromatography (silica gel, heptane/EtAOc = 8:2). 
                                        
2-(4-Chlorophenyl)-6-(3,5-dimethylphenyl)benzoxazole (10a):       
 Starting with 7 (70 mg, 0.372 nmol), 3c (66 mg, 
0.446 mmol) and Pd(pph3)4 (13 mg, 3 mol-%, 
0.01125 mmol), K2CO3 (2 M, 1.0 ml). 3a (66 mg, 
0.446 mmol) and Pd(pph3)4 (13 mg, 3 mol-%, 
0.01125 mmol) , K2CO3 (2 M, 1.0 ml), and 1,4-dioxane (3 ml), 10a was isolated as a 
white solid (104 mg, 84 %), mp 57-59°C.  1H NMR (300 MHz, CDCl3): δ = 2.31 (s, 6H, 
2xCH3), 6.94 (d, J = 5.2 Hz, 1H, ArH), 7.15-7.19 (m, 3H, ArH), 7.49 (dd, J = 1.9, 8.6 Hz, 
1H, ArH ), 7.63-7.71 (m, 3H, ArH), 8.21 (d, J = 8.4 Hz, 2H, ArH).13C NMR (62.9 MHz, 
CDCl3): δ = 20.3 (2xCH3), 107.9, 118.6, 121.2 (CH), 123.2, 124.0, 124.3 (C), 124.7, 
126.5, 126.9, 128.0 (CH), 128.6, 137.3, 137.4, 139.8, 140.4, 143.4 (C). IR (KBr, cm-1): v 
= 3015, 2961, 2913, 2853, 2730, 1614, 1598, 1573, 1556, 1552, 1538, 1531, 1497, 1487, 
1462 (w). GC-MS (EI, 70 eV): m/z (%) = 335 ([M]+ , [37Cl],  34), 334 ([M+H]+, [35Cl],  
21), 333 ([M]+, [ 35Cl], 100), 331 (17), 167 (12) . HRMS (EI, 70 eV) calcd for   
C21H16
37Cl NO ([M]+, [37Cl]): 335.08854; found: 335.08862.calcd for C21H16
35Cl NO 
([M]+, [35Cl]):  333.09149;  found: 333.09147. 
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2-(4-Tert-butylphenyl)-6-(4-methoxyphenyl)benzoxazole (10b):                                 
Starting with 7 (70 mg, 0.372 nmol), 3i (79 mg, 
0.446 mmol) and Pd(pph3)4 (13mg, 3mol-%, 
0.01125 mmol), K2CO3  (2 M, 1.0 ml), 3b (67 
mg, 0.446 mmol) and Pd(pph3)4 (13mg, 3mol-%, 0.01125 mmol) , K2CO3 (2 M, 1.0 ml), 
and 1,4-dioxane(3 ml), 10b  was isolated as awhite solid (96 mg, 72%), mp 100°C.1H 
NMR (300 MHz, CDCl3): δ = 1.27 (s, 9H, 3xCH3), 3.74 (s, 3H, OCH3), 6.90 (d, J = 8.0 
Hz, 2H, ArH), 7.42 - 7.48 (m, 5H, ArH), 7.62 (d, J = 1.3 Hz, 1H, ArH ), 7.67 (d, J = 8.4 
Hz, 1H, ArH), 8.08 (d, J = 8.4 Hz, 2H, ArH).13C NMR (75.4 MHz, CDCl3): δ = 30.1 
(3xCH3), 54.2 (OCH3), 107.4, 113.3, 118.6, 122.6 (CH), 123.3 (C), 124.8, 126.3, 127.3 
(CH), 132.3, 137.3, 140.0, 150.3, 154.0, 157.6, 158.2, 162.3 (C). IR (KBr, cm-1): v = 
3064, 3032, 3002, 2961, 2953, 2927, 2900, 2865, 2832, 1617 (w), 1605 (m), 1573, 1552 
(w), 1517, 1495, 1471, 1434 (m) . GC-MS (EI, 70 eV): m/z (%) = 358 ([M+H]+, 25), 357 
([M]+, 100), 342 (66), 157 (11). HRMS (EI, 70 eV) calcd for C24H23NO2 [M]
+: 
357.17233; found: 357.17182. 
 
4-Oxo-3-[4-(trifluoromethylsulfonyloxy)phenyl]-4H-chromen-7-yl trifluoro-
methanesulfonate (12): 
A solution of 11  (0.5 g, 1.96 mmol) in CH2Cl2 (20 ml) 
was added pyridine (0.6 ml, 7.86 mmol) and the 
solution was stirred at room temperature. To the 
solution was added Tf2O (0.8 ml, 4.72 mmol) and the solution was stirred at room 
temperature for 10 min. Subsequently, the solution was stirred at 40°C for 30 min. After 
cooling, the reaction mixture was concentrated in vacuo. Product  was isolated by rapid 
column chromatography (flash silica gel, heptane-EtOAc = 8:2) as a white solid (0.90 g, 
90 %); mp 182-184 °C. 1 H NMR (300 MHz, CDCl3): δ 7.61 - 7.70  (m, 3H, ArH), 7.80 
(d, J = 2.3 Hz, 1H, ArH), 7.90 (d, J = 2.2 Hz, 1H, ArH), 7.92 - 8.00 (m, 2H, ArH), 8.75 
(s, 1H, CH=).13C- NMR (75.4 MHz, CDCl3):  = 112.5 (CH), 116.0 (q, JCF = 320 Hz, 
CF3),119.20 (CH), 120.0 (q, JCF = 320 Hz, CF3), 121.3 (CH), 122, 123.8 (C), 128.5, 
131.2 (CH), 132.1, 148.8, 151.8, 155.9 (C), 156.0 (CH),174.0 (CO). 19F NMR (282.4 
MHz. CDCl3): = -72.53 (3F, CF3), -72.74 (3F, CF3). IR (KBr, cm
-1): v = 3093, 2918, 
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2849 (w), 1648 (s), 1614 (m), 1578, 1551, 1536, 1530 (w). GC-MS (EI, 70 eV): m/z (%) 
= 519 ([M+H]+, 23), 518 ([M]+, 100), 454 (12). HRMS (EI, 70 eV): calcd for 
C17H8F6O8S2 [M]
+: 517.95593; found: 517.95651. 
 
General procedure for synthesis (13a-d) 
The reactions were carried out in a pressure tube. A solution of 12 (70 mg, 0.135 mmol), 
K2CO3 (2 M, 2 ml), Pd(PPh3)4 (6 mol-%) and arylboronic acid  (2.2 equiv.) in DMF (4 
ml) was stirred at 130°C for 10 h. under argon atmosphere. To the reaction mixture H2O 
(20 ml) and CH2Cl2 (25 mL) were added. The organic and the aqueous layers were 
separated and the latter was extracted with CH2Cl2 (2 x 20 ml). The combined organic 
layers were dried (Na2SO4), filtered and the filtrate was concentrated in vacuum .The 
residue was purified by column chromatography (silica gel, heptane/EtOAc = 9:1).  
                                                                                                                       
3-(4'-Methoxybiphenyl-4-yl)-7-(4-methoxyphenyl)-4H-chromen-4-one (13a): 
Starting with 12 ( 70 mg, 0.135 
mmol) , 3b (45 mg, 0.297 mmol), 
Pd(PPh3)4 (10 mg, 6 mol-%, 
0.008658 mmol),  K2CO3 (2 M, 2 ml),  and DMF (4 ml), 13a was isolated as a white solid 
(48 mg, 82 %);  mp 188-190°C. 1H NMR (300 MHz, CDCl3): δ =  3.81 (s, 6H, 2xOCH3), 
6.97 (d, J = 8.5 Hz, 4H, ArH), 7.18 (s, Hz, 2H, ArH), 7.54 -7.56 (m, 7H, ArH), 7.97 (s, 
2H, ArH), 8.25 (d, J = 8.7, 1H, CH=).13C-NMR (75.4 MHz, CDCl3):  = 29.7, 54.4 
(2xOCH3), 114.5, 115.1, 122.8, 122.9 (CH), 123.2, 125.5 (C), 126.8, 128.1, 128.4, 128.5 
(CH), 128.6, 128.7, 128.8. 129.1, 135.2, 135.8, 136.6, 153.0 (C), 156.6 (CH), 160.5 (CO). 
IR (KBr, cm-1): v = 3073, 3053, 3013, 2959, 2918, 2849 (w), 1901, 1732 (w), 1641, 1620, 
1606, 1578, 1555, 1518 (m). GC-MS (EI, 70 eV): m/z (%) = 434 ([M]+, 100), 344 (24), 
343 (35), 315 (13). HRMS (EI, 70 eV): calcd for C29H22O4 [M]
+: 434.15181; found: 
434.15156. 
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3-(4'-Ethylbiphenyl-4-yl)-7-(4-ethylphenyl)-4H-chromen-4-one (13b): 
Starting with 12 ( 70 mg,  0.135 mmol ), 
3e (45 mg, 0.297 mmol), Pd(PPh3)4 (10 
mg, 6 mol- %, 0.008658 mmol ), K2CO3 
(2 M, 2 ml),  and DMF (4 ml), 13b was isolated as a white solid (45 mg, 71 %);  mp 182 
- 184°C. 1H NMR (300 MHz, CDCl3): δ 1.22 (t, J = 6.89 Hz, 6H, 2xCH3), 2.80 (q, J = 
6.97, 2.33 Hz, 4H, 2xCH2), 6.22 (d, J = 8.5 Hz, 4H, ArH), 7.11 (s, Hz, 2H, ArH), 7.52 -
7.54 (m, 7H, ArH), 7.88 (s, 2H, ArH), 8.22 (d, J = 8.5, 1H, CH=).13C-NMR (75.4 MHz, 
CDCl3):  = 14.44 (2xCH3), 44.5 (2xCH2), 114.2, 115.1, 122.6, 122.8,122.9 (CH), 123.2, 
124.5 (C), 125.9, 128.2, 128.3, 128.4 (CH), 128.5, 128.6, 128.8. 129.1, 135.2, 135.6, 
136.6, 153.2 (C), 156.6 (CH), 160.8 (CO). IR (KBr, cm-1): v = 3062, 3041, 3023, 2946, 
2927, 2839 (w), 1911, 1723 (w), 1632, 1610, 1605, 1568, 1544, 1528 (m). GC-MS (EI, 
70 eV): m/z (%) = 430 ([M]+, 100), 333 (22), 243 (33), 215 (13), 112 (10). HRMS (EI, 70 
eV): calcd for C31H26O2 [M]
+: 430.19273; found: 430. 19253. 
 
3-(4'-Ethoxybiphenyl-4-yl)-7-(4-ethoxyphenyl)-4H-chromen-4-one (13c): 
Starting with 12 ( 70 mg,  0.135 
mmol ) , 3g (49 mg, 0.297 mmol), 
Pd(PPh3)4 (10 mg, 6 mol- %, 
0.008658 mmol),  K2CO3 (2 M, 2 ml), and DMF (4 ml), 13c was isolated as a white solid 
(48 mg, 77 %);  mp 108-110°C. 1H NMR (300 MHz, CDCl3): δ 1.33 (t, J = 6.89 Hz, 6H, 
2xCH3), 3.90 (q, J = 6.97, 2.33 Hz, 4H, 2xOCH2), 6.97 (d, J = 8.5 Hz, 4H, ArH), 7.18 (s, 
Hz, 2H, ArH), 7.54 -7.56 (m, 7H, ArH), 7.97 (s, 2H, ArH), 8.25 (d, J = 8.7, 1H, CH=). 
13C-NMR (75.4 MHz, CDCl3):  = 14.72 (2xCH3), 63.5 (2xOCH2), 114.3, 115.1, 122.7, 
122.9, 123.1 (CH), 123.3, 125.5 (C), 126.9, 128.1, 128.3, 128.5,  (CH), 128.6, 128.7, 
128.9. 129.2, 135.2, 135.7, 136.6, 153.1 (C), 156.7 (CH), 160.4 (CO). IR (KBr, cm-1): v = 
3072, 3051, 3013, 2956, 2917, 2849 (w), 1901, 1733 (w), 1642, 1620, 1605, 1578, 1554, 
1518 (m). GC-MS (EI, 70 eV): m/z (%) = 462 ([M]+, 100), 444 (24), 443 (35), 315 (13), 
122 (10). HRMS (EI, 70 eV): calcd for C31H26O4 [M]
+: 462.18311; found: 462.18322. 
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3-(4'-Isopropoxybiphenyl-4-yl)-7-(4-isopropoxyphenyl)-4H-chromen-4-one (13d): 
Starting with 12 ( 70 mg,  0.135 
mmol ) , 3h (54 mg, 0.297 mmol), 
Pd(PPh3)4 (10 mg, 6 mol-%, 
0.008658 mmol),  K2CO3 (2 M, 2 
ml),  and DMF (4 ml), 13d was isolated as a white solid (53 mg, 80 %);  mp 190-192 
°C.1H NMR (300 MHz, CDCl3): δ 1.23 (d, J = 6.05 Hz, 12H, 4xCH3), 4.47 - 4.59 (m, 2H, 
2xOCH),  6.97 (d, J = 8.5 Hz, 4H, ArH), 7.18 (s, Hz, 2H, ArH), 7.54 -7.56 (m, 7H, ArH), 
7.97 (s, 2H, ArH), 8.25 (d, J = 8.7, 1H, CH=).13C-NMR (75.4 MHz, CDCl3):  = 12.72 
(4xCH3), 53.5 (2xOCH2), 114.3, 115.1, 122.7, 122.9 (CH), 123.3, 125.5 (C), 126.9, 
128.1, 128.2, 128.3, 128.5 (CH), 128.6, 128.7, 128.9. 129.2, 135.2, 135.7, 136.6, 153.1 
(C), 156.7 (CH), 160.4 (CO). IR (KBr, cm-1): v = 3072, 3051, 3013, 2956, 2917, 2849 
(w), 1901, 1733 (w), 1642, 1620, 1605, 1578, 1554, 1518 (m). GC-MS (EI, 70 eV): m/z 
(%) = 490 ([M]+, 100), 465 (20), 440 (35), 211 (13). HRMS (EI, 70 eV): calcd for 
C33H30O4 [M]
+: 490.21441, found 490. 21455. 
 
General procedure for synthesis (14a-k) 
The reactions were carried out in a pressure tube. A solution of 12 (70 mg, 0.135 mmol ), 
K2CO3 (2 M, 2 ml), Pd(PPh3)4 (3 mole-%) and arylboronic acid  (1.2 equiv.) in DMF (4 
ml) was stirred at 85°C for 6 h under argon atmosphere. To the reaction mixture H2O (20 
ml) and CH2Cl2 (25 ml) were added. The organic and the aqueous layers were separated 
and the latter was extracted with CH2Cl2 (2 x 20 ml). The combined organic layers were 
dried (Na2SO4), filtered and the filtrate was concentrated in vacuo. The residue was 
purified by column chromatography (silica gel, heptane/EtOAc = 9:1). 
 
4-[7-(3,5-Dimethylphenyl)-4-oxo-4H-chromen-3-yl]phenyl trifluorome-
thanesulfonate (14a): 
Starting with 12 (70 mg, 0.135 mmol), 3a (25 mg, 
0.162 mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 
0.004327 mmol), K2CO3 (2 M, 2 ml), and DMF (4 
ml), 14a was isolated  as a white solid (49 mg, 76 %); mp 173-175°C. 1H NMR (300 
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MHz, CDCl3): δ =  2.23 (s, 6H, 2xCH3), 7.23 (s, 2H, ArH), 7.34 (d, J = 8.41 Hz, 2H, ArH 
).7.50 - 7.53 (m, 5H, ArH), 7.71 (s, 1H, ArH), 7.97 (d, J = 8.5 Hz, 1H, CH=).13C-NMR 
(75.4 MHz, CDCl3):  = 21.3 (2xCH3), 114.9 (CH), 115.9, 117.5 (C), 120.4 (CH), 122.6 
(q, JCF = 318 Hz, CF3),122.9, 123.8 (C), 124.7, 125.2, 126.6, 129.1, 130.7 (CH), 132.4, 
138.7, 138.8, 147.5, 149.3, 153.4 (C), 156.5 (CH), 175.6 (CO).19F NMR (282.4 MHz 
CDCl3): = -72.75 (3F, CF3), IR (KBr, cm
-1): v = 3088, 3040, 2921, 2850 (w), 1636, 1621, 
1603 (m), 1555, 1499 (w). GC-MS (EI, 70 eV): m/z (%) = 474 ([M]+, 100), 342 (24), 341 
(32), 313 (13). HRMS (EI, 70 eV): calcd for C24H17O5F3S [M]
+: 474.07433, found 
476.07403. 
 
4-[7-(4-Methoxyphenyl)-4-oxo-4H-chromen-3-yl]phenyl trifluoro-methanesulfonate 
(14b): 
Starting with 12 (70 mg, 0.135 mmol), 3b (25 
mg, 0.162 mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 
0.004327 mmol), K2CO3 (2 M, 2 ml),and 
DMF (4 ml), 14b was isolated  as a white solid (51 mg, 80 %); mp 173-175°C. 1H NMR 
(300 MHz, CDCl3): δ =  3.80 (s, 3H, OCH3), 6.94 (d, J = 1.5 Hz, 2H, ArH), 7.26 (d, J = 
1.5 Hz, 2H, ArH), 7.53-7.63 (m, 5H, ArH), 7.97 (s, 1H, ArH), 8.25 (d, J = 6.7, 1H, 
CH=).13C-NMR (75.4 MHz, CDCl3):  = 54.4 (OCH3), 113.2, 114.1 (CH), 115.2 (q, JCF 
= 320 Hz, CF3),, 120.3 (C), 121.5 (CH), 122.8 (C), 123.2, 125.7, 127.5 (CH), 129.7 (C), 
130.1(CH), 131.4, 145.7, 148.3, 152.3, 155.6 (C), 159.3 (CH), 174.5 (CO).19F NMR 
(282.4 MHz CDCl3): = -72.75 (3F, CF3), IR (KBr, cm
-1): v = 3085, 3036, 2955, 2916, 
2848, 2670, 2559 (w), 1633, 1621, 1604 (m), 1585, 1552, 1518 (w). GC-MS (EI, 70 eV): 
m/z (%) = 476 ([M]+, 100), 344 (24), 343 (35), 315 (13). HRMS (EI, 70 eV): calcd for 
C23H15O6F3S [M]
+: 476.05359; found: 476.05270. 
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4-[7-(4-Chlorophenyl)-4-oxo-4H-chromen-3-yl]phenyl trifluoromethanesulfonate 
(14c): 
Starting with 12 (70 mg, 0.135 mmol), 3c (25 
mg, 0.162 mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 
0.004327 mmol), K2CO3 (2 M, 2 ml), and DMF 
(4 ml), 14c was isolated  as a white solid (37 mg, 58 %); mp 173-175°C. 1H NMR (300 
MHz, CDCl3): δ = 7.28 (d, J = 8.77 Hz, 2H, ArH ),  7.40 (d, J = 8.79 Hz, 2H, ArH ), 7.49 
-7.63 (m, 7H, ArH), 8.25 (d, J = 8.85 Hz, 1H, CH=).13C-NMR (75.4 MHz, CDCl3):  = 
115.9 (CH), 120.9 (C), 121.4 (CH), 123.3 (q, JCF = 320 Hz, CF3), 123.3 (C), 123.4, 123.9, 
127.1 (CH), 128.3 (C), 128.6 (CH), 129.0 (C), 129.3, 130.7 (CH), 132.2, 135.0, 135.1, 
137.3, 145.5, 149.4 (C), 156.5 (CH), 175.9 (CO).19F NMR (282.4 MHz CDCl3): = -72.74 
(3F, CF3), IR (KBr, cm
-1): v = 3084, 3067, 3048, 2958, 2918, 2849 (w), 1635, 1621 (s), 
1589, 1570, 1552, 1521, 1501, 1476 (w). GC-MS (EI, 70 eV): m/z (%) = 480 ([M]+,[ 
35Cl], 100), 350 (10), 349 (36), 348 (23) 347 (80), 319 (17). HRMS (EI, 70 eV): calcd for 
C22H12O5
35Cl1F3S [M]
+: 480.00406; found: 480.00333. 
 
4-[7-(4-Ethylphenyl)-4-oxo-4H-chromen-3-yl]phenyltrifluoro methanesulfonate 
(14d):   
Starting with 12 (70 mg, 0.135 mmol), 3e (24 
mg, 0.162 mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 
0.004327 mmol), K2CO3 (2 M, 2 ml),and DMF 
(4 ml), 14d was isolated  as a white solid (45 mg, 70 %), mp 173-175°C. 1H NMR (300 
MHz, CDCl3): δ =  1.21 (t, J = 7.59 Hz, 3H, CH3), 2.68 (q, J = 7.50 Hz, 2H, CH2),  7.53 - 
7.63 (m, 4H, ArH), 7.53 - 7.63 (m, 5H, ArH), 6.94 (d, J = 8.5 Hz, 1H, ArH), 8.23 (d, J = 
8.5 Hz, 1H, CH=).13C-NMR (75.4 MHz, CDCl3):  = 15.5 (CH3), 29.3 (CH2), 115.6 
(CH), 121.4 (q, JCF = 318 Hz, CF3), 124.3 (CH), 126.8, 127.1, 128.3, 128.6, 128.7, 129.2 
(CH), 130.5, 130.8, 136.2, 138.1, 141.0, 143.6, 147.2 (C), 153.4 (CH), 156.6 (CO).19F 
NMR (282.4 MHz CDCl3): = -72.74 (3F, CF3), IR (KBr, cm
-1): v = 3083, 3025, 2964, 
2918, 2873, 2849 (w), 1635, 1620 (m), 1571, 1548, 1536, 1530 (w). GC-MS (EI, 70 eV): 
m/z (%) = 474 ([M]+, 100), 342 (24), 341 (32). HRMS (EI, 70 eV): calcd for 
C24H17O5F3S [M]
+: 474.07433, found 474.07410.  
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4-[7-(4-Fluorophenyl)-4-oxo-4H-chromen-3-yl]phenyltrifluoromethanesulfona (14e):                        
Starting with 12 (70 mg, 0.135 mmol), 3f (22 
mg, 0.162 mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 
0.004327 mmol), K2CO3 (2 M, 2 ml),and DMF 
(4 ml), 14e was isolated  as a white solid (38 mg, 62 %); mp 214-216°C. 1H NMR (300 
MHz, CDCl3): δ = 7.09 -7.13 (m, 4H, ArH), 7.27 (d, J = 8.85 Hz, 2H, ArH), 7.54 - 7.57 
(m, 3H, ArH), 7.16 (d, J = 8.17 Hz, 2H, ArH), 8.24 (d, J = 8.17 Hz, 1H, CH=).13C-NMR 
(62.9 MHz, CDCl3):  = 105.4, 106.2 (CH), 109.6 (C), 110.0, 116.0 (d, J = 21.6 Hz, 
(CH)), 126.4, 129.0 (d, J = 8.2 Hz, (CH)), 129.1 (CH), 131.1 (C), 132.0 (CH), 135.4 (d, J 
= 3.2 Hz), 147.4, 156.6, 160.8 (C), 163.2 (d, JCF = 248.9 Hz, CF3), 164.6 (CH), 183.1 
(CO). 19F NMR (282 MHz, CDCl3):  = -112.90 (ArF),  , -72.72 (3F,CF3) . IR (KBr, cm
-1): 
v = 3083, 3047, 2952, 2920, 2850 (w), 1633, 1621 (m), 1605, 1555 (w), 1514, 1502, 1482 
(w). GC-MS (EI, 70 eV): m/z (%) = 464 ([M]+, 100), 332 (23), 331 (88), 303 (18), 157 
(10). HRMS (EI, 70 eV): calcd for C22H12O5F4S [M]
+: 464.03361; found: 464.03350. 
 
4-[7-(4-Ethoxyphenyl)-4-oxo-4H-chromen-3-yl]phenyltrifluoromethanesulfonate 
(14f): 
Starting with 12 (70 mg, 0.135 mmol), 3g 
(27 mg, 0.162 mmol), Pd(PPh3)4 (5 mg, 3 
mol-%, 0.004327 mmol), K2CO3 (2 M, 2 
ml), and DMF (4 ml), 14f was isolated  as a white solid (58 mg, 88 %), mp 173-175°C. 
1H NMR (300 MHz, CDCl3): δ =  1.33 (t, J = 6.89 Hz, 3H, CH3), 3.90 (q, J = 6.97, 2.33 
Hz, 2H, OCH2), 6.91 (d, J = 8.85 Hz, 2H, ArH), 7.25 (d, J = 8.70 Hz, 2H, ArH), 7.46 - 
7.60 (m, 7H, ArH), 8.22 (d, J = 8.70 Hz, 1H, CH=).13C-NMR (75.4 MHz, CDCl3):  = 
14.76 (CH3), 63.6 (OCH2), 115.1, 121.4, (CH), 122.5 (C), 123.7 (q, JCF = 319 Hz, CF3), 
124.2, 126.7, 128.5, 130.7 (CH), 130.9, 132.4, 146.8, 149.3, 153.3, 156.6, 156.7 (C), 
159.7 (CH), 175.5 (CO). 19F NMR (282.4 MHz CDCl3): = -72.76 (3F, CF3), IR (KBr, cm
-
1): v = 3090, 3037, 2918, 2849 (w), 1657 (m), 1637, 1623, 1604 (s),1574, 1552, 1536, 
1518, 1501 (w). GC-MS (EI, 70 eV): m/z (%) =490 ([M]+, 100), 358 (24), 357 (90), 330 
(10), 329 (45), 301 (13), 300 (10). HRMS (EI, 70 eV): calcd for C24H17O6F3S [M]
+: 
490.06925; found: 490.06905.  
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4-[7-(4-Isopropoxyphenyl)-4-oxo-4H-chromen-3-yl]phenyltrifluoromethanesulfonate 
(14g):  
Starting with 12 (70 mg, 0.135 mmol), 3h 
(29 mg, 0.162 mmol), Pd(PPh3)4 (5 mg, 3 
mol-%, 0.004327 mmol), K2CO3 (2 M, 2 
ml), and DMF (4 ml), 14g  was isolated  as a white solid (53 mg, 78 %); mp 173-175°C. 
1H NMR (300 MHz, CDCl3): δ = 1.27 (d, J = 6.05 Hz, 6H, 2xCH3), 4.49 - 4.55 (m, 
1H,OCH), 6.88 (d, J = 8.16 Hz, 2H, ArH), 7.26 (d, J = 8.96 Hz, 2H, ArH), 7.48 - 7.60 
(m, 6H, ArH), 7.91 (s, 1H, ArH), 8.98 (d, J = 8.96 Hz, 1H, CH=).13C-NMR (75.4 MHz, 
CDCl3):  = 22.0 (2xCH3), 69.9 (OCH), 115.9, 116.3, 121.4 (CH), 122.5 (q, JCF = 320 
Hz, CF3), 123.8 (C), 124.2, 126.7, 128.5 (CH), 129.2 (C), 130.8 (CH),  132.4, 146.8, 
149.3, 153.4, 156.6 (C), 158.8 (CH), 175.6 (CO).19F NMR (282.4 MHz CDCl3): = -72.75 
(3F, CF3), IR (KBr, cm
-1): v = 3388, 3086, 3041, 2981, 2918, 2849 (w), 1639, 1624 (m), 
1602, 1553, 1524 (w), 1502 (m). GC-MS (EI, 70 eV): m/z (%) =504 ([M]+, 100), 426 
(24), 330 (23), 329 (80), 301 (13). HRMS (EI, 70 eV): calcd for C25H19O6F3S [M]
+: 
504.08490; found: 504.08522. 
 
4-[7-(4-Tert-butylphenyl)-4-oxo-4H-chromen-3-yl]phenyl trifluoromethanesulfonate 
(14h): 
Starting with 12 (70 mg, 0.135 mmol), 3i (29 
mg, 0.162 mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 
0.004327 mmol), K2CO3 (2 M, 2 ml), and 
DMF (4 ml), 14h was isolated  as a white solid (44 mg, 65 %); mp 173-175°C. 1H NMR 
(300 MHz, CDCl3): δ =  1.31 (s, 9H, 3xCH3), 7.27 (d, J = 8.67 Hz, 2H, ArH ), 7.45 (d, J 
= 8.60 Hz, 2H, ArH ), 7.54 -7.63 (m, 7H, ArH), 8.28 (d, J = 8.57 Hz, 1H, CH=).13C-
NMR (75.4 MHz, CDCl3):  = 31.2 (3xCH3), 115.7, 121.4 (CH), 122.9 (C), 123.8 (q, JCF 
= 316 Hz, CF3), 124.5, 126.1 (CH), 126.8 (C), 127.0, 127.4 (CH), 129.1 (C), 130.8 (CH), 
132.4, 127.0, 127.4, 130.8, 149.3, 153.4 (C), 156.6 (CH), 175.6 (CO).19F NMR (282.4 
MHz CDCl3): = -72.75 (3F, CF3), IR (KBr, cm
-1): v = 3091, 3037, 2989, 2920, 2850 (w), 
1636, 1623, 1604 (m), 1575, 1552, 1519, 1500, 1475 (w). GC-MS (EI, 70 eV): m/z (%) = 
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502 ([M]+, 100), 489 (10), 488 (28), 487 (80), 370 (14), 369 (54), 354 (29) 326 (11), 325 
(12). HRMS (EI, 70 eV): calcd for C26H21O5F3S [M]
+: 502.10563; found: 502.10544. 
 
4-[7-(4-Acetylphenyl)-4-oxo-4H-chromen-3-yl]phenyltrifluoromethanesulfonate 
(14i): 
Starting with 12 (70 mg, 0.135 mmol), 3l (27 
mg, 0.162 mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 
0.004327 mmol), K2CO3 (2 M, 2 ml),and DMF 
(4 ml), 14i was isolated  as a white solid (34 mg, 52 %); mp 173-175°C. 1H NMR (300 
MHz, CDCl3): δ =  2.50 (s, 3H, COCH3), 7.27 - 7.30 (m, 4H, ArH), 7.37 - 7.46 (m, 4H, 
ArH), 7.60 (d, J = 8.62 Hz, 2H, ArH ), 8.26 (d, J = 8.40 Hz, 1H, CH=).13C-NMR (75.4 
MHz, CDCl3):  = 2.28 (COCH3), 115.5, 121.3 (CH), 122.9 (C), 123.7 (q, JCF = 319 Hz, 
CF3), 124.4, 126.3 (CH), 126.9 (C), 127.2, 127.5 (CH), 129.2 (C), 130.9 (CH), 127.0, 
127.4, 130.8, 149.3, 153.5 (CH), 156.6 (CO), 175.6 (CO).19F NMR (282.4 MHz CDCl3): 
= -73.50 (3F, CF3), IR (KBr, cm
-1): v = 3078, 2959, 2918, 2849, 1732, 1684 (w), 1636 
(s), 1616, 1572, 1539, 1502 (w). GC-MS (EI, 70 eV): m/z (%) = 488 ([M]+, 100), 372 
(14), 362 (54), 351 (29) 322 (11), 311 (10). HRMS (EI, 70 eV): calcd for C24H15O6F3S 
[M]+: 488.05414; found: 488.05409. 
 
4-[4-Oxo-7-(4-(trifluoromethyl)phenyl)-4H-chromen-3-yl]phenyl trifluoromethane-
sulfonate (14j): 
Starting with 12 (70 mg, 0.135 mmol), 3q (31 
mg, 0.162 mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 
0.004327 mmol), K2CO3 (2 M, 2 ml), and 
DMF (4 ml), 14j was isolated  as a white solid (46 mg, 66 %); mp 214-216°C. 1H NMR 
(300 MHz, CDCl3): δ = 7.29 (d, J = 8.16 Hz, 4H, ArH), 7.55 - 7.62 (m, 7H, ArH), 8.29 
(d, J = 8.64 Hz, 1H, CH=).13C-NMR (62.9 MHz, CDCl3):  = 116 (CH), 116.6, 118.7 
(C), 120.9 (d, JCF = 248.9 Hz, CF3),  121.5 (d, J = 21.6 Hz, CH), 122.1, 123.3 (C), 124.0, 
124.4 (d, J = 8.2 Hz, CH), 127.1, 127.2, 128.4 (CH), 132.2 (C), 133.0 (CH), 134.4 (d, J = 
3.2 Hz), 146.4, 153.6, 160.5 (C), 163.2 (d, JCF = 248.9 Hz, CF3), 183.1 (CO).
19F NMR 
(282 MHz, CDCl3):  = -67.31, -56.31 (3F,CF3) . IR (KBr, cm
-1): v = 3058, 2955, 2918, 
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2849 (w), 1633, 1622, 1607 (m), 1556, 1522, 1485, 1441 (w). GC-MS (EI, 70 eV): m/z 
(%) = 514 ([M]+, 100), 382 (24), 381 (90), 353 (19). HRMS (EI, 70 eV): calcd for 
C23H12O5F4S [M]
+: 514.03041; found: 514.0300. 
                                     
4-[7-(3-Chlorophenyl)-4-oxo-4H-chromen-3-yl]phenyl trifluoromethanesulfonate 
(14k): 
Starting with 12 (70 mg, 0.135 mmol), 3s (25 mg, 
0.162 mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 0.004327 
mmol), K2CO3 (2 M, 2 ml),and DMF (4 ml), 14k 
was isolated  as a white solid (37 mg, 58 %); mp 173-175°C. 1H NMR (300 MHz, 
CDCl3): δ =7.27 -7.31 (m, 7H, ArH), 7.40 (d, J = 8.20 Hz, 2H, ArH ), 7.57 (d, J = 8.16 
Hz, 2H, ArH ),  8.25 (d, J = 8.85 Hz, 1H, CH=).13C-NMR (75.4 MHz, CDCl3):  = 111.6, 
113.6, 114.5 (CH), 116.5 (C), 119.0 (CH), 120.8 (q, JCF = 315 Hz, CF3), 121.6 (CH), 
122.2, 124.1, 124.5 (C), 129.2, 130.7 (CH), 131.4 (C), 134.7, 135.8 (CH), 149.6, 152.3, 
153.7 (C), 156.3 (CH), 174.5 (CO).19F NMR (282.4 MHz CDCl3): = -72.54 (3F, CF3). IR 
(KBr, cm-1): v = 3094, 2919, 2850 (w), 1648, 1615 (s), 1578, 1552, 1536 (w), 1503 (m), 
1482, 1468 (m). GC-MS (EI, 70 eV): m/z (%) = 480 ([M]+,[35Cl] 100), 334 (10), 333 
(36), 321 (23) , 319 (17). HRMS (EI, 70 eV): calcd for C22H12O5
35ClF3S [M]
+: 
480.00416; found: 480.00413. 
 
4-[7-(3,4-Dimethylphenyl)-4-oxo-4H-chromen-3-yl]phenyl trifluoromethane-
sulfonate (14l):  
Starting with 12 (70 mg, 0.135 mmol), 3t (24 
mg, 0.162 mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 
0.004327 mmol), K2CO3 (2 M, 2 ml),and DMF 
(4 ml), 14l was isolated  as a white solid (44 mg, 70 %); mp 173-175°C. 1H NMR (300 
MHz, CDCl3): δ =  2.25 (d, J = 6.30 Hz, 6H, 2xCH3), 7.17 (d, J = 8.15 Hz, 1H, ArH ), 
7.25 - 7.36 (m, 5H, ArH), 7.58 - 7.62 (m, 4H, ArH), 7.22 (d, J = 8.58 Hz, 1H, CH=).13C-
NMR (75.4 MHz, CDCl3):  = 19.5, 19.95 (2xCH3), 115.6, 121.4 (CH), 122.8 (q, JCF = 
319 Hz, CF3),122.9, 123.8 (C), 124.5, 124.7, 126.7, 128.5, 130.4, 130.8 (CH), 132.4, 
136.4, 137.4, 137.7, 147.3, 149.3, 153.4 (C), 156.6 (CH), 175.6 (CO).19F NMR (282.4 
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MHz CDCl3): = -72.72 (3F, CF3), IR (KBr, cm
1): v = 3070, 3048, 3013, 2974, 2948, 
2922, 2856 (w), 1640, 1622 (m), 1570, 1553, 1499 (w). GC-MS (EI, 70 eV): m/z (%) = 
474 ([M]+, 100), 342 (25), 341 (88), 313 (14). HRMS (EI, 70 eV): calcd for C24H17O5F3S 
[M]+: 474.07433; found: 474.07428. 
 
General procedure for synthesis (15a-c) 
The reactions were carried out in a pressure tube. A DMF solution of 12 (70 mg, 0.135 
mmol), Ar1B(OH)2 (1.2 equiv.), K2CO3 2 M (2 ml) and Pd(PPh3)4 (3 mol-%) was heated 
at 60 °C for 6h under argon atmosphere. After cooling to 20°C, Ar2B(OH)2 (1.2 equiv.), 
Pd(PPh3)4 (3 mol-%) were added and the reaction mixture was heated at 130°C for 
further 10 h. The reaction mixture was cooled again to 20°C, H2O was added and the 
reaction mixture was extracted with CH2Cl2 (3 x 25 ml).The combined organic layers 
were dried (Na2SO4), filtered and the filtrate was concentrated in vacuo. The residue was 
purified by column chromatography (heptane / EtOAc = 9:1). 
 
7-(4-Ethylphenyl)-3-(4'-methoxybiphenyl-4-yl)-4H-chromen-4-one (15a): 
Starting with 12 ( 70 mg,  0.135 mmol 
) , 3e (24 mg, 0.162 mmol), Pd(PPh3)4 
(5 mg, 3 mol-%, 0.004327 mmol),  
K2CO3 (2 M, 2 ml), 3b (25 mg, 0.162 mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 0.004327 
mmol),  K2CO3 (2 M, 2 ml), and DMF (4 ml), 15a was isolated as a white solid (41 mg, 
70 %);  mp 203-204°C. 1H NMR (300 MHz, CDCl3): δ =  1.21 (t, J = 7.55 Hz, 3H, CH3), 
2.68 (q, J = 7.51 Hz, 2H, CH2), 3.82 (s, 3H, OCH3), 6.97 (d, J = 8.3 Hz, 5H, ArH), 7.11 
(s, Hz, 2H, ArH), 7.52 -7.54 (m, 6H, ArH), 7.93 (s, 2H, ArH), 8.22 (d, J = 8.1, 1H, 
CH=).13C-NMR (75.4 MHz, CDCl3):  = 1.6 (CH3), 2.2 (CH), 55.5 (OCH3), 113.4, 
114.1, 121.5, 122.4 (CH), 123.2, 124.4 (C), 125.8, 128.1, 128.5, 128.6 (CH), 128.7, 
128.8, 128.9. 129.1, 135.3, 135.9, 136.6, 153.2 (C), 156.3 (CH), 160.5 (CO). IR (KBr, 
cm-1): v = 3059, 3053, 3012, 2958, 2916, 2849 (w), 1902, 1730 (w), 1641, 1620, 1606, 
1578, 1554, 1518 (m). GC-MS (EI, 70 eV): m/z (%) = 432 ([M]+, 100), 411 (20), 222 
(33), 100 (23). HRMS (EI, 70 eV): calcd for C30H24O3 [M]
+: 432.17254; found: 
432.17223. 
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7-(3,5-dimethylphenyl)-3-(4'-methoxybiphenyl-4-yl)-4H-chromen-4-one (15b): 
Starting with 12 (70 mg,  0.135 mmol ), 
3a (25 mg, 0.162 mmol), Pd(PPh3)4 (5 
mg, 3 mol-%, 0.004327 mmol),  K2CO3 
(2 M, 2 ml), 3b (25 mg, 0.162 mmol), 
Pd(PPh3)4 (5 mg, 3 mol-%, 0.004327 mmol),  K2CO3 (2 M, 2 ml), and DMF (4 ml), 15b 
was isolated as a white solid (47 mg, 81 %);  mp 152-154°C. 1H NMR (300 MHz, 
CDCl3): δ =  2.53 (s, 6H, 2xCH3), 3.82 (s, 3H, OCH3), 6.97 (d, J = 8.5 Hz, 4H, ArH), 
7.11 (s, Hz, 2H, ArH), 7.50 -7.52 (m, 6H, ArH), 7.93 (s, 2H, ArH), 8.20 (d, J = 8.3, 1H, 
CH=).13C-NMR (75.4 MHz, CDCl3):  = 22.4 (2xCH3), 50.8 (OCH3), 113.5, 114.1, 
121.7, 122.6 (CH), 123.4, 124.4 (C), 125.8, 126.1, 126.5, 126.6, 127.2, 127.8 (CH), 
128.5, 128.6, 128.8, 129.2, 135.3, 135.7, 136.6, 152.1 (C), 155.8 (CH), 163.8 (CO). IR 
(KBr, cm-1): v = 3059, 3053, 3012, 2958, 2916, 2849 (w), 1902, 1730 (w), 1641, 1620, 
1606, 1578, 1554, 1518 (m). GC-MS (EI, 70 eV): m/z (%) = 432 ([M]+, 100), 341 (22), 
323 (30), 315 (23), 133 (10). HRMS (EI, 70 eV): calcd for C30H24O3 [M]
+: 432.17200 
;found: 432.17244. 
 
7-(3,4-Dimethylphenyl)-3-(4'-methoxybiphenyl-4-yl)-4H-chromen-4-one (15c): 
Starting with 12 (70 mg,  0.135 
mmol) , 3t (25 mg, 0.162 mmol), 
Pd(PPh3)4 (5 mg, 3 mol-%, 0.004327 
mmol),  K2CO3 (2 M, 2 ml), 3b (25 mg, 0.162 mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 
0.004327 mmol),  K2CO3 (2 M, 2 ml), and DMF (4 ml), 15c was isolated as a white solid 
(35 mg, 60 %);  mp102-105°C. 1H NMR (300 MHz, CDCl3): δ =  2.50 (s, 6H, 2xCH3),  
3.80 (s, 3H, OCH3), 6.97 (d, J = 8.5 Hz, 5H, ArH), 7.11 (s, Hz, 2H, ArH), 7.53 -7.56 (m, 
6H, ArH), 7.93 (s, 2H, ArH), 8.11 (d, J = 8.1, 1H, CH=).13C-NMR (75.4 MHz, CDCl3):  
= 25.6 (2xCH3), 52.8 (OCH3), 112.5, 113.1, 120.8, 121.8 (CH), 123.2, 124.4 (C), 125.7, 
128.2, 128.4, 128.5 (CH), 128.6, 128.7, 128.8, 129.2, 134.3, 135.8, 136.4, 153.2 (C), 
156.7 (CH), 161.8 (CO). IR (KBr, cm-1): v = 3059, 3053, 3012, 2958, 2916, 2849 (w), 
1902, 1730 (w), 1641, 1620, 1606, 1578, 1554, 1518 (m). GC-MS (EI, 70 eV): m/z (%) = 
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432 ([M]+, 100), 340 (20), 333 (30), 310 (23), 123 (22). HRMS (EI, 70 eV): calcd for 
C30H24O3 [M]
+: 432.17254; found: 432.17244. 
 
4-Methyl-2-oxo-2H-chromene-6,7-diyl bis(trifluoromethanesulfonate) (17): 
To a solution of 4-methyl-6,7-dihydroxycoumarine 16 (0.5 g, 2.60 
mmol) in CH2Cl2 (30 ml) was added triethylamine (0.36 ml, 10.4 
mmol) at room temperature under an argon atmosphere. After 10 
min, Tf2O (1.0 ml , 6.2 mmol) was added at -78°C. The mixture was allowed to warm to 
20°C and stirred for 6 h. The reaction mixture was filtered and the filtrate was 
concentrated in vacuo. The residue was purified by chromatography (flash silica gel, 
heptane / EtOAc = 8 : 2) without aqueous work up to give 17 as a white solid (0.9 g, 75 
%);  mp 125-127°C. 1H NMR (300 MHz, CDCl3):  δ = 2.41 (d, J = 1.5 Hz, CH3), 6.37 (d, 
J = 1.2 Hz, 1H, CH=), 7.41 (br. s , 1H, ArH), 7.59 (br. s, 1H, ArH).13C NMR (75.46 
MHz, CDCl3):   = 18.64 (CH3), 110.9, 112.7, 113.1 (CH), 116.0 (q, JF,C = 317.0 Hz, 
CF3), 117.3 (q, JF,C = 317.0 Hz, CF3), 118.1, 136.4, 141.7, 150.5, 152.6 (C), 158.2 (CO).
 
19F NMR (282.4, MHz): δ = -72.8, -72.7 (3F, CF3). IR (KBr, cm-1):  v = 3124, 3053,  
2964,  2926 (w), 1740 (s), 1673, 1625, 1613, 1570 (w), 1498 (m). GC-MS (EI, 70 eV): 
m/z (%) = 455 ([M]+, 100), 324 (10), 323 (84), 232 (10), 203 (33), 162 (13), 134 (26), 69 
(55).  HRMS (EI, 70 eV) calcd for  C12H6F6O8S2 ([M]
+):  455.94028;  found:  455.94130. 
  
General procedure for synthesis (18a-e) 
The reactions were carried out in a pressure tube. To a 1,4-dioxane suspension (3 ml) of 
bis(triflates) analogue 17 (70 mg, 0.1534 mmol), Pd(PPh3)4 (11 mg, 6 mol -%, 0.0092  
mmol), and arylboronic acid (2.2 equiv.), was added K3PO4 (98 mg, 0.4602 mmol). The 
mixture was heated at 120oC under Argon atmosphere for 6 h. The reaction mixture was 
diluted with water and extracted with CH2Cl2 (3 x 25 ml). The combined organic layers 
were dried (Na2SO4), filtered and the filtrate was concentrated in vacuo. The residue was 
purified by flash chromatography (silica gel, heptane/EtOAc = 9:1). 
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6,7-Bis(3,5-dimethlyphenyl)-4-methyl-2H-chromen-2-one (18a):  
Starting with 17 ( 70 mg,  0.1534 mmol ) , 3a (51 mg, 
0.3374 mmol), Pd(PPh3)4 (11 mg, 6 mol -%, 0.0092  mmol),  
K3PO4 (98 mg, 0.4602 mmol),  and 1,4-dioxane (3 ml), 18a  
was isolated as a white solid (42 mg, 75 %);  mp 121-122°C. 
1H NMR (300 MHz, CDCl3): δ =  2.13 (s, 6H, 2xCH3), 2.14 
(s, 6H, 2xCH3), 2.39 (d, J = 1.3 Hz, 3H, CH3), 6.24 (d, J = 
1.2 Hz, 1H, CH=), 6.67 - 6.80 (m, 6H, ArH), 7.30 (br. s, 1H, ArH) , 7.49 (br. s, 1H, ArH).  
13C NMR (75.46 MHz, CDCl3):   = 17.6 (2xCH3) , 20.1 (2xCH3), 26.1 (CH3), 113.9, 
117.2  (CH), 117.7, 120.1  (C), 125.1, 126.4, 126.6, 127.4, 127.9 (CH), 136.3, 136.3, 
138.5, 139.1, 143.7, 151.2, 151.5, 154.4, 156.1 (C), 160.9 (CO).  IR (KBr,   cm-1): v  = 
3015, 3082, 3066,  2868,  2732,  2645 (w), 1722  (s), 1618, 1607 (m), 1573, 1537, 1516, 
1485 (w).  GC-MS (EI, 70 eV):  m/z (%) =  368 ([M]+,100),  353 (12), 338 (10) . HRMS 
(EI, 70 eV) calcd for  C26H24O2   [M]
+:  368.17708;  found:  368.17685. 
 
6,7-Bis(4-methoxyphenyl)-4-methyl-2H-chromen-2-one (18b): 
Starting with 17 (70 mg,  0.1534 mmol ) , 3b (51 mg, 
0.3374 mmol), Pd(PPh3)4 (11 mg, 6 mol-%, 0.0092  mmol),  
K3PO4 (98 mg, 0.4602 mmol),  and 1,4-dioxane (3 ml), 18b  
was isolated as a white solid (47 mg, 83 %);  mp 103-105 
°C. 1H NMR (300 MHz, CDCl3): δ =  2.38 (d, J = 1.2 Hz, 
3H, CH3), 3.72  (s, 6H, 2OCH3), 6.23 (d, J = 1.2 Hz, 1H, CH=), 6.69 - 6.74 (m, 4H, 
ArH), 6.97 - 7.01 (m, 4H, ArH), 7.27 (br. s, 1H, ArH) , 7.47 (br. s, 1H, ArH).13C NMR 
(75.46 MHz, CDCl3):   = 18.6  (CH3), 22.6, 29.3 (OCH3), 55.2, 113.6, 114.8, 118.2 
(CH), 118.6 (C), 126.3, 130.7, 130.8 (CH), 132.1, 132.7, 136.6, 144.1, 152.1, 152.5, 
158.6, 158.8 (C), 160.9 (CO).    IR (KBr, cm-1): v  = 3115, 3092, 3076,  2968,  2932,  
2845 (w), 1732  (s), 1628, 1607 (m), 1583, 1547, 1526, 1495 (w).  GC-MS (EI, 70 eV):  
m/z (%) =  372 ([M]+,100),  357 (12), 341 (11),  229 (10). HRMS (EI, 70 eV) calcd for  
C24H20O4   [M]
+:  372.13561;  found:  372.13535. 
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7-Bis(4-chlorophenyl)-4-methyl-2H-chromen-2-one (18c):                            
Starting with 17 ( 70 mg,  0.1534 mmol ) , 3c (51 mg, 0.3374 
mmol), Pd(PPh3)4 (11 mg, 6 mol- %, 0.0092  mmol),  K3PO4 
(98 mg, 0.4602 mmol),  and 1,4-dioxane (3 ml), 18c was 
isolated as a white solid (49 mg, 83 %);  mp 221-222°C.1H 
NMR (300 MHz, CDCl3): δ =  2.40 (d, J = 1.3 Hz, 3H, CH3), 
6.27 (d, J = 1.2 Hz, 1H, CH=), 6.97 - 6.99 (m, 4H, ArH),  7.15 - 7.19 (m, 4H, ArH),  7.28 
(br. s, 1H, ArH) , 7.48 (br. s, 1H, ArH).13C NMR (75.46 MHz, CDCl3):  = 17.6 (CH3), 
114.5, 117.5  (CH), 118.3 (C), 125.4, 127.4, 127.5, 129.8, 130.0 (CH), 132.4, 132.9, 
134.7, 136.7, 137.2, 142.0, 150.8, 151.8 (C), 159.4 (CO).  IR (KBr, cm-1): v  = 3065, 
2959, 2922, 2852 (w), 1727, 1715  (s), 1621, 1614 (m), 1594, 1573, 1568, 1543, 1510, 
1505, 1479 (w).  GC-MS (EI, 70 eV):  m/z (%) = 380  ([M]+, 2x[35Cl], 100),  352 (11), 
252 (18), 253 (13) . HRMS (EI, 70 eV)  calcd for  C22H14
35Cl2O2  ([M]
+, 2x[35Cl]):  
380.03654,  found:  380.03632. 
 
6,7-Bis(4-ethoxyphenyl)-4-methyl-2H-chromen-2-one (18d): 
Starting with 17 ( 70 mg,  0.1534 mmol ) , 3g (56 mg, 
0.3374 mmol), Pd(PPh3)4 (11 mg, 6 mol- %, 0.0092  mmol),  
K3PO4 (98 mg, 0.4602 mmol),  and 1,4-dioxane (3 ml), 18d  
was isolated as a white solid (54 mg, 88 %);  mp 188-190 
°C.1H NMR (300 MHz, CDCl3): δ =  1.33 (t, J = 6.5 Hz, 
6H, 2xCH3), 2.38 (d, J = 1.2 Hz, 3H, CH3), 3.94  (q, J = 6.9 
Hz, 4H, 2xOCH2), 6.22  (d, J = 1.2 Hz, 1H, CH=), 6.68 - 6.72 (m, 4H, ArH), 6.95 - 6.9 
(m, 4H, ArH), 7.27 (br. s, 1H, ArH) , 7.46 (br. s, 1H, ArH).13C NMR (75.46 MHz, 
CDCl3):   = 13.8, 17.6, 20.3 (CH3), 28.6, 62.3 (OCH2), 113.2, 113.8, 114.4, 117.2 (CH), 
117.6 (C), 125.2, 129.7, 129.8 (CH), 130.9, 131.6, 135.7, 143.1, 151.2, 151.5, 157.0, 
157.3 (C), 160.9 (CO).  IR (KBr, cm-1): v  = 3118, 3093, 3079,  2971,  2935,  2848 (w), 
1735  (s), 1631, 1609 (m), 1585, 1549, 1528, 1497 (w).  GC-MS (EI, 70 eV):  m/z (%) =  
400 ([M]+,100),  344 (15) . HRMS (EI, 70 eV) calcd for  C26H24O4   [M]
+:  400.16691;  
found:  400.16654. 
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4-Methyl-6,7-diphnyl-2H-chromen-2-one (18e):                 
Starting with 17 ( 70 mg,  0.1534 mmol ), 3p (46 mg, 0.3374 
mmol), Pd(PPh3)4 (11 mg, 6 mol-%, 0.0092  mmol),  K3PO4 (98 
mg, 0.4602 mmol),  and 1,4-dioxane (3 ml), 18e  was isolated as 
a white solid (34 mg, 70 %);  mp 163-165°C. 1H NMR (300 
MHz, CDCl3): δ =  2.40 (d, J = 1.1 Hz, 3H, CH3), 6.25 (d, J = 1.2 Hz, 1H, CH=), 7.04 -
7.07 (m, 4H, ArH),  7.16 -7.18 (m, 6H, ArH), 7.33 (br. s, 1H, ArH) , 7.53 (br. s, 1H, 
ArH).13C NMR (75.46 MHz, CDCl3):   = 18.6  (CH3), 30.8, 115.1, 118.5, 126.4, 126.9, 
127.4, 128.1, 129.6, 129.8  (CH), 137.1, 139.6, 140.1, 144.4, 152.1, 152.6, 153.6 (C), 
160.8 (CO).  IR (KBr, cm-1): v  = 3110, 3087,  3071, 2963,  2927, 2840 (w),1727 (s), 
1623, 1602 (m), 1578, 1542, 1521, 1490 (w).  GC-MS (EI, 70 eV): m/z (%) = 312 
([M]+,100), 311 (12), 284 (11), 283 (15), 252 (10), 239 (17).  HRMS (EI, 70 eV) calcd 
for  C22H16O2   [M]
+:  312.11448;  found:  312.11468.  
 
General procedure for synthesis (19a-m) 
The reactions were carried out in a pressure tube.To a 1,4-dioxane suspension (3 ml) of 
17 (70 mg, 0.1534 mmol), Pd(PPh3)4 (5 mg, 3 mol -%, 0.00432  mmol), and arylboronic 
acid )1.2 equiv.), was added K3PO4 (49 mg, 0.230 mmol). The mixture was heated at 70 
oC under Argon atmosphere for 6 h. The reaction mixture was diluted with water and 
extracted with CH2Cl2 (3 x 25 ml). The combined organic layers were dried (Na2SO4), 
filtered and the filtrate was concentrated in vacuo. The residue was purified by flash 
chromatography (silica gel, heptane/EtOAc = 9:1). 
 
7-(3,5-Dimethylphenyl)-4-methyl-2-oxo-2H-chromen-6-yl trifluoromethane-
sulfonate (19a): 
Starting with 17 (70 mg, 0.1534 mmol), 3a (28 mg, 0.184 
mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 0.00432  mmol), K3PO4 (49 
mg, 0.230 mmol), and 1,4-dioxane (3 ml), 19a was isolated as 
a white solid (47 mg, 75 %); mp 165-167°C. 1H NMR (300 
MHz, CDCl3): δ =  1.45 (s, 6H, 2xCH3), 2.31 (d, J = 1.4 Hz, 3H, CH3), 6.31 (d, J = 1.4 
Hz, 1H, CH=), 6.67 (br. s, 1H, ArH), 7.17 (d, J = 8.8  Hz, 3H, ArH), 7.33 (d, J = 8.4  Hz, 
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1H, ArH), 7.48 (br. s, 1H, ArH).13C NMR (75.47 MHz, CDCl3): δ = 17.6 (2xCH3), 20.1 
(CH3), 113.9, 115.2, 118.7 (CH), 125.4  (q, JF,C = 320.4 Hz, CF3), 126.4, 127.9  (CH), 
129.8, 132.8, 136.3, 137.3, 138.4, 141.5, 149.8, 151.3 (C), 160.1 (CO). 19F NMR (282.4, 
MHz): δ = -73.8 (3F, CF3). IR (KBr, cm-1):  v = 3057, 2950, 2910, 2838 (w), 1721 (s), 
1611, 1606 (m), 1538 (w), 1509, 1491 (m).  GC-MS (EI, 70 eV): m/z (%) = 412 ([M]+, 
100), 280 (20), 279 (30), 264 (12), 235 (11). HRMS (EI, 70 eV) calcd for C19H15F3O5S 
[M]+: 412.05868;  found:  412.05840. 
 
7-(4-Methoxyphenyl)-4-methyl-2-oxo-2H-chromen-6-yltrifluoro-methanesulfonate 
(19b): 
Starting with 17 (70 mg, 0.1534 mmol), 3b (28 mg, 0.184 
mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 0.00432  mmol), 
K3PO4 (49 mg, 0.230 mmol), and 1,4-dioxane (3 ml), 19b  
was isolated as a white solid (51 mg, 80 %); mp 134-
136°C. 1H NMR (300 MHz, CDCl3): δ =  2.39 (d, J = 1.2 Hz, 3H, CH3), 3.80 (s, 3H, 
OCH3), 6.30 (d, J = 1.3 Hz, 1H, CH=), 6.93 (d, J = 8.9 Hz, 2H, ArH), 7.33 - 7.37 (m, 3H, 
ArH), 7.48 (br. s, 1H, ArH).13C NMR (75.46 MHz, CDCl3):  = 18.5 (CH3), 55.3 
(OCH3), 114.3, 116.1, 118.4,  (CH), 119.1 (q, JF,C = 320.1 Hz, CF3), 119.5 (CH), 120.4, 
126.3 (C), 130.6 (CH), 138.8, 142.6, 150.9, 152.4, 159.7 (C), 160.9 (CO). 19F NMR  (282 
MHz, CDCl3):    =   -73.6 (3F, CF3). IR (KBr, cm-1): v = 3112, 3089, 3074, 2965, 2929, 
2841 (w), 1729 (s), 1621, 1605 (m), 1576, 1543, 1520, 1491 (w).  GC-MS (EI, 70 eV): 
m/z (%) = 414 ([M]+,100), 282 (20), 281 (30).  HRMS (EI, 70 eV) calcd for  C18H13F3O6S 
[M]+:  414.03794;  found:  414.03813.  
 
7(4-Chlorophenyl)-4-methyl-2-oxo-2H-chromen-6-yltrifluoro-methanesulfonate 
(19c):  
Starting with 17 (70 mg, 0.1534 mmol), 3c (28 mg, 0.1840 
mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 0.00432  mmol ), K3PO4 
(49 mg, 0.230 mmol), and 1,4-dioxane (3 ml), 19c was 
isolated as a white solid (55 mg, 85 %); mp 124-125°C. 1H  
NMR (300 MHz, CDCl3): δ = 2.40 (d, J = 1.1 Hz, 3H, CH3), 6.33 (d, J = 1.0 Hz, 1H, 
O
O
Me
OTf
OMe
O
O
Me
OTf
Cl
 108 
 
CH=), 6.96 -7.42 (m, 6H, ArH).13C NMR (62.9 MHz, CDCl3):  = 17.6 (CH3), 115.6, 
117.5, 119.3,128.1 (CH), 129.4  (q, JF,C = 320.3 Hz, CF3), 129.6 (CH), 131.4, 134.6, 
136.7, 141.3, 149.7,  150.0, 151.3 (C), 158.4 (CO). 19F NMR (282.4, MHz): δ =  -73.5 
(3F, CF3).  IR (KBr, cm
-1):  v = 3080, 3065, 2921, 2850 (w), 1738, 1732, 1615 (s), 1592, 
1574, 1538 (w), 1505 (m), 1477 (m). GC-MS (EI, 70 eV): m/z (%) = 418 ([M]+, [35Cl], 
100), 287 (34), 285 (20), 251 (10), 222 (41), 165 (25). HRMS (EI, 70 eV) calcd for 
C17H10O5
35ClF3S ([M]
+): 417.98841;  found:  417.98743. 
 
4-Methyl-2-oxo-7-(p-tolyl)-2H-chromen-6-yl trifluoromethanesulfonate (19d): 
Starting with 17 (70 mg, 0.1534 mmol), 3d (25 mg, 0.184 
mmol), Pd(PPh3)4 (5 mg, 3 mol -%, 0.00432  mmol), K3PO4 
(49 mg, 0.230 mmol), and 1,4-dioxane (3 ml), 19d was 
isolated as a white solid (46 mg, 75 %); mp 135-136°C. 1H 
NMR (300 MHz, CDCl3): δ =  2.25 (s, 3H, CH3), 2.40 (d, J = 1.3 Hz, 3H, CH3), 6.32 (d, 
J = 1.4 Hz, 1H, CH=), 7.11 (d, J = 8.2 Hz, 1H, ArH), 7.417 (d, J = 8.3 Hz, 1H, ArH),7.32 
- 7.42 (m, 3H, ArH), 7.50 (br. s, 1H, ArH).13C NMR (75.47 MHz, CDCl3): δ = 17.51, 
17.62 (CH3), 114.8, 115.1, 115.5, 117.2 (CH), 118.5 (q, JF,C = 319.4 Hz, CF3), 118.7 
(CH),130.3, 136.9, 141.4, 149.7, 151.3, 159.5, 160.6 (C), 163.9 (CO). 19F NMR (282.4, 
MHz): δ =  -73.8 (3F, CF3).  IR (KBr, cm-1):  v = 3067, 2960, 2920, 2848 (w), 1731 (s), 
1621, 1606 (m),1548 (w), 1519, 1491 (m).  GC-MS (EI, 70 eV): m/z (%) = 398 ([M]+, 
100), 265 (16), 238 (17), 237 (85), 209 (34), 165 (32). HRMS (EI, 70 eV) calcd for 
C18H13F3O5S [M]
+:  398.04303;  found:  398.04309. 
 
7-(4-Ethylphenyl)-4-methyl-2-oxo-2H-chromen-6-yltrifluoromethanesulfonate (19e): 
Starting with 17 (70 mg, 0.1534 mmol), 3e (22 mg, 0.1840 
mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 0.00432  mmol), K3PO4 
(49 mg, 0.230 mmol), and 1,4-dioxane (3 ml), 19e was 
isolated as a white solid (53 mg, 84 %); mp 92-94°C. 1H 
NMR (300 MHz, CDCl3): δ = 1.15 (t, J = 6.3 Hz, 3H, CH3), 2.38 (d, J = 1.3 Hz, 3H, 
CH3), 2.61 (q, J = 6.2 Hz, 2H, CH2), 6.23 (d, J = 1.4 Hz, 1H, CH=), 6.96 -7.02 (m, 5H, 
ArH), 7.50 (br. s, 1H, ArH).13C NMR (75.47 MHz, CDCl3): δ = 14.38, 17.62  (CH3), 28.6 
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(CH2), 113.9, 117.4 (CH), 117.7 (C),125.4, 126.5, 128.5 (CH), 128.6 (C), 136.0 (q, JF,C = 
320.6 Hz, CF3), 141.9, 142.4, 143.4, 151.2, 151.5 (C), 159.9 (CO).
 19F NMR (282 MHz, 
CDCl3): δ =  -73.7 (3F, CF3).  IR (KBr, cm-1): v =  3458, 3074, 3040 (w), 2962, 2920, 
2847 (m), 2351, 1805 (w), 1736, 1612 (s), 1574, 1529, 1495 (w). GC-MS (EI, 70 eV): 
m/z (%) = 412 ([M]+, 100), 280 (19), 279 (84), 222 (25), 221 (15), 165 (15). HRMS (EI, 
70 eV) calcd for  C19H15O5F3S [M]
+ :  412.0568;  found:  412.05853.  
 
7(4-Fluorophenyl)4-methyl-2-oxo-2H-chromen-6-yltrifluoromethanesulfonate (19f):            
Starting with 17 (70 mg, 0.1534 mmol), 3f (25 mg, 0.1840 
mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 0.00432  mmol), K3PO4 
(49 mg, 0.230 mmol), and 1,4-dioxane (3 ml), 19f was 
isolated as a white solid (48 mg, 78 %); mp 111-112°C. 1H 
NMR (300 MHz, CDCl3): δ = 2.38 (d, J = 1.3 Hz, 3H, CH3), 6.23  (d, J = 1.2 Hz, 1H, 
CH=), 6.94 - 6.98  (m, 4H, ArH), 7.29 (br. s, 1H, ArH), 7.49 (br. s, 1H, ArH).13C NMR 
(75.46 MHz, CDCl3):  = 17.6 (CH3), 20.1, 117.4, 117.8 (CH), 118.8 (q, JF,C = 320.1 Hz, 
CF3), 127.8 (d, J = 21.6 Hz ), 128.6 (d, J = 8.2 Hz) (CH), 135.6, 135.8 (d, J = 3.3 Hz), 
136.1, 136.4, 143.4, 146.8 (d, JF,C = 248.9 Hz) (CF), 151.7 (C), 159.9 (CO).
 19F NMR 
(282 MHz, CDCl3): δ =  -112.4 (ArF),  -73.8 (3F, CF3). IR (KBr, cm-1): v  =  3022,  2961, 
2918, 2851 (w), 1731, 1715 (s), 1651 (w), 1621, 1610 (m), 1573,  1568,  1543,  1519, 
1514, 1485 (w). GC-MS (EI, 70 eV):  m/z (%) =  402 ([M]+, 100),  270 (17),  269 (30), 
165 (12).  HRMS (EI, 70 eV)   calcd for  C17H10F4O5S [M]
+:  402.01796;  found:  
402.01766. 
 
7-(4-Ethoxyphenyl)-4-methyl-2-oxo-2H-chromen-6-yltrifluoromethanesulfonate 
(19g): 
Starting with 17 (70 mg, 0.1534 mmol), 3g  (31 mg, 
0.1840 mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 0.00432  
mmol), K3PO4 (49 mg, 0.230 mmol), and 1,4-dioxane (3 
ml), 19g was isolated as a white solid (59 mg, 90 %); mp 
122 -124°C. 1H NMR (300 MHz, CDCl3): δ =  1.48 (t, J = 6.9 Hz, 3H, CH3), 2.39 (s, 3H, 
CH3), 4.03 (q, J = 9.0 Hz, CH2), 6.29 (d, J = 1.6  Hz, 1H, CH=), 6.92 (d, J = 8.8  Hz, 2H, 
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ArH), 7.29 - 7.39 (m, 3H, ArH), 7.48 (br. s, 1H, ArH).13C NMR (75.46 MHz, CDCl3):  
= 18.4, 18.6 (CH3), 63.5 (OCH2), 114.7, 116.0, 117.3 (CH), 118.2  (q, JF,C = 320.2 Hz, 
CF3), 119.5 (CH), 127.3 (C), 130.5 (CH), 138.8, 142.6, 150.0, 150.8, 152.5, 158.2 (C), 
159.8 (CO). 19F NMR (282 MHz, CDCl3):  = -73.7 (3F, CF3).  IR (KBr, cm-1): v = 3119, 
3081, 2988, 2923, 2852 (w), 1728 (s), 1660 (w), 1607 (m), 1576, 1542, 1522, 1496 (w).  
GC-MS (EI, 70 eV): m/z (%) = 428 ([M]+,100), 296 (19), 295 (30), 267 (69).  HRMS (EI, 
70 eV) calcd for  C19H15F3O6S [M]
+:  428.05359;  found:  428.05397. 
 
7-(4-Tert-butylphenyl)-4-methyl-2-oxo--2H-chromen-6-yltrifluoromethanesulfonate 
(19h): 
Starting with 17 (70 mg, 0.1534 mmol), 3i (33 mg, 0.1840 
mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 0.00432  mmol), K3PO4 
(49 mg, 0.230 mmol), and 1,4-dioxane (3 ml), 19h  was 
isolated as a white solid (52 mg,77 %); mp 131-133°C. 1H 
NMR (300 MHz, CDCl3): δ = 1.23 (s, 9H, 3CH3), 2.40 (d, J = 1.2 Hz, 3H, CH3), 6.31 (d, 
J = 1.4 Hz, 1H, CH=), 7.34 (d, J = 8.8 Hz, 3H, ArH), 7.44  (d, J = 8.3 Hz, 2H, ArH),7.50 
(br. s, 1H, ArH).13C NMR  (75.47 MHz, CDCl3): δ  = 17.5 (CH3), 30.20 (3CH3), 33.7 
(C), 115.2, 117.1, 118.7, 124.7 (CH), 125.1 (q, JF,C = 320.4 Hz, CF3), 127.9 (CH), 138.0, 
141.7, 138.0, 141.7, 149.9, 151.3, 151.6 (C), 158.7 (CO). 19F NMR (282.4, MHz): δ =  -
73.7 (3F, CF3). IR (KBr, cm
-1):  v  = 3070, 2963, 2923, 2851 (w), 1734 (s), 1624, 1609 
(m), 1551 (w), 1521, 1494 (m). (w). GC-MS (EI, 70 eV): m/z (%) = 440 ([M]+, 100), 265 
(16), 238 (17), 237 (85), 209 (34), 165 (32). HRMS (EI, 70 eV)  calcd for  C21H19F3O5S  
[M]+: 440.08998;  found:  440.04309. 
 
4-Methyl-2-oxo-7-(m-tolyl)-2H-chromen-6-yl trifluoromethanesulfonate (19i):        
Starting with 17 (70 mg, 0.1534 mmol), 3j (25 mg, 0.1840  
mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 0.00432  mmol), K3PO4 (49 
mg, 0.230 mmol), and 1,4-dioxane (3 ml), 19i was isolated as a 
white solid (48 mg, 80 %); mp 85-86°C. 1H NMR (300 MHz, 
CDCl3): δ =  2.20 (s, 3H, CH3), 2.39 (d, J = 1.2 Hz, 3H, CH3), 6.24 (d, J = 1.3 Hz, 1H, 
CH=), 6.8 (d, J = 8.3 Hz, 2H, ArH), 7.01 - 7.03 (m, 2H, ArH), 7.31 (br. s, 1H, ArH) , 
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7.50 (br. s, 1H, ArH).13C NMR (75.47 MHz, CDCl3): δ = 17.51, 17.62 (CH3), 114.8, 
115.1, 115.5, 117.2 (CH), 118.5 (q, JF,C = 319.4 Hz, CF3), 118.7 (CH), , 130.3, 136.9, 
141.4, 149.7, 151.3, 159.5, 160.6 (C), 163.9 (CO). 19F NMR (282.4, MHz):  δ = -73.7 
(3F, CF3).   IR (KBr,  cm
-1):  v = 3070, 2961, 2921, 2849 (w), 2961 (s), 2905, 2855 (m), 
1548 (w), 1519, 1491 (m). GC-MS (EI, 70 eV): m/z (%) = 398 ([M]+, 100), 266 (18), 265 
(30), 209 (11). HRMS (EI, 70 eV) calcd for  C18H13F3O5S [M]
+:  398.04303;  found: 
398.04297. 
4-Methyl-2-oxo-7-(2,3,4-trimethoxyphenyl)- 2H-chromen-6-yl trifluoromethane-
sulfonate (19j): 
Starting with 17 (70 mg, 0.1534 mmol), 3o (33 mg, 0.184 
mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 0.00432  mmol), 
K3PO4 (49 mg, 0.230 mmol), and 1,4-dioxane (3 ml), 19j 
was isolated as a white solid (65 mg, 90 %); mp 155-
157°C. 1H NMR (300 MHz, CDCl3): δ =  2.39 (d, J = 1.2 Hz, 3H, CH3), 3.78 (s, 3H, 
OCH3), 3.84 (d, J = 6.9 Hz, 6H, 2xOCH3 ), 6.31 (d, J = 1.3 Hz, 1H, CH=), 6.68 (d, J = 
8.4 Hz, 1H, ArH), 6.89 (d, J = 8.3 Hz, 1H, ArH), 7.31 (br. s, 1H, ArH), 7.45 (br. s, 1H, 
ArH). 13C NMR (75.46 MHz, CDCl3):  = 17.4 (CH3), 55.0, 59.8, 59.9 (OCH3), 106.1, 
115.1, 116.1 (CH), 118.8 (C), 119.1 (q, JF,C = 319.1 Hz, CF3), 119.5 (CH), 119.6 (C), 
124.4 (CH), 135.2, 141.1, 142.5, 149.9, 150.3, 151.0, 154.0, (C), 158.8 (CO). 19F NMR 
(282 MHz, CDCl3): δ  =  -73.9 (3F, CF3). IR (KBr, cm-1): v = 3110, 3087, 3072, 2963, 
2927, 2839 (w), 1727 (s), 1619, 1603 (m), 1574, 1541, 1520, 1492 (w).  GC-MS (EI, 70 
eV): m/z (%) = 474 ([M]+,100), 341 (22), 310 (30), 295 (12).  HRMS (EI, 70 eV) calcd 
for  C20H17F3O8S [M]
+:  474.05907;  found: 474.05931. 
  
4-Methyl-2-oxo-7-phenyl-2H-chromen-6-yl trifluoromethanesulfonate (19k):        
Starting with 17 (70 mg, 0.1534 mmol), 3p (22 mg, 0.1840 
mmol), Pd(PPh3)4 (5 mg, 3mol-%, 0.00432  mmol), K3PO4 (49 
mg, 0.230 mmol), and 1,4-dioxane (3 ml), 19k was isolated as a 
white solid (42 mg, 72 %);  mp 95-96°C. 1H NMR (300 MHz, 
CDCl3): δ =  2.40 (s, 3H, CH3), 6.26  (s, 1H, CH=), 7.07 - 7.18 (m, 5H, ArH), 7.36 (d, J = 
8.3 Hz, 1H, ArH),  7.53 (br. s, 1H, ArH) .13C NMR (75.47 MHz, CDCl3): δ = 17.64 
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(CH3), 114.2, 117.5, 125.4, 126.4 (CH), 127.7  (q, JF,C = 320.2 Hz, CF3), 128.2, 128.8 
(CH), 136.1, 138.6, 139.2, 143.4, 151.1, 151.7  (C), 159.8  (CO). 19F NMR (282.4, MHz): 
δ = -73.7 (3F, CF3).  IR (KBr, cm-1):  v  = 3090,  2981,  2941,  2869 (w), 2981 (s), 2925, 
2875 (m), 1568 (w),  1529, 1496  (m).  GC-MS (EI, 70 eV): m/z (%) = 384 ([M]+, 100), 
252 (18), 251 (30), 195 (19), 152 (13). HRMS (EI, 70 eV) calcd for C17H11F3O5S [M]
+:  
384.02738;  found:  384.02760. 
4-Methyl-2-oxo-7-[4-(trifluoromethan)phenyl]-2H-chromen-6-yl trifluorometha-
nesulfonate (19l):   
Starting with 17 (70 mg, 0.1534 mmol), 3g (35 mg, 0.184 
mmol), Pd(PPh3)4 (5 mg, 3 mol -%, 0.00432 mmol), K3PO4 
(49 mg, 0.230 mmol), and 1,4-dioxane (3 mL), 19l was 
isolated as a white solid (58 mg, 83 %); mp 101-102°C. 1H 
NMR (300 MHz, CDCl3): δ = 2.42  (d, J = 1.3 Hz, 3H, CH3), 6.30  (d, J = 1.2 Hz, 1H, 
CH=), 7.17 (d,  J = 8.07 Hz, 2H, ArH), 7.33 (br. s, 1H, ArH), 7.46  (d,  J = 8.24  Hz,  2H, 
ArH), 7.54 (br. s, 1H, ArH) .13C NMR (75.46 MHz, CDCl3):  = 17.6 (CH3), 114.9, 
117.8, 118.8  (CH), 122.2  (q, JF,C = 320.4  Hz, CF3),   124.3 (d, J = 21.6 Hz ), 125.7 (d, J 
= 8.2 Hz) (CH), 135.6 (d,  J = 32.6 Hz ), 135.8, 136.1(d,  J = 1.1 Hz ),, 136.4, 143.4, 
146.8 (d, JF,C = 248.9 Hz, CF3) , 151.7, 152.1  (C), 159.9 (CO).
 19F NMR (282 MHz, 
CDCl3): δ  =  -112.4,  - 62.6 (3F, CF3)  . IR (KBr, cm-1): v  = 3053, 2961, 2905, 2854 (w), 
1723, 1614 (s), 1574, 1547, 1488 (w). GC-MS (EI, 70 eV): m/z (%) =  452 ([M]+, 100),  
270 (17),  269 (30), 165 (12).  HRMS (EI, 70 eV) calcd for  C18H10F6O5S [M]
+: 
452.01476 ;  found:  452.12567. 
 
7-(3-Methoxyphenyl)-4-methyl-2-oxo-2H-chromen-6-yltrifluoromethanesulfonate 
(19m):  
Starting with 17 (70 mg, 0.1534 mmol), 3r (28 mg, 0.184 
mmol), Pd(PPh3)4 (5 mg, 3 mol- %, 0.00432  mmol), K3PO4 
(49 mg, 0.230 mmol), and 1,4-dioxane (3 ml), 19m was 
isolated as a white solid (44 mg,70 %); mp 112-114°C. 1H 
NMR (300 MHz, CDCl3): δ =  2.40 (d, J = 1.3 Hz, 3H, CH3), 3.78 (s, 3H, OCH3), 6.32 
(d, J = 1.3 Hz, 1H, CH=), 6.91 - 6.93 (m, 2H, ArH),   6.95 (d, J = 8.8 Hz, 1H, ArH), 7.30 
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(d, J = 8.8 Hz 1H, ArH), 7.36 (br. s, 1H, ArH), 7.49 (br. s, 1H, ArH).13C NMR (75.46 
MHz, CDCl3):  = 17.5 (CH3), 54.3 (OCH3), 113.8, 113.9, 115.1, 115.4, 118.8  (CH), 
119.1 (q, JF,C = 320.1 Hz, CF3), 120.6, 128.8 (CH), 134.2, 137.9, 141.5, 149.7, 151.3, 
158.6, 159.1 (C), 160.9 (CO). 19F NMR (282 MHz, CDCl3):   =  -73.7 (3F, CF3). IR 
(KBr, cm-1): v = 3112, 3089, 3074, 2965,  2929,  2841 (w), 1731 (s), 1621, 1600, 1582 
(m), 1547, 1506, 1482, 1468 (w).  GC-MS (EI, 70 eV): m/z (%) = 414 ([M]+,100), 282 
(18), 281 (40), 67 (18).  HRMS (EI, 70 eV) calcd for   C18H13F3O6S [M]
+:  414.03794;  
found:  414.03799. 
 
 General procedure for synthesis (20a-d) 
The reactions were carried out in a pressure tube. A 1,4-dioxane suspension (3 ml) of 
bis(triflates) analogue 17 (70 mg, 0.1534 mmol), Pd(PPh3) (5 mg, 3 mol -%, 0.00432  
mmol), and Ar1B(OH)2 (1.2 equiv.), K3PO4 (49 mg, 0.2301 mmol) was added. The 
mixture was heated at 70oC under Argon atmosphere. After 6 h, a dioxan (3 ml) 
suspension of Ar2B(OH)2 (1.2 equiv.), Pd(PPh3)4 (5 mg, 3mol-%, 0.00432  mmol), 
K3PO4 (49 mg, 0.2301 mmol) was added. The reaction mixture was diluted with water 
and extracted with CH2Cl2 (3 x 25 ml). The combined organic layers were dried 
(Na2SO4), filtered and the filtrate was concentrated in vacuo. The residue was purified by 
flash chromatography (silica gel, heptane/EtOAc = 8:2).    
 
6-(4-Chlorophenyl)-7-(4-methoxyphenyl)-4-methyl-2H-chromen-2-one (20a):        
Starting with 17 ( 70 mg,  0.1534 mmol ) , 3b (28 mg, 
0.1840 mmol), Pd(PPh3)4 (5 mg, 3 mol -%, 0.00432  mmol 
),  K3PO4 (49 mg, 0.2301 mmol), 3c (28 mg, 0.1840 
mmol), Pd(PPh3)4 (5 mg, 3mol-%, 0.00432 mmol),  K3PO4 
(49 mg, 0.2301 mmol),   and 1,4-dioxane (3 ml), 20a was 
isolated as a white solid (42 mg, 73 %);   mp 172-174°C.  1H NMR (300 MHz, CDCl3):  
δ =  2.39 (d, J = 1.1 Hz, 3H, CH3), 3.73 (s,  3H,  OCH3), 6.24 (d, J = 1.3 Hz, 1H, CH=), 
6.72 (d, J = 8.1 Hz,  2H,  ArH), 6.95 - 6.99 (m, 5H, ArH), 7.16 (d, J = 8.1 Hz,  2H,  ArH), 
7.46 (br. s, 1H, ArH) .13C NMR (75.46 MHz, CDCl3):  = 17.6  (CH3), 54.2 (OCH3), 
112.7, 114.1, 117.4 (CH), 117.8 (C), 125.3, 127.4, 129.8, 130.0 (CH), 130.5, 132.0, 
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134.7, 137.8, 143.1, 151.0, 151.9, 158.1 (C), 159.7 (CO).  IR (KBr, cm-1): v  = 3115, 
3092, 3076,  2966,  2932,  2845 (w), 1731  (s), 1620, 1600 (m), 1580, 1540, 1522, 1493 
(w).  GC-MS (EI, 70 eV):  m/z (%) =  376  ([M]+,[35Cl], 100),  348 (13) . HRMS (EI, 70 
eV)  calcd for  C23H17
35ClO3  ([M]
+):  376.08607;  found  376.08589. 
 
6-(4-Florophenyl)-7-(4-methoxyphenyl)-4-methyl-2H-chromen-2-one (20b):                     
Starting with 17 ( 70 mg,  0.1534 mmol ) , 3b (28 mg, 
0.1840 mmol), Pd(PPh3)4 (5 mg, 3 mol -%, 0.00432  
mmol),  K3PO4 (49 mg, 0.2301 mmol), 3f (25 mg, 0.1840 
mmol), Pd(PPh3)4 (5 mg, 3mol-%, 0.00432 mmol),  K3PO4 
(49 mg, 0.2301 mmol),   and 1,4-dioxane (3 ml), 20b was isolated as a white  solid  (43 
mg, 78 %);  mp 192-194°C. 1H NMR (300 MHz, CDCl3): δ =  2.39 (d, J = 1.3 Hz, 3H, 
CH3), 3.72 (s, 3H, OCH3), 6.24 (d, J = 1.2  Hz, 1H, CH=), 6.70 (d, J = 8.4 Hz, 2H, ArH), 
6.88 - 7.03 (m, 6H, ArH),  7.28 (br. s, 1H, ArH), 7.46 (br. s, 1H, ArH)  .13C NMR (75.46 
MHz, CDCl3):   =  17.6 (CH3), 54.2 (OCH3), 112.7, 114.2 (d, J = 8.2 Hz), 117.3 (CH), 
117.7 (C) ,125.3, 129.8, 130.3 (d, J = 21.6 Hz ), 130.7  (CH), 134.9  (q, JF,C = 273.1 
Hz)(CF), 135.4   143.1, 151.0, 151.8, 158.1, 159.3, 159.8 (C), 162.5 (CO). 19F NMR (282 
MHz, CDCl3): δ  =  - 115.3 (ArF) . IR (KBr, cm-1): v  = 3115, 3092, 3076,  2966,  2932,  
2845 (w), 1731  (s), 1620, 1600 (m), 1580, 1540, 1522, 1493 (w).  GC-MS (EI, 70 eV):  
m/z (%) =  360  ([M]+, 100),  348 (13) . HRMS (EI, 70 eV)  calcd for  C23H17FO3  ([M]
+):  
360.11562;  found:  360.11580. 
 
7-(4-Methoxyphenyl)-4-methyl-6-(m-tolyl)-2H-chromen-2-one (20c):                             
Starting with 17 ( 70 mg,  0.1534 mmol ) , 3b (28 mg, 
0.1840 mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 0.00432 mmol),  
K3PO4 (49 mg, 0.2301 mmol as solid?), 3j (25 mg, 0.1840 
mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 0.00432 mmol),  K3PO4 
(49 mg, 0.2301 mmol),   and 1,4-dioxane (3 ml), 20c was isolated as a white   solid (41 
mg, 75 %);   mp 209-211°C. 1H NMR (300 MHz, CDCl3): δ =  2.21 (s, 3H, CH3), 2.37 
(d, J = 1.2 Hz, 3H, CH3), 3.69  (s,  3H,  OCH3), 6.21 (d, J = 1.3 Hz, 1H, CH=), 6.70 (d, J 
= 8.4 Hz,  2H,  ArH), 6.81 (d, J = 8.9 Hz,  2H,  ArH),  6.93 - 7.06 (m, 4H, ArH),  7.27 
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(br. s, 1H, ArH) , 7.48 (br. s, 1H, ArH).13C NMR (75.46 MHz, CDCl3):  = 17.6, 20.3 
(CH3), 54.1 (OCH3), 112.5, 113.8, 117.1 (CH), 117.6 (C), 152.4, 125.9, 126.6, 126.9, 
129.3, 129.7 (CH), 131.0, 136.1, 136.8, 139.3, 143.1, 151.2, 151.6, 158.0 (C), 159.9 
(CO).   IR (KBr, cm-1): v  = 3111, 3094, 3077,  2967,  2931,  2846 (w), 1732  (s), 1624, 
1606 (m), 1583, 1547, 1526, 1495 (w). GC-MS (EI, 70 eV):  m/z (%) =  356 ([M]+,100),  
341(10) . HRMS (EI, 70 eV) calcd for  C24H20O3  ([M]
+) :  356.14070;  found:  
356.14106.; 
 
6-(3,5-Dimethlyphenyl)-7-(4-methoxyphenyl)-4-methyl-2H-chromen-2-one (20d):                                   
Starting with  17 ( 70 mg,  0.1534 mmol ) , 3b (28 mg, 
0.1840 mmol), Pd(PPh3)4 (5 mg, 3 mol-%, 0.00432 mmol),  
K3PO4 (49 mg, 0.2301 mmol), 3a (27 mg, 0.1840 mmol), 
Pd(PPh3)4 (5 mg, 3 mol-%, 0.00432 mmol),  K3PO4 (49 
mg, 0.2301 mmol), and 1,4-dioxane (3 ml), 20d was 
isolated as a white solid (46 mg, 81 %);  mp 203-205°C.   1H NMR (300 MHz, CDCl3): δ 
=  2.15 (6H, 2xCH3), 2.38 (d, J = 1.4 Hz, 3H, CH3), 3.71  (s,  3H,  OCH3), 6.22 (d, J = 
1.3 Hz, 1H, CH=), 6.67 - 6.79 (m, 5H, ArH), 6.99 (d, J = 8.4 Hz, 2H,  ArH), 7.28 (br. s, 
1H, ArH) , 7.47 (br. s, 1H, ArH).13C NMR (75.46 MHz, CDCl3):   = 17.6  (2xCH3), 21.6 
(CH3), 54.2 (OCH3), 113.8, 114.1 (CH), 117.1 (C), 117.5 (CH), 125.3 (C), 126.4, 126.6, 
127.5, 129.7, 131.0 (CH), 136.2, 136.5, 136.6, 139.2, 143.1, 151.2, 151.6, 157.9 (C), 
159.9 (CO). IR (KBr, cm-1): v  = 3117, 3094, 3078,  2969,  2934,  2847 (w), 1734  (s), 
1627, 1609 (m), 1585, 1549, 1528, 1497 (w).  GC-MS (EI, 70 eV):  m/z (%) =  370 
([M]+,100),  355 (12), 300 (11). HRMS (EI, 70 eV) calcd for  C25H22O3  ([M]
+) : 
370.15635;  found:  370.15622.  
 
3-Bromo-6,7-dihydroxy-4-methyl-2H-chromen-2-one (21):  
To asolution of 4-Methyl-6,7-dihydroxycoumarin 16 (1.0 equive,  
0.0026 mol, 0.5 gm ) in glacial acetic acid (20 ml) bromine (2.0 
equive, 0.0052 mol, 0.8 gm ) were added dropwise under argon 
atmosphere, the reaction mixture was stirred at 30°C for 2 hr, the reaction monitored by 
TLC (heptane / EtOAc = 9.5 : 0.5). the reaction mixture mpoured in ice-cold water (250 
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ml), stirred with a solution of sodium hydrogen sulphite till the yellow color disappears, 
filtered and the residue was purified by column chromatography (silica gel, heptane / 
EtOAc = 10 : 1).to give 21  as a yellow solid (0.52 g, 75 %), mp 181-183oC. NMR (300 
MHz, CDCl3): δ = 2.50 (s, 3H, CH3), 6.77 (s, 1H, ArH), 7.09 (s, 1H, ArH), 9.80 (s, 1H, 
OH), 10.30 (s, 1H, OH).13C NMR (75.4 MHz, CDCl3): δ = 19.4 (CH3), 102.4 (CH), 107.6 
(C) , 109.9 (CH), 111.2, 143.3, 146.1, 150.5 (C), 161.3 (CO). IR (KBr, cm-1): v = 3057, 
2995, 2950, 2930, 2831 (w), 1599 (s), 1574, 1551 (w). GC-MS (EI, 70 eV): m/z (%) = 
272 ([M+H]+, [81Br], 100), 271 ([M]+, [81Br], 26), 270 ([M+H]+, [79Br], 99), 269 ([M]+, 
[79Br], 10),  244 (20), 242 (22), 192 (12), 191 (17),164 (58), 89 (16). HRMS (EI, 70 eV) 
calcd for  C10H8
81BrO4 [M+H]
+:  272.9581,  found:  272.9574, C10H8
79BrO4 [M+H]
+:  
270.96005,  found:  270.95949 
 
3-Bromo-4-methyl-2-oxo-2H-chromene-6,7-diylbis-(trifluoromethanesulfonate) (22):  
To a solution of 3-bromo-4-methyl-6,7-dihydroxycoumarine 21 
(0.5 g, 2.60 mmol) in CH2Cl2 (30 ml) was added triethylamine 
(0.36 ml, 10.4 mmol) at room temperature under an argon 
atmosphere. After 10 min, Tf2O (1.0 ml, 6.2 mmol) was added at -78°C. The mixture was 
allowed to warm to 20°C and stirred for 6 h. The reaction mixture was filtered and the 
filtrate was concentrated in vacuo. The residue was purified by chromatography (flash 
silica gel, heptane / EtOAc = 8 : 2) without aqueous work up to give 22 as a white solid 
(0.9 g, 75 %);  mp 125-27°C. 1H NMR (300 MHz, CDCl3):  δ = 2.58 (CH3), 7.45 (s , 1H, 
ArH), 7.79 (s, 1H, ArH). 13C NMR (75.46 MHz, CDCl3):   = 18.80 (CH3), 111.6 (CH), 
115.2 (C), 115.5 (q, JF,C = 316.0 Hz, CF3), 118.9 (C), 119.2 (CH), 120.3 (q, JF,C = 316.0 
Hz, CF3), 135.9, 140.6, 147.6, 149.7 (C), 153.9 (CO).
 19F NMR (282.4, MHz): δ = -72.7, 
-72.9 (3F, CF3). IR (KBr, cm
-1):  v = 3123, 3051,  2962,  2925 (w), 1742 (s), 1670, 1621, 
1612, 1571 (w), 1492 (m). GC-MS (EI, 70 eV): m/z (%) = 535 ([M]+,[81Br], 19), 533 
([M]+,[79Br], 17),  403 (27), 401 (24), 311 (28), 281 (11), 309 (29), 202 (13), 77 (25).  
HRMS (EI, 70 eV) calcd for  C12H5O8
81BrF6S2 [M]
+:  535.84875,  found:  535.84860, 
C12H5O8
79BrF6S2 [M]
+:  533.85079,  found:  533.85079. 
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General procedure for synthesis (23a-o) 
The reactions were carried out in a pressure tube. A 1,4-dioxane solution (3 ml) of 22, 
arylboronic acid (3.1equiv.), aqueous K2CO3 (2 M, 2 ml) and Pd(PPh3)4 (14 mg, 9 mol-
%, 0.01212 mmol) was heated at 120°C for 10 h under argon atmosphere. After cooling 
to 20°C, H2O was added and the reaction mixture was extracted with CH2Cl2 (3 x 25 ml). 
The organic layers were dried (Na2SO4), filtered and concentrated in vacuo. The residue 
was purified by column chromatography (silica gel, heptane/EtOAc = 9:1). 
 
3,6,7-Tris(3,5-dimethylphenyl)-4-methyl-2H-chromen-2-one (23a): 
Starting with 22 (70 mg, 0.1308 mmol), 3a  (61 mg, 
0.406 mmol) and Pd(pph3)4 (14 mg, 9 mol-%, 
0.01212 mmol) , K2CO3  (2 M, 2 ml), and 1,4-
dioxane (3 ml), 23a was isolated as a white solid 
(43 mg, 70 %), mp 190-192oC.1H NMR (300 MHz, 
CDCl3): δ = 2.13 (s, 6H, 2xCH3), 2.14 (s, 6H, 
2xCH3), 2.24 (s, 3H, CH3), 2.28 (s, 6H, 2xCH3),  6.68 - 6.69 (m, 5H, ArH), 6.79 - 6.84 
(m, 5H, ArH),  6.94 (d, J = 8.6, Hz, 1H, ArH), 7.32 (s, 1H, ArH). 7.55 (br. s, 2H, ArH). 
13C NMR (75.4 MHz, CDCl3): δ = 15.5 (2xCH3), 20.2 (2xCH3), 20.3 (2xCH3), 28.6 
(CH3), 116.9 (CH), 118.3 (C), 125.6, 126.4, 126.5, 126.6, 127.3, 127.8, 127.9 (CH), 
133.4, 136.3, 136.3, 136.8, 138.6, 139.3, 143.1, 143.1, 143.2, 146.3, 147.4, 150.6, 154.2 
(C),161.2 (CO). IR (KBr, cm-1): v =  3012, 2955 (w), 2919 (m), 2853 (w), 1707 (s), 1610, 
1597 (m), 1552, 1495 (w). GC - MS (EI, 70 eV): m/z (%) = 472 ([M]+, 100), 444 (15), 
429 (12), 214 (14), 179 (10). HRMS (EI, 70 eV) calcdfor C34H32O2 [M]
+: 472.240 ; 
found: 472.24014. 
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3,6,7-Tris(4-methoxyphenyl)-4-methyl-2H-chromen-2-one (23b):                               
Starting with 22  (70 mg, 0.1308 mmol), 3b   (62 
mg, 0.406 mmol), Pd(PPh3)4 (14 mg, 9 mol-%, 
0.01212 mmol), K2CO3 (2 M, 2 ml), and 1,4-
dioxane (3 ml),  23b was isolated as a white 
solid (50 mg, 80 %), mp 169-170oC.1H NMR 
(300 MHz, CDCl3): δ = 2.28 (s, 3H, CH3), 3.72 (s, 6H, 2xOMe), 3.78 (s, 3H, OMe), 6.73 
(dd, J = 1.7, 8.3 Hz, 4H, ArH),  6.93 (d, J = 8.6, Hz, 2H, ArH), 6.99 (dd, J = 1.6, 8.6 Hz, 
4H, ArH), 7.23 (d, J = 8.6, Hz, 2H, ArH), 7.30 (s, 1H, ArH), 7.53 (s, 1H, ArH).13C NMR 
(75.4 MHz, CDCl3): δ = 16.6 (CH3), 55.2, 55.3, 55.5 (OMe), 113.6, 113.8, 117.9, 119.4, 
126.6 (CH), 126.7, 126.9 (C), 130.8, 130.9, 131.3, 131.6 (CH),132.2, 132.9, 136.6, 143.4, 
147.1, 151.6, 158.6, 158.9, 159.4 (C), 161.3 (CO). IR (KBr, cm-1): v = 3059, 2993, 2952, 
2931, 2834 (w), 1715, 1599 (s), 1574, 1551 (w). GC-MS (EI, 70 eV): m/z (%) =  478 
([M]+, 100), 450 (14), 207 (13). HRMS (EI, 70 eV) calcd for C31H26O5 [M]
+: 478.53514; 
found: 478.53412. 
 
 3,6,7-Tris(4-chlorophenyl)-4-methyl-2H-chromen-2-one (23c):     
Starting with 22  (70 mg, 0.1308 mmol), 3c  (61 mg, 
0.406 mmol) and Pd(pph3)4 (14 mg, 9 mol-%, 
0.01212 mmol) , K2CO3 (2 M, 2 ml), and 1,4-
dioxane (3 ml), 23c was isolated as a white solid (39 
mg, 60 %), mp 200-201oC.1H NMR (300 MHz, CDCl3): δ = 2.28 (s, 3H, CH3), 6.97 - 
7.02 (m, 3H, ArH), 7.14 - 7.21 (m, 5H, ArH), 7.27 - 7.40 (m, 6H, ArH) .13C NMR (75.4 
MHz, CDCl3): δ = 16.6 (CH3), 114.1, 114.2, 114.3, 115.2, 117.8, 119.3 (CH), 124.4 (C), 
124.7, 124.8 (CH), 128.7, 128.8, 130.3, 132.0, 132.8, 134.6, 143.4, 145.2, 150.5, 151.5, 
156.9 (C), 160.4 (CO). IR (KBr, cm-1): v = 3067, 3032, 2979, 2927, 2918, 2888, 2839 
(w), 1715, 1599 (s), 1572, 1548, 1519 (w), 1512 (m). GC-MS (EI, 70 eV): m/z (%) = GC 
- MS (EI, 70 eV): m/z (%) = 490 ([M]+, 3×[35Cl], 99), 345 (45), 270 (15). HRMS (EI, 70 
eV) calcd for C28H17
35Cl3O2 [M]
+:  490.02886, found  490.02834. 
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4-Methyl-3,6,7-trip-tolyl-2H-chromen-2-one (23d): 
Starting with 22 (70 mg, 0.1308 mmol),  3d  (55 
mg, 0.406 mmol) and Pd(pph3)4 (14 mg, 9 mol-%, 
0.01212 mmol) , K2CO3 (2 M, 2 ml), and 1,4-
dioxane (3 ml), 23d was isolated as a white solid 
(42 mg, 75 %), mp 163-165oC.1H NMR (300 MHz, 
CDCl3): δ = 2.09 (s, 3H, CH3), 2.12 (s, 3H, CH3), 2.22 (s, 3H, CH3), 2.32 (s, 3H, CH3), 
6.99 (br. s, 1H, ArH) 7.12 (d, J = 8.3, Hz, 2H, ArH),  7.18 - 7.23 (m, 5H, ArH),  7.28 - 
7.34 (m, 2H, ArH), 7.55 (s, 2H, ArH), 7.64 (br. s, 2H, ArH). 13C NMR (75.4 MHz, 
CDCl3): δ = 15.2, 16.3, 20.1, 20.3 (CH3), 28.5 (C), 117.2, 118.1, 118.2 (CH), 118.5 (C), 
125.6, 125.9, 126.1, 126.4, 126.3 (CH), 129.4, 133.2, 136.1, 136.3, 137.0, 138.5, 139.4, 
143.2, 146.2, 150.6 (C), 160.3 (CO). IR (KBr, cm-1): v =  2962, 2923, 2854 (w), 1715 (s), 
1608 (m), 1586, 1551, 1479 (w). GC-MS (EI, 70 eV): m/z (%) = 430 ([M]+, 100), 420 
(22), 413 (13), 186 (18). HRMS (EI, 70 eV) calcd for C31H26O2 [M]
+: 430.19328 ; found: 
430.19355.  
 
3,6,7-Tris(4-ethylphenyl)-4-methyl-2H-chromen-2-one (23e): 
Starting with 22  (70 mg, 0.1308 mmol), 3e   (61 mg, 
0.406 mmol) and Pd(pph3)4 (14 mg, 9 mol-%, 
0.01212 mmol) , K2CO3 (2 M, 2 ml), and 1,4-
dioxane (3 ml), 23e was isolated as a white solid (46 
mg, 75 %), mp 134-135oC.1H NMR (300 MHz, 
CDCl3): δ = 1.11 - 1.23 (m, 9H, 3xCH3), 2.26 (s, 3H, 
CH3), 2.50 - 2.61 (m, 6H, 3xCH2), 6.68 - 6.71 (m, 4H, ArH),  6.77 (d, J = 8.6, Hz, 2H, 
ArH), 6.87 (dd, J =  1.6, 8.6 Hz, 4H, ArH), 7.13 (d, J = 8.6, Hz, 3H, ArH), 7.51 (s, 1H, 
ArH). 13C NMR (75.4 MHz, CDCl3): δ = 15.3, 15.4, 15.5, 16.6 (CH3), 28.4, 28.6, 28.7 
(CH2), 118.1, 119.5, 127.1 (CH), 127.2, 127.6 (C), 127.9, 129.6, 129.7, 130.1, 131.7 
(CH), 137.0, 137.1, 137.8, 142.9, 143.4, 143.9, 144.2, 147.3, 151.7, 152.8, (C), 161.2 
(CO). IR (KBr, cm-1): v =  3407, 3071, 3024, 2962,  2927, 2871, 2854 (w), 1722 (s), 
1613, 1604 (m), 1573, 1568, 1556, 1552 (w). GC-MS (EI, 70 eV): m/z (%) = 472 ([M]+, 
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100), 444 (13), 443 (12). HRMS (EI, 70 eV) calcd for C34H32O2 [M]
+: 472.23968; found: 
472.23912. 
  
 3,6,7-Tris(4-fluorophenyl)-4-methyl-2H-chromen-2-one (23f): 
Starting with 22  (70 mg, 0.1308 mmol), 3f   (59 mg, 
0.406 mmol), Pd(PPh3)4 (14 mg, 9 mol-%, 0.01212 
mmol), K2CO3 (2 M, 2 ml), and 1,4-dioxane (3 ml), 
23f was isolated  as a white solid (40 mg, 70 %), mp. 
222- 224°C. 1H NMR (300 MHz, CDCl3): δ = 2.28 (s, 
3H, CH3) , 6.86 - 6.92 (m, 4H, ArH), 7.00 - 7.04 (m, 4H, ArH), 7.12 (d, J = 8.52 Hz, 2H, 
ArH), 7.21 - 7.26 (m, 2H, ArH), 7.32 (s, 1H, ArH), 7.56 (s, 1H, ArH).13C NMR (62.9 
MHz, CDCl3): δ = 15.6 (CH3), 114.1 (d, JF,C  = 21.4 Hz), 114.4 (d, JF,C  = 21.4 Hz), 115.6 
(d, JF,C  = 21.4 Hz), 117.2 (CH), 118.6, 125.6 (C), 126.0 (CH), 129.1 (d, JF,C  = 3.5 Hz) 
(C), 130.2, 130.3 (CH), 130.4 (C), 130.8 (d, JF,C  = 1.7 Hz) (CH), 142.0, 146.5, 150,9, 
159.3, 159.6, 159.7 (C), 159.9 (d, JF,C  = 246.9 Hz)(CF), 162.6 (d, JF,C  = 246.0 Hz) (CF), 
162.9 (d, JF,C  = 247.4 Hz)(CF), 163.2 (CO).
 19F NMR (282.4, MHz): δ = -113.1, -144.8, 
-114.9 (ArF). IR (KBr, cm-1): v = 3038, 2929, 2859, 1892 (w), 1604 (m), 1558 (w), 1507 
(s), 1490 (m). GC-MS (EI, 70 eV): m/z (%) = 442 ([M]+, 100), 441 (21), 415 (10), 414 
(38), 413 (20). HRMS (EST-TOF/MS): calcd for. C28H17O2F3 [M]
+  : 442.11752 ; found: 
442.11697. 
 
3,6,7-Tris(4-ethoxyphenyl)-4-methyl-2H-chromen-2-one (23g):                                
Starting with 22  (70 mg, 0.1308 mmol),  
3g  (67 mg, 0.406 mmol) and Pd(pph3)4 (14 
mg, 9 mol-%, 0.01212 mmol) , K2CO3 (2 
M, 2 ml), and 1,4-dioxane (3 ml), 23g was 
isolated as a white solid (57 mg, 84 %), mp 
179-180oC.1H NMR (300 MHz, CDCl3): δ 
= 1.30 - 1.35 (m, 9H, 3xCH3), 2.26 (s, 3H, 
CH3), 3.91 - 3.98 (m, 6H, 3xOCH2), 6.67 - 6.72 (m, 4H, ArH),  6.88 (d, J = 8.6, Hz, 2H, 
ArH), 6.97 (dd, J = 1.9, 8.6 Hz, 4H, ArH), 7.15 (d, J = 8.6, Hz, 3H, ArH), 7.53 (s, 1H, 
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ArH).13C NMR (75.4 MHz, CDCl3): δ = 14.7, 14.8, 14.9, 16.6 (CH3), 63.4, 63.5, 63.6 
(OCH2), 113.1, 113.2, 113.3, 114.2, 116.8, 118.3 (CH), 125.4 (C), 125.7, 125.8 (CH), 
129.7, 129.8, 130.3, 131.0, 131.8, 135.6, 142.4, 146.2, 150.5, 150.5, 156.9 (C), 160.4 
(CO). IR (KBr, cm-1): v = 3066, 3031, 2978, 2928, 2919, 2887, 2849 (w), 1716, 1599 (s), 
1573, 1548, 1519 (w), 1510 (m). GC-MS (EI, 70 eV): m/z (%) = 520 ([M]+, 100), 492 
(14), 209 (13). HRMS (EI, 70 eV) calcd for C34H32O5 [M]
+: 520.22497 ; found:  
520.22478. 
 
3,6,7-Tris(4-isopropoxyphenyl)-4-methyl-2H-chromen-2-one (23h): 
Starting with 22 (70 mg, 0.1308 mmol),  3h  
(73 mg, 0.406 mmol) and Pd(pph3)4 (14 
mg, 9 mol-%, 0.01212 mmol) , K2CO3 (2 
M, 2 ml), and 1,4-dioxane (3 ml), 23h was 
isolated as a white solid (57 mg, 77 %), mp 
210-211oC.1H NMR (300 MHz, CDCl3): δ 
= 1.28 (q, J = 7.4 Hz, 18H, 6xCH3), 2.28 (s, 
3H, CH3), 4.38 - 4.59 (m, 3H, 3xOCH), 6.64 - 6.72 (m, 4H, ArH),  6.97 (d, J = 8.4 Hz, 
3H, ArH), 6.99 (dd, J = 1.7, 8.2 Hz, 4H, ArH), 7.18 (d, J = 8.3 Hz, 2H, ArH), 7.30 (s, 1H, 
ArH).13C NMR (75.4 MHz, CDCl3): δ = 15.6 (2xCH3),  21.0 (2xCH3), 21.1 (2xCH3), 
23.7 (CH3), 67.2, 68.8, 68.8 (OCH), 114.4, 114.5, 114.6, 116.8, 118.3 (CH), 125.3, 125.7 
(C), 129.8, 129.9, 130.4 (CH), 130.9, 131.7, 135.6, 142.4, 146.1, 150.5, 150.6, 155.8, 
156.2, 156.7 (C), 160.4 (CO). IR (KBr, cm-1) : v = 3062, 3030, 2970, 2920, 2851 (w), 
1721 (s), 1650, 1644, 1633 (w), 1599 (m), 1573 (w), 1518, 1506, 1484, 1463, 1455 (w). 
GC-MS (EI, 70 eV): m/z (%) = 562 ([M]+, 100), 520 (10), 478 (10), 473 (27), 436 (93), 
435 (19), 408 (24), 407 (14). HRMS (EI, 70 eV) calcd for C37H38O2 [M]
+: 562.27138 ; 
found  :  562.27101. 
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 3,6,7-Tris(4-tert-butylphenyl)-4-methyl-2H-chromen-2-one (23i): 
Starting with 22  (70 mg, 0.1308 mmol), 3i   (72 
mg, 0.406 mmol) and Pd(pph3)4 (14 mg, 9 mol-%, 
0.01212 mmol) , K2CO3 (2 M, 2 ml), and 1,4-
dioxane (3 ml), 23i was isolated as a white solid 
(45 mg, 62 %), mp 150-152oC.1H NMR (300 
MHz, CDCl3): δ = 1.22 (s, 9H, 3xCH3), 1.23 (s, 9H, 3xCH3), 1.28 (s, 9H, 3xCH3), 2.27 
(s, 3H, CH3), 7.01 (d, J = 8.3, Hz , 4H, ArH),  7.16 - 7.20 (m, 7H, ArH), 7.38 (t, J = 7.2, 
Hz, 3H, ArH).13C NMR (75.4 MHz, CDCl3): δ = 15.7 (CH3), 30.2 (3xCH3), 30.3 
(3xCH3), 30.4 (3xCH3), 33.4, 33.5, 33.6, 117.0 (C), 118.4, 123.8, 123.8, 124.2 (CH), 
125.9, 126.1 (C), 128.3, 128.4, 128.7 130.4 (CH),135.7, 136.0, 136.5, 142.9, 146.3, 
148.8, 149.3, 149.9, 150.6 (C), 160.2 (CO). IR (KBr, cm-1): v = 3030 (w), 2959 (s), 2903, 
2865 (w), 1719 (s), 1609, 1604, 1564, 1557, 1547, 1505 (w). GC-MS (EI, 70 eV): m/z 
(%) = 556 ([M]+, 100), 542 (18), 541 (49), 385 (11), 251 (18), 149 (18), 71 (10).  HRMS 
(EI, 70 eV) calcd for  C40H44O2 [M]
+: 556.33358 ; found : 556.33339.  
 
4-Methyl-3,6,7-trim-tolyl-2H-chromen-2-one (23j): 
Starting with 22  (70 mg, 0.1308 mmol), 3j   (55 mg, 
0.406 mmol) and Pd(pph3)4 (14 mg, 9 mol-%, 0.01212 
mmol) , K2CO3 (2 M, 2 ml), and 1,4-dioxane (3 ml), 
23j  was isolated as a white solid (39 mg, 70 %), mp 
143- 145oC. 1H NMR (300 MHz, CDCl3): δ = 2.20 (s, 
3H, CH3), 2.21 (s, 3H, CH3), 2.26 (s, 3H, CH3), 2.34 (s, 3H, CH3), 6.83 (br. s, 2H, ArH)  
6.94 - 7.06 (m, 6H, ArH),  7.15 (t, J = 7.3, Hz, 2H, ArH), 7.25 (t, J = 7.2, Hz, 2H, ArH), 
7.35 (s, 1H, ArH), 7.58 (br. s, 1H, ArH). 13C NMR (75.4 MHz, CDCl3): δ = 15.6, 16.6, 
20.4, 20.5 (CH3), 28.6 (C), 117.1, 118.2, 118.3 (CH), 118.4 (C), 125.8, 125.9, 126.0, 
126.5, 126.6, 126,8, 127.0, 127.3, 127.9, 129.3, 129.4 (CH),129.5, 133.4, 136.2, 136.6, 
137.0, 138.6, 139.3, 143.1, 146.3, 150.7 (C), 160.2 (CO). IR (KBr, cm-1): v =  2961, 
2920, 2853 (w), 1711 (s), 1607 (m), 1585, 1552, 1478 (w). GC-MS (EI, 70 eV): m/z (%) 
= 430 ([M]+, 100), 429 (21), 415 (10), 402 (18), 186 (10). HRMS (EI, 70 eV) calcd for 
C31H26O2 [M]
+: 430.19328 ; found: 430.19373.  
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4-Methyl-3,6,7-tris(2,3,4-trimethoxyphenyl)-2H-chromen-2-one (23k): 
Starting with 22 (70 mg, 0.1308 mmol), 3k   
(86 mg, 0.406 mmol) and Pd(pph3)4 (14 mg, 
9 mol-%, 0.01212 mmol) , K2CO3  (2 M, 2 
ml), and 1,4-dioxane (3 ml), 23k was isolated 
as a white solid (69 mg, 80 %), mp 110-112 
oC.1H NMR (300 MHz, CDCl3): δ =  2.20 (s, 
3H, CH3), 3.63 (s, 9H, 3xOCH3), 3.66 (s, 9H, 3xOCH3), 3.85 (s, 9H, 3xOCH3), 6.99 (dd, 
J = 1.9, 8.4 Hz, 2H, ArH), 6.62 - 6.70 (m, 3H, ArH), 6.18 (d, J = 8.3 Hz, 1H, ArH), 7.34 
(s, 1H, ArH), 7.59 (s, 1H, ArH). 13C NMR (75.4 MHz, CDCl3): δ = 15.5 (CH3), 28.6 
(3xOCH3), 54.9 (3xOCH3), 55.0 (3xOCH3), 105.3, 105.4, 106.3, 108.3, 108.4, 112.2, 
112.4, 117.2 (CH), 120.3, 122.7, 124.2, 124.3, 124.7, 125.7, 126.0, 133.3, 140.5, 140.8, 
140.9, 141.3, 147.8, 150.1, 150.3, 150.9, 152.0, 152.2, 153.0 (C), 160.2 (CO). IR (KBr, 
cm-1) : v = 3065, 3034 (w), 2971 (m), 2931, 2920, 2881, 1887 (w), 1721, 1600 (s), 1573, 
1557, 1552, 1518, 1506, 1485 (w). GC-MS (EI, 70 eV): m/z (%) = 658 ([M]+, 100), 620 
(10), 577 (20), 438 (17), 411 (25), 207 (14). HRMS (EI, 70 eV) calcd for C37H38O11 
[M]+: 658.24141 ; found  :  658.24135. 
    
4-Methyl-3,6,7-tris[4-(trifluoromethyl)phenyl]-2H-chromen-2-one(23l):                          
Starting with 22   (70 mg, 0.1308 mmol), 3q   (77 
mg, 0.406 mmol), Pd(PPh3)4 (14 mg, 9 mol-%, 
0.01212 mmol), K2CO3 (2 M, 2 ml), and 1,4-
dioxane (3 ml),  23l was isolated  as a white solid 
(49 mg, 63 %), m.p 188-189°C. 1H NMR (300 
MHz, CDCl3): δ = 2.30 (s, 3H, CH3) , 6.52 - 6.59 (m, 5H, ArH), 7.00 - 7.06 (m, 3H, 
ArH), 7.14 (d, J = 8.52 Hz, 2H, ArH), 7.23 - 7.27 (m, 2H, ArH), 7.30 (s, 1H, ArH), 7.53 
(s, 1H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 16.6 (CH3), 115.1 (d, J F,C = 21.4 Hz), 
115.4 (d, J F,C = 21.4 Hz), 115.6 (d, J F,C = 21.4 Hz), 117.3 (CH), 118.7, 125.8 (C), 126.2 
(CH), 129.4 (d, J F,C = 3.5 Hz) (C), 130.1, 130.3 (CH), 130.4 (C),    130.9 (d, J F,C = 1.7 
Hz) (CH), 133.2 (d, J F,C = 3.6 Hz),  142.1, 146.6 (d, J F,C = 3.3 Hz), 150. 9, 159.2, 159.5, 
159.6, 159.8 (C), 159.9 (d, J F,C = 246.9 Hz) (CF3), 162.7 (d, J F,C = 246.0 Hz) (CF3), 
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162.9 (d, J F,C = 247.4 Hz) (CF3), 163.3 (CO).
 19F NMR (282.4, MHz): δ = - 62.5, - 62.6, 
- 62.7(3F,CF3). IR (KBr, cm
-1): v = 3069, 2959, 2921, 2850 (w), 1721 (s), 1650, 1645, 
1615, 1575, 1556, 1486, 1463, 1455 (w) . GC-MS (EI, 70 eV): m/z (%) = 592 ([M]+, 
100), 591 (45), 573 (13), 565 (11), 564 (37), 563 (18), 419 (15). HRMS (EST-TOF/MS): 
calcd for. C31H17O2F9 [M]
+: 592.10794 ; found: 592.10714. 
 
3,6,7-Tris(3-methoxyphenyl)-4-methyl-2H-chromen-2-one (23m):   
Starting with 22  (70 mg, 0.1308 mmol), 3k  (62 
mg, 0.406 mmol) and Pd(pph3)4 (14 mg, 9 mol-%, 
0.01212 mmol) , K2CO3 (2 M, 2 ml), and 1,4-
dioxane (3 ml), 23m was isolated as a white solid 
(50 mg, 80 %), mp 101-103oC. 1H NMR (300 
MHz, CDCl3): δ = 2.27 (s, 3H, CH3), 3.57 (s, 6H, 2x OCH3), 3.76 (s, 3H, OCH3), 6.60 - 
6.62 (m, 3H, ArH),  6.68 - 6.74 (m, 3H, ArH), 6.78 - 6.81(m, 3H, ArH), 7.10 (d, J = 8.6, 
Hz, 1H, ArH), 7.17 (d, J = 8.4, Hz, 1H, ArH), 7.28 - 7.37 (m, 2H, ArH), 7.61 (s, 1H, 
ArH). 13C NMR (75.4 MHz, CDCl3): δ = 16.6 (CH3), 55.1, 55.2, 55.3 (OCH3), 112.7, 
113.5, 113.7, 115.0, 115.4, 115.7, 118.1 (CH), 119.6 (C), 122.0, 122.2, 122.3, 126.9 
(CH), 127.7 (C), 129.2, 129.3, 129.5 (CH), 136.4, 136.9, 141.4, 141.7, 143.8, 147.5, 
151.9, 159.2, 159.3, 159.5 (C), 160.8 (CO). IR (KBr, cm-1): v = 3054, 2998, 2952, 2934, 
2823 (w), 1712, 1598, 1575, (s), 1556 (m),1477 (w). GC - MS (EI, 70 eV): m/z (%) =  
478 ([M]+, 100), 477 (22), 207 (13). HRMS (EI, 70 eV) calcd for C31H26O5  [M]
+ : 
478.17748 ; found : 478.17709. 
 
 3,6,7-Tris(3,4-dimethylphenyl)-4-methyl-2H-chromen-2-one (23n): 
Starting with 22  (70 mg, 0.1308 mmol), 3t   (61 
mg, 0.406 mmol) and Pd(pph3)4 (14 mg, 9 mol-%, 
0.01212 mmol) , K2CO3  (2 M, 2 ml), and 1,4-
dioxane (3 ml), 23n was isolated as a white solid 
(37 mg, 60 %), mp 171-172oC.1H NMR (300 MHz, 
CDCl3): δ = 2.11 (s, 3H, CH3), 2.13 (s, 6H, 2xCH3), 2.16 (s, 6H, 2xCH3), 2.23 (s, 6H, 
2xCH3), 6.75 (br. s, 2H, ArH)  6.87 - 7.01 (m, 5H, ArH),  7.16 (t, J = 7.4, Hz, 2H, ArH), 
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7.31 (s, 1H, ArH), 7.53 (s, 1H, ArH). 13C NMR (75.4 MHz, CDCl3): δ = 15.5 (2xCH3), 
18.3 (2xCH3), 18.6 (2xCH3), 18.7 (CH3), 28.6 (C), 117.1 (CH), 118.3 (C), 125.9, 126.1, 
126.2, 126.3, 126.4, 128.2, 128.6, 129.7, 129.8, 1390.0 (CH), 131.2, 134.1, 134.6, 135.2, 
135.3, 135.5, 135.6, 136.0, 126.3, 137.1, 142.9, 146.2, 149.5 (C), 160.3 (CO). IR (KBr, 
cm-1): v =  2961, 2919, 2854 (w), 1713 (s), 1609 (m), 1573, 1568, 1549, 1503, 1484 (w). 
GC-MS (EI, 70 eV): m/z (%) = 472 ([M]+, 100), 471 (26), 457 (10), 445 (17), 443 (11), 
429 (13), 414 (11),  207 (16). HRMS (EI, 70 eV) calcd for C34H32O2 [M]
+: 472.23968 ; 
found: 472.23921.  
      
3,6,7-Tris(4-isopropylphenyl)-4-methyl-2H-chromen-2-one (23o): 
Starting with 22  (70 mg, 0.1308 mmol), 3u   (66 
mg, 0.406 mmol) and Pd(pph3)4 (14 mg, 9 mol-%, 
0.01212 mmol) , K2CO3 (2 M, 2 ml), and 1,4-
dioxane (3 ml),  23o  was isolated as a white solid 
(47 mg, 70 %), mp 120-122oC. 1H NMR (300 
MHz, CDCl3): δ = 1.14 (s, 6H, 2xCH3), 1.16 (s, 
6H, 2xCH3), 1.22 (s, 6H, 2xCH3), 2.25 (s, H, CH3), 2.27 - 2.91 (m, 3H, 3xCH), 6.96 - 
7.01 (m, 8H, ArH),  7.15 (d, J = 8.4, Hz, 2H, ArH), 7.24 (d, J = 8.2, Hz, 2H, ArH),  7.33 
(s, 1H, ArH), 7.56 (s, 1H, ArH).13C NMR (75.4 MHz, CDCl3): δ = 15.6 (2xCH3), 22.8 
(2xCH3), 22.9 (2xCH3), 24.7 (CH3), 32.6, 32.7, 32,9 (CH), 117.0 (C), 118.4, 124.7 (CH), 
125.0, 125.4 (C), 126.0, 126.1, 128.3, 128.5, 128.9, 130.7 (CH) 136.1, 136.2, 136.9, 
142.9, 146.3, 146.5, 147.1, 147.6, 150.6 (C),  160.3 (CO). IR (KBr,   cm-1) : v  = 3064, 
3041, 3024 (w), 2957 (s), 2924, 2865 (w), 1724 (s), 1613, 1604 (m),  1568, 1551, 1510, 
1506, 1484 (w). GC-MS (EI, 70 eV): m/z (%) = 514 ([M]+, 100), 500 (10), 499 (17), 
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X-Ray Crystals Data 
 
Crystal data and structure refinement for 7-Chloro-4-(4-methoxyphenyl)-1-
methylindoline-2,3-dione (5b): 
 
Identification code  is_ac13 
Empirical formula  C16H12ClNO3 
Formula weight  301.72 
Temperature  173 (2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group (H.-M.)  C c  
Space group (Hall)  C -2yc 
Unit cell dimensions a = 16.9602 (3) Å = 90.00 (0)° 
 b = 25.6488 (5) Å = 105.2530 (3)° 
 c = 12.4814 (4) Å  = 90.00 (0)° 
Volume 5381.42 (17) Å3 
Z 12 
Density (calculated) 1.386 Mg/m3 
Absorption coefficient 0.10 mm-1 
F(000) 2328 
Crystal size 0.30 x 0.19 x 0.17 mm 
 range for data collection 2.75° to 27.62°. 
Reflections collected 57186 
Independent reflections 15084 
Completeness to  = 32.50° 99.2 % 
Absorption correction multi-scan 
Max. and min. transmission 0.9165 and 0.9514 
Refinement method Full-matrix least-squares on F2 
Goodness-of-fit on F2 1.024 
Final R indices [F2>2(F2)] R1 = 0.0472, wR = 0.0885 
R indices (all data) R1 = 0.0750, wR(F2) = 0.0966 
Largest diff. peak and hole 0.326 and -0.227 e.Å-3 
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Crystal data and structure refinement for 7-Chloro-1-methyl-4-p-tolylindoline-2,3-
dione (5d): 
 
Identification code  is_ac 7 
Empirical formula  C16H12ClNO2 
Formula weight  285.72 
Temperature  173 (2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group (H.-M.)  C c  
Space group (Hall)  C -2yc 
Unit cell dimensions a = 16.9602 (3) Å = 90.00 (0)° 
 b = 25.6488 (5) Å = 105.2530 (3)° 
 c = 12.4814 (4) Å  = 90.00 (0)° 
Volume 5381.42 (17) Å3 
Z 12 
Density (calculated) 1.386 Mg/m3 
Absorption coefficient 0.10 mm-1 
F(000) 2328 
Crystal size 0.99 x 0.03 x 0.03 mm 
 range for data collection 2.75° to 27.62°. 
Reflections collected 57186 
Independent reflections 15084 
Completeness to  = 27.50° 99.1 % 
Absorption correction multi-scan 
Max. and min. transmission 0.7563 and 0.9911 
Refinement method Full-matrix least-squares on F2 
Goodness-of-fit on F2 1.024 
Final R indices [F2>2(F2)] R1 = 0.0472, wR = 0.0885 
R indices (all data) R1 = 0.0750, wR(F2) = 0.0966 
Largest diff. peak and hole 0.363 and -0.387 e.Å-3 
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Crystal data and structure refinement for 2-(4-Tert-butylphenyl)-6-(4-
methoxyphenyl)benzoxazole (10b): 
 Identification code  is_ax0199 
Empirical formula  C24H23NO2 
Formula weight  357.43 
Temperature  173 (2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group (H.-M.)  C c  
Space group (Hall)  C -2yc 
Unit cell dimensions a = 16.9602 (3) Å = 90.00 (0)° 
 b = 25.6488 (5) Å = 105.2530 (3)° 
 c = 12.4814 (4) Å  = 90.00 (0)° 
Volume 5381.42 (17) Å3 
Z 12 
Density (calculated) 1.386 Mg/m3 
Absorption coefficient 0.10 mm-1 
F(000) 2328 
Crystal size 0.39 x 0.24 x 0.14 mm 
 range for data collection 1.16° to 27.99°. 
Reflections collected 57186 
Independent reflections 15084 
Completeness to  = 27.99° 100 % 
Absorption correction multi-scan 
Max. and min. transmission 0.9166 and 0.9923 
Refinement method Full-matrix least-squares on F2 
Goodness-of-fit on F2 1.024 
Final R indices [F2>2(F2)] R1 = 0.0472, wR = 0.0885 
R indices (all data) R1 = 0.0750, wR(F2) = 0.0966 
Largest diff. peak and hole 0.197 and -0.162 e.Å-3 
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Crystal data and structure refinement for  4-Oxo-3-(4-
(trifluoromethylsulfonyloxy)phenyl)-4H-chromen-7-yl trifluoromethanesulfonate 
(12): 
 
Identification code  is_fi 
Empirical formula  C17H8F6O8S2 
Formula weight  518.35 
Temperature  173 (2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group (H.-M.)  C c  
Space group (Hall)  C -2yc 
Unit cell dimensions a = 16.9602 (3) Å = 90.00 (0)° 
 b = 25.6488 (5) Å = 105.2530 (3)° 
 c = 12.4814 (4) Å  = 90.00 (0)° 
Volume 5381.42 (17) Å3 
Z 12 
Density (calculated) 1.386 Mg/m3 
Absorption coefficient 0.10 mm-1 
F(000) 2328 
Crystal size 0.23 x 0.12 x 0.02 mm 
 range for data collection 2.73° to 28.00°. 
Reflections collected 57186 
Independent reflections 15084 
Completeness to  = 28.00° 99.9 % 
Absorption correction multi-scan 
Max. and min. transmission 0.9166 and 0.9923 
Refinement method Full-matrix least-squares on F2 
Goodness-of-fit on F2 1.024 
Final R indices [F2>2(F2)] R1 = 0.0472, wR = 0.0885 
R indices (all data) R1 = 0.0750, wR(F2) = 0.0966 
Largest diff. peak and hole 0.506 and -0.403 e.Å-3 
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Crystal data and structure refinement for 4-[7-(3,5-Dimethylphenyl)-4-oxo-4H-
chromen-3-yl]phenyl trifluoromethanesulfonate (14a): 
 
Identification code  is_fi5 
Empirical formula  C24H17F3O5S 
Formula weight  456.29 
Temperature  173 (2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group (H.-M.)  C c  
Space group (Hall)  C -2yc 
Unit cell dimensions a = 16.9602 (3) Å = 90.00 (0)° 
 b = 25.6488 (5) Å = 105.2530 (3)° 
 c = 12.4814 (4) Å  = 90.00 (0)° 
Volume 5381.42 (17) Å3 
Z 12 
Density (calculated) 1.386 Mg/m3 
Absorption coefficient 0.10 mm-1 
F(000) 2328 
Crystal size 0.39 x 0.12 x 0.11 mm 
 range for data collection 2.34° to 35.50°. 
Reflections collected 57186 
Independent reflections 15084 
Completeness to  = 28.00° 99.9 % 
Absorption correction multi-scan 
Max. and min. transmission 0.9223 and 0.9772 
Refinement method Full-matrix least-squares on F2 
Goodness-of-fit on F2 1.024 
Final R indices [F2>2(F2)] R1 = 0.0472, wR = 0.0885 
R indices (all data) R1 = 0.0750, wR(F2) = 0.0966 
Largest diff. peak and hole 0.331 and -0.425 e.Å-3 
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Crystal data and structure refinement for 4-Methyl-2-oxo-2H-chromene-6,7-diyl 
bis(trifluoromethanesulfonate) (17): 
 
Identification code  is_aq1 
Empirical formula  C12H6F6O8S2 
Formula weight  456.29 
Temperature  173 (2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group (H.-M.)  C c  
Space group (Hall)  C -2yc 
Unit cell dimensions a = 16.9602 (3) Å = 90.00 (0)° 
 b = 25.6488 (5) Å = 105.2530 (3)° 
 c = 12.4814 (4) Å  = 90.00 (0)° 
Volume 5381.42 (17) Å3 
Z 12 
Density (calculated) 1.386 Mg/m3 
Absorption coefficient 0.10 mm-1 
F(000) 2328 
Crystal size 0.30 x 0.19 x 0.17 mm 
 range for data collection 2.77° to 25.00°. 
Reflections collected 57186 
Independent reflections 15084 
Completeness to  = 25.00° 98.2 % 
Absorption correction multi-scan 
Max. and min. transmission 0.9174 and 0.9850 
Refinement method Full-matrix least-squares on F2 
Goodness-of-fit on F2 1.024 
Final R indices [F2>2(F2)] R1 = 0.0472, wR = 0.0885 
R indices (all data) R1 = 0.0750, wR(F2) = 0.0966 
Largest diff. peak and hole 0.518 and -0.339 e.Å-3 
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Crystal data and structure refinement for 6,7-Bis(4-ethoxyphenyl)-4-methyl-2H-
chromen-2-one (18g): 
 
Identification code  is_aq6 
Empirical formula  C26H24O4 
Formula weight  456.29 
Temperature  173 (2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group (H.-M.)  C c  
Space group (Hall)  C -2yc 
Unit cell dimensions a = 16.9602 (3) Å = 90.00 (0)° 
 b = 25.6488 (5) Å = 105.2530 (3)° 
 c = 12.4814 (4) Å  = 90.00 (0)° 
Volume 5381.42 (17) Å3 
Z 12 
Density (calculated) 1.386 Mg/m3 
Absorption coefficient 0.10 mm-1 
F(000) 2328 
Crystal size 0.24 x 0.16 x 0.15 mm 
 range for data collection 1.91° to 29.73°. 
Reflections collected 57186 
Independent reflections 15084 
Completeness to  = 29.73° 99.3 % 
Absorption correction multi-scan 
Max. and min. transmission 0.9795 and 0.9871 
Refinement method Full-matrix least-squares on F2 
Goodness-of-fit on F2 1.024 
Final R indices [F2>2(F2)] R1 = 0.0472, wR = 0.0885 
R indices (all data) R1 = 0.0750, wR(F2) = 0.0966 
Largest diff. peak and hole 0.184 and -0.218 e.Å-3 
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Crystal data and structure refinement for 7-(4-Methoxyphenyl)-4-methyl-2-oxo-2H-
chromen-6-yl trifluoromethanesulfonate (19b): 
 
Identification code  is_aq3 
Empirical formula  C18H13F3O3S 
Formula weight  414.34 
Temperature  173 (2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group (H.-M.)  C c  
Space group (Hall)  C -2yc 
Unit cell dimensions a = 16.9602 (3) Å = 90.00 (0)° 
 b = 25.6488 (5) Å = 105.2530 (3)° 
 c = 12.4814 (4) Å  = 90.00 (0)° 
Volume 5381.42 (17) Å3 
Z 12 
Density (calculated) 1.386 Mg/m3 
Absorption coefficient 0.10 mm-1 
F(000) 2328 
Crystal size 0.60 x 0.13 x 0.08 mm 
 range for data collection 2.24° to 30.50°. 
Reflections collected 57186 
Independent reflections 15084 
Completeness to  = 30.50° 98.6 % 
Absorption correction multi-scan 
Max. and min. transmission 0.7563 and 0.9911 
Refinement method Full-matrix least-squares on F2 
Goodness-of-fit on F2 1.024 
Final R indices [F2>2(F2)] R1 = 0.0472, wR = 0.0885 
R indices (all data) R1 = 0.0750, wR(F2) = 0.0966 
Largest diff. peak and hole 0.349 and -0.296 e.Å-3 
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Crystal data and structure refinement for 3-Bromo-4-methyl-2-oxo-2H-chromene-
6,7-diyl bis(trifluoromethanesulfonate) (22): 
 
  
Identification code  is_qb1 
Empirical formula  C12H5BrF6O3S2 
Formula weight  535.19 
Temperature  173 (2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group (H.-M.)  C c  
Space group (Hall)  C -2yc 
Unit cell dimensions a = 16.9602 (3) Å = 90.00 (0)° 
 b = 25.6488 (5) Å = 105.2530 (3)° 
 c = 12.4814 (4) Å  = 90.00 (0)° 
Volume 5381.42 (17) Å3 
Z 12 
Density (calculated) 1.386 Mg/m3 
Absorption coefficient 0.10 mm-1 
F(000) 2328 
Crystal size 0.29 x 0.05 x 0.02 mm 
 range for data collection 2.55° to 27.50°. 
Reflections collected 57186 
Independent reflections 15084 
Completeness to  = 29.00° 94.3 % 
Absorption correction multi-scan 
Max. and min. transmission 0.5096 and 0.9482 
Refinement method Full-matrix least-squares on F2 
Goodness-of-fit on F2 1.024 
Final R indices [F2>2(F2)] R1 = 0.0472, wR = 0.0885 
R indices (all data) R1 = 0.0750, wR(F2) = 0.0966 
Largest diff. peak and hole 0.504 and -0.681 e.Å-3 
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Crystal data and structure refinement for 3,6,7-Tris(4-tert-butylphenyl)-4-methyl-
2H-chromen-2-one (23i): 
 
Identification code  is_ qb 16 
Empirical formula  C40H44O2 
Formula weight  556.75 
Temperature  173 (2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group (H.-M.)  C c  
Space group (Hall)  C -2yc 
Unit cell dimensions a = 16.9602 (3) Å = 90.00 (0)° 
 b = 25.6488 (5) Å = 105.2530 (3)° 
 c = 12.4814 (4) Å  = 90.00 (0)° 
Volume 5381.42 (17) Å3 
Z 12 
Density (calculated) 1.386 Mg/m3 
Absorption coefficient 0.10 mm-1 
F(000) 2328 
Crystal size 0.25 x 0.14x 0.09 mm 
 range for data collection 2.75° to 27.62°. 
Reflections collected 57186 
Independent reflections 15084 
Completeness to  = 27.62° 99.1 % 
Absorption correction multi-scan 
Max. and min. transmission 0.9833 and 0.9939 
Refinement method Full-matrix least-squares on F2 
Goodness-of-fit on F2 1.024 
Final R indices [F2>2(F2)] R1 = 0.0472, wR = 0.0885 
R indices (all data) R1 = 0.0750, wR(F2) = 0.0966 
Largest diff. peak and hole 0.198 and -0.209 e.Å-3 
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